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1GENERAL INTRODUCTION
The advent of drugs possessing the ability 
to produce a specific relaxation of skeletal muscle 
has had far reaching implications in surgery and 
anaesthetics. Their introduction, approximately 
twenty years ago, as adjuncts in anaesthesia, has 
obviated the need for the high doses of the 
anaesthetic agent otherwise required for the dual 
purpose of relieving pain and preparing the skeletal 
muscles for surgical manipulation. Lower doses of the 
anaesthetic could thus be used solely for the analgesic 
function, with a consequent gain in the safety margin. 
Muscle relaxants have also proved valuable in the 
treatment of tetanus, epilepsy, in the prevention of 
trauma during electroshock therapy and in several 
types of orthopaedic procedures.
Each of the three muscle relaxant preparations 
in current clinical use, namely gallamine, tubocurarine 
and suxamethonium are capable of producing undesirable 
side effects. Gallamine may produce tachycardia 
(Riker & Wescoe, 1951), tubocurarine can cause both 
histamine release (Sniper, 1952) and ganglion blockade 
(Foldes, 1960), while the occurrence of muscle pain 
and the irreversible nature of the paralysis produced
2by suxamethonium and other depolarizing drugs are 
disadvantages to their use (Foldes, 1960). The need 
for an easily reversible neuromuscular blocking agent, 
free from side effects and preferably possessing a 
tubocurarine-like mode of action persists and remains 
the mandate for continued chemical and pharmacological 
research in this field.
A very large number of compounds have been 
prepared since the introduction of the first 
biologically standardized muscle relaxant preparation, 
Intocostrin, into clinical anaesthesia (Griffith 8c 
Johnson, 1942). The continuing search for better 
muscle relaxants has necessitated a vigorous laboratory 
investigation of the precise pharmacological properties 
of these drugs and present day knowledge stems largely 
from experiments using laboratory animals. Yfhile the 
correlation of such information with clinical experience 
is often difficult, only a detailed and accurate, 
experimental assessment of their basic mode of action 
will permit the safe and rational clinical use of 
muscle relaxant compounds. The mode of action of 
Intocostrin was believed to be characteristic of all 
muscle relaxant compounds but the introduction of 
decamethonium (Barlow 8c Ing, 1948a,b; Paton 8c
3Zaimis, 1948a) revealed a second and different 
mechanism. Present day concepts distinguish at 
least three basic types of muscle relaxants (Van Rossum, 
Ariens & Linssen, 1958)* Moreover, the existence of 
drugs possessing a dual mode of action, first 
demonstrated by Zaimis (1952), has emphasized the 
necessity for a careful pharmacological evaluation of 
these compounds prior to their clinical assessment.
Progress towards an accurate pharmacological 
investigation of muscle relaxant drugs has been made by 
the planned preparation of many series of compounds 
closely related in chemical structure. Among these 
have been several series of homologous compounds, for 
example, polymethylene bisquaternary methonium compounds 
(Barlow & Ing, 1948a,b; Paton & Zaimis, 1948a,b), from 
the study of which certain correlations between chemical 
structure and pharmacological activity were derived.
The dominant characteristic of the majority of these 
drugs was the presence of one or more quaternary 
ammonium groups in the molecule, yet the observed 
biological response was also affected by other molecular 
constituents. Among the more interesting chemical 
features associated with muscle relaxant activity in 
synthetic compounds, is the ether oxygen function.
4While many ether-containing muscle relaxants have "been 
prepared, attempts to evaluate the precise role of the 
ether link have been vague and inconclusive. On the 
other hand, its presence in many clinically useful 
drugs, for example, tubocurarine, tubocurarine dimethyl 
ether, laudexium, gallamine and oxydipentonium, has 
underlined the association of this chemical function 
with the phenomenon of neuromuscular block. One of 
the principal contributions of pharmacology is to 
establish the basic mode of action of groups of drugs 
which appear to act in a similar fashion. By a 
careful evaluation of the effect of individual 
structural features on pharmacological behaviour, 
desirable chemical features may be retained in new 
drugs and those believed to be responsible for the 
development of undesirable properties eliminated. 
Moreover this contribution will be enhanced if the 
activity of the compounds investigated can be placed in 
a perspective embracing the entire field of muscle 
relaxant drugs.
The work undertaken in this thesis represents 
an attempt to establish the basic mode of action of a 
number of synthetic muscle relaxant compounds and 
where possible to correlate their chemical structure
5with the pharmacological activity observed* Particular 
attention was paid to the presence of the ether oxygen 
function in certain of the compounds studied, and an 
endeavour was made to assess its contribution to the 
muscle relaxant potency of these drugs*
The Mechanism of Action of Neuromuscular Blocking Agents* 
The classic experiments of Claude Bernard 
(1856), were not only the first demonstrations that 
curare exerted its paralyzing action peripherally at 
the junction of nerve and muscle, leaving both structures 
unimpaired, but also indicated the specialized nature 
of this region and stimulated interest in its 
properties* Subsequent histological and physiological 
investigations have led to the view that while the nerve 
impulse traverses the fibres by electrical propagation 
(Bernstein, 1902), its transmission from neuron to 
neuron or from neuron to effector cell is mediated by 
specific chemical substances liberated from the nerve 
terminals* The existence of chemical mediators or 
neuro-hormones was first suggested by Elliott (1905), 
who postulated the existence of sympathin to explain 
transmission in the sympathetic nervous system* The 
same concept was subsequently applied to parasympathetic 
fibres (Le Heux, 191S, 1921; Dale, 1914; Dale & Dudley,
61929; Loewi, 1921; Loewi & Navratil, 1926) and 
conclusive proof was provided nearly twenty years later 
by the elegant demonstration by Dale, Feldberg and 
Vogt (1936) of the existence of acetylcholine in the 
perfusion fluid from the mammalian neuromascular 
junction following stimulation of the motor nerve.
The acetylcholine-intensifying action and the anti­
curare effect of anticholinesterase drugs (Brown, Dale 
& Peldberg, 1936; Bacq & Brown, 1937; see also reviews 
by: Dale, 1937; Brown, 1937a,b; Eccles, 1936, 1937) 
lent further support to this view, as did the effect 
of curare-like substances in preventing acetylcholine- 
induced twitch-like responses of skeletal muscle 
(Brown et £1. 1936).
In order to understand the mechanism of action 
of muscle relaxant drugs, it is necessary to consider 
both the structure of the neuromuscular synapse and the 
normal physiological sequence of events occurring there. 
Present day concepts are derived from improved recording 
techniques using microelectrodes by which the intimate 
mode of action of acetylcholine has been studied 
intensively (Patt & Katz, 1951; Patt, 1954; Del Castillo 
& Katz, 1956; Eccles, 1957/).;. Recent histological 
studies of the neuromuscular synapse (Couteaux, 1947,
-7
1955; Robertson, 1956, 1957a,b) have revealed the 
extensive branching of the motor nerve prior to its 
termination (Eccles, 1955).y ■ and the structural 
differentiation of the junctional region. The evidence 
suggests that there is no direct cytoplasmic continuity 
but merely a close association between the nerve endings 
and the muscle fibre, the former lying in troughs in 
the surface of the latter (Eccles, 1957b; Katz, 1959; 
Couteaux, 1955). Physiological observations have 
confirmed the apparently specialized role of the motor 
end plate in neuromuscular transmission (Katz, 1958).
The neuromuscular synapse is more readily fatigued 
in a nerve-muscle preparation than either nerve or 
muscle fibres (Kachmansohn, 1959a). Furthermore the 
junctional region possesses not only a high and specific 
sensitivity to acetylcholine (Buchthal & Lindhard, 1942; 
Kuffler, 1943, 1945), but also a relatively higher 
concentration of acetylcholinesterase than other tissues 
(Couteaux & Nachmansohn, 1940; Couteaux, 1955). Moreover 
it differs qualitatively and quantitatively from other 
parts of the muscle and nerve in its response to many 
drugs, including certain muscle relaxants (Katz, 1959).
Acetylcholine is synthesized by a reaction 
involving choline and acetylcoenzyme A (Nachmansohn,
81946; Lipmann & Kaplan, 1946) in the presence of 
choline acetylase which appears to occur in the 
mitochondria (Hebb & Smallman, 1956)* The energy for 
this reaction is supplied by adenosinetriphosphate 
(Nachmansohn & Machado, 1943) or from the metabolism 
of glucose or pyruvate (Mcllwain, 1959)* In the 
resting state the acetylcholine is stored in an inactive 
protein-bound form (Nachmansohn, 1952b) within the motor 
nerve fibre (Feldberg, 1945, 1950). The presence of 
vesicles in the terminal portion of motor neurones 
(De Robertis & Bennett, 1955; Palade, 1954; Palay, 1954) 
is believed to be intimately associated with this 
storage of bound acetylcholine*
The release of acetylcholine takes place in 
response to nerve impulses passing along the motor 
fibre (Kuffler, 1949). The transmitter may then diffuse 
across the junctional region to become momentarily 
attached to a hypothetical specific receptor site on 
the post synaptic membrane of the motor end plate 
(Eccles, 1953;; Del Castillo & Katz, 1957). There is 
also evidence to suggest that acetylcholine-receptors 
exist both in nerve terminals (Masland & 7/igton, 1940; 
Riker, Roberts, Standaert & Fujimori, 1957; Riker,
Werner, Roberts & Kuperman, 1959), and in the axon itself
9(Rosenberg & Ehrenpreis, 1961). The process of 
liberation of acetylcholine is neither fully understood 
nor easily investigated (Del Castillo & Katz, 1956).
While its release from the nerve terminal has been 
frequently studied (Eccles, 1937), this site is not the 
only source of acetylcholine (Kachmaiisohn, 1959b). 
Histochemical (Koelle & Koelle, 1958) and biochemical 
(Hachmansohn, 1959b,jc) evidence has confirmed the 
presence of acetylcholine in sensory fibres (Chang,
Hsieh, Lee, Li 8c Lim, 1939; Lissak & Pasztor, 1941) and 
also its release from within both the axon itself 
(Brecht 8c Corsten, 1941) and from stimulated denervated 
muscle (Jarcho, Berman, Lilienthal 8c Eyzaguirre, 1951; 
McIntyre, 1958, 1959)*
The concentrations of certain cations in the 
environment, for example sodium, potassium, calcium and 
magnesium, may influence transmitter release (Nastuk, 
1959). By the use of intracellular microelectrode 
techniques, it has been observed that high concentrations 
of magnesium ions and low concentrations of calcium ions 
may reduce the overall amount of acetylcholine liberated 
(Del Castillo 8c Engbaek, 1953, 1954). Large 
concentrations of the latter produce the opposite 
effect (Del Castillo 8c Stark, 1952). An intermediate,
10
mutually antagonistic reaction involving calcium ions 
and magnesium ions may take place between the arrival 
of a nerve impulse and the release of acetylcholine 
(Del Castillo & Katz, 1956; Jenkinson, 1957)* High 
concentrations of both magnesium and calcium cations 
depress the direct excitability of the muscle membrane 
(Del Castillo & Engbaek, 1954). Excess potassium ions 
applied externally to the neuromuscular junction also 
liberate acetylcholine from nerve endings but the 
precise role of sodium in this connection has not been 
clearly established (Del Castillo & Katz, 1956; Hastuk, 
1959).
A spontaneous and intermittent release of 
discrete quanta of acetylcholine occurs at rest at the 
neuromuscular junction, eliciting minute potential 
changes in the post junctional membrane which are, 
however, belov/ the 'threshold* of the adjacent muscle 
membrane and insufficient to elicit a response (Patt & 
Katz, 1952). The synchronous release of a large 
number of quanta of acetylcholine in response to impulses 
in the motor nerve (Robertson, 1956; Del Castillo & Katz, 
1956j Werner, 1961) produces a depolarization of the end 
plate of the muscle membrane (Gopfert & Schaefer, 1938; 
Kuffler, 1942 ; Patt 8c Katz, 1951, 1952; Eccles, Katz
11
& Kuffler, 1941), which is sufficient to generate a 
wave of excitation in areas adjacent to the end plate 
region. This excitatory depolarizing effect, producing 
the so called fspike action1 potential, propagates in 
both directions along the membrane of the muscle fibre 
inducing contraction. Acetylcholine-induced
depolarization is associated with rapid alterations in 
the permeability of the muscle-cell membrane to sodium 
ions (Hodgkin, 1951), and to potassium and ammonium ions 
(Uastuk, 1959) and possibly opens up an indiscriminate 
aqueous channel to all small ions on each side of the 
membrane (Katz, 1959). Under normal resting conditions, 
the post synaptic membrane is moderately permeable to 
potassium but only sparingly permeable to sodium ions.
On depolarization, hov/ever, a large, transient increase 
in the permeability of the end plate membrane to sodium 
ions takes place (during the rising phase of the action 
potential), causing a reversal of the potential 
difference across the cell membrane. This is followed 
by an increased, more prolonged, permeability to 
potassium ions. It has been suggested that the energy 
associated with this ionic transfer may contribute to 
the propagation of the impulse along the muscle fibre 
(Hodgkin, 1951). Sites on the muscle cell membrane
12
which at rest, are occupied by calcium ions, may, on 
depolarization, be taken up by sodium and potassium ions 
(Shanes, Preygang, Grundfest 5c Amatniek, 1959; Adelman 
5c Dalton, 1960). Calcium ions may thus be important 
in maintaining a selective ionic gradient across the 
muscle cell membrane (Hodgkin, Huxley 5c Katz, 1949).
The rapid removal of acetylcholine from the site of 
activity (0.5 to 1 msec), a prerequisite for its 
essential role in conduction, may be accomplished by 
several contributing mechanisms. Among these the 
importance of acetylcholinesterase as a specific 
(Hachmansohn 5c Rothenberg, 1944, 1945) hydrolyzing 
enzyme (Augustinsson 5c Hachmansohn, 19,49) for acetylcholine, 
has been clearly established. This enzyme, the existence 
of which was suggested by Dale (1914) to explain the 
rapid removal of acetylcholine and which was first 
demonstrated in 1932 (Stedman, Stedman 5c Easson, 1932), 
occurs in high concentrations at the neuromuscular 
synapse (Marnay 5c Hachmansohn, 1937) probably at the 
lamellae of the subneural apparatus (Couteaux, 1955).
Histochemical evidence for its presence at the motor end 
plate has also been provided (Couteaux 5c Hachmansohn,
1940; Couteaux, 1955; Koelle & Priedenwald, 1949).
The relatively high rate of hydrolysis of acetylcholine
13
(Hachmansohn, 1959b) together with the significant 
prolongation of the transmitter effect by means of 
acetylcholinesterase inhibitors (Brown et al. 1936; 
Eccles & MacFarlane, 1949; Fatt 8c Katz, 1951), have 
further confirmed the specialized role of acetyl­
cholinesterase in the physiological function of 
acetylcholine*
Other means of removing acetylcholine by its 
diffusion into interstices (Brown e t al* 1936)9 its 
restitution to presynaptic terminals in a way analgous 
to that demonstrated for choline at nerve endings 
(Perry, 1953), or by the development of receptors 
refractory to the transmitter (Thesleff, 1955a,b), have 
not been experimentally substantiated.
In contrast to the vie?/ that transmission was a 
purely electrical process (Eccles, 1946), the essential 
role of acetylcholine has now been widely accepted 
(Eccles, 1949; Katz, 1959; Hachmansohn, 1959b), although 
chemical transmission at all synapses has not been 
established and electrical transmission has been 
demonstrated in the crayfish (Furshpan & Potter, 1957).
A, difference of opinion, however, persists concerning 
the precise mechanism of action of acetylcholine at the 
neuromuscular junction. One school of thought
14
(Feldberg, 1951; Del Castillo & Katz, 1956) has 
proposed that acetylcholine is secreted at the terminal 
nerve membrane and reaches the postsynaptic membrane 
by diffusion across the subneural space. On the other 
hand there are proponents of the view that the current 
generated at the terminal nerve membrane traverses the 
subneural space liberating acetylcholine at the post­
junctional membrane (Hacbmansohn, 1952a); i.e. the 
combination of acetylcholine with the receptor is 
responsible for the change of conductance and the 
initiation of ionic movements across the synapse. The 
existence of protective barriers, surrounding the axon, 
impermeable to lipid-insoluble quaternary ammonium 
compounds including acetylcholine (Bullock, Hachmansohn 
Sc Rothenberg, 1946; Rothenberg, Sprinson 8c Kachmansohn,
1948), has proved a serious objection to the latter view. 
Recent work has, however, revealed that when these are 
removed, for example by ionic detergents, fcurare1 can 
exert its characteristic blocking action both at the 
nodes of Ranvier (Walsh & Deal, 1959; Dettbarn, 1960) 
and in the axon proper (Rosenberg 8c Ehrenpreis, 1961). 
Moreover, the liberation of acetylcholine from a nerve 
fibre has also been confirmed (Brecht 8c Corsten, 1941). 
Acceptance of these results supports the view that the
15
action of acetylcholine at the neuromuscular synapse 
is merely 1 a local intensification of a general process 
for the propagation of impulses along the nerve fibrer 
(Dale, 1937, 1954).
It is apparent, despite this controversy, that 
any drug affecting the synthesis or removal of 
acetylcholine, or the formation of the acetylcholine- 
receptor complex, may interrupt the physiological 
process of neuromuscular transmission. Such drugs can 
he classified according to their anatomical site of 
action (neuromuscular blocking agents), their therapeutic 
effect (muscle relaxants), their pharmacological 
mechanism of activity, or their chemical or 
pharmacognostical source of origin (Lewis, 1960al. 
Consequently, while the term, muscle relaxant, may 
correctly be given to any drug Interfering with any stage 
in the normal physiological sequence of events, the term, 
neuromuscular blocking agent, is reserved for those drugs 
interfering with the actual functioning of the transmitter 
itself rather than to its presynaptic release or its 
enzymatic destruction. By definition, both conduction 
in the motor nerve and the response of the skeletal 
muscle to direct stimulation remain unimpaired. However, 
in spite of valid objections (Hunt 8c Huffier, 1950;
16
Paton, 1951), neuromas collar blocking agents are often 
collectively termed ^curariform* or !curarizing drugs*, 
irrespective of whether or not their precise mode of 
action is identical with that of tubocurarine.
Prom the clinical point of view, neuromuscular 
blocking agents constitute the most important group 
of muscle relaxant drugs. Muscle relaxant drugs 
have been conveniently classified into two main 
categories, on the basis of their intimate effects on 
transmitter functions
(a) Non-depolarizing compounds which compete with 
acetylcholine for receptors on the postsynaptic muscle 
membrane and interfere with the formation of the 
acetylcholine-receptor complex. Tubocurarine is 
generally considered to be the classic example.
(b) Drugs which mimic the action of the transmitter and 
induce block by a depolarization of the motor end plate, 
e.g. de came thonium.
In addition, both types of action may be observed in 
the same molecule, e.g., Tridecamethonium, (Paton & 
Zaimis, 1952; Zaimis, 1952).
Non-Depolarizing Muscle Relaxant Drugs.
These selectively combine with acetylcholine- 
receptors in the post-junctional muscle membrane and
17
so reduce or prevent the depolarizing effect of the 
transmitter• The combination of acetylcholine and
the receptor takes place by a 2 to 3 stage process 
(Del Castillo & Katz, 1957), but tubocurarine appears 
only to Interfere with the initial site of attachment 
ivlthout being involved in the subsequent changes in the 
physical properties of the membrane Itself, ?ftiile 
considerable evidence supports the belief that this 
antagonism Is simply competitive (Patt & Katz, 1952), 
this may be an over-simplified view (Bel Castillo 8c 
Katz, 1957). ,
Drugs of this type principally affect the end 
plate potential, which undergoes a progressive reduction 
In duration, rate of development and amplitude 
terminating in its complete disappearance (Patt & Katz, 
1951; Thesleff, 1955^) • When the amplitude has fallen 
below the threshold value necessary to ’trigger offf 
the action potential in the membrane of the muscle 
fibre, conduction ceases and block is induced (Eccles 
et.al* 1941). Elimination of the drug causes a rapid 
and complete recovery of transmission (Thesleff, 1955c). 
A muscle treated with tubocurarine is electrically 
normal (Paton, 1951), there being no apparent alteration 
In either the potential or Ionic permeability of the
18.
membrane. Although tubocurarine has been observed 
to cause contractions of denervated muscle when 
injected intra-arterially (McIntyre, King Sc Dunn, 1945; 
Jarcho et al. 1951), the direct excitability of muscle 
treated with tubocurarine appears indistinguishable 
from that of the normal fibre (Fatt Sc Katz, 1951;
Paton, 1951; Del Castillo Sc Katz, 1957). On account 
of the competitive nature of the block, any local 
increase in the concentration of acetylcholine, for 
example, by repetitive stimulation of the motor nerve 
(Thesleff, 1955c), or the use of anticholinesterase 
drugs (Riker, 1953), will antagonize the effect of 
tubocurarine and other members of this group. Moreover, 
any reduction in the ’ threshold1 of the muscle fibre 
will produce similar effects. The action of competitive 
neuromuscular blocking agents may also be antagonized 
by increasing the excitability of the muscle membrane to 
the transmitter, inducing a 1 subthreshold1 depolarization 
of the muscle fibre. The anticurare activity of a 
cathodal current (Burns Sc Paton, 1951) and the effect 
of externally applied potassium ions can be explained 
on this basis. Conversely, agents raising the membrane 
’threshold*, for example, an anodal current (Paton, 1951), 
will intensify this type of block.
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Depolarizing Muscle Relaxant Drugs,
These achieve their effects primarily hy a 
marked depolarization of the motor end plate in a way 
analogous to the action of acetylcholine itself.
Unlike the tubocurarine-treated muscle, that affected 
by decamethonium is electrically depolarized at those 
regions containing motor end plates. This sets up an 
area of electrical inexcitability at the end plate 
region preventing the generation of potentials to 
excite the adjacent muscle membrane. Evidence from 
experiments describing the development of this effect 
(Burns, Paton & Dias, 1949; Burns & Paton, 1951;
Paton, 1951) in the cat, indicated that the 
depolarization effect was persistent and long lasting, 
but more recent observations have opposed this view 
(Zaimis, 1953; Jenden, Kamijo & Taylor, 1954; Thesleff, 
1955a,£; Axelsson & Thesleff, 1958). These have shown 
that the period of depolarization produced is brief and 
is followed by a rapid and complete repolarization of 
the muscle membrane. Ueuromuscular block commences 
during the period of depolarization and the muscle 
membrane remains insensitive to acetylcholine even in 
the repolarized condition.
The ability of the muscle membrane to undergo
iTABLE I (contd.)
On Cat
9. Effect of 
electric 
current applied 
to the end plate 
region
Anodal current
Cathodal
current
10. Effect on block 
of reduction in 
temperature
Eon-
Depolarizing 
Type Drugs
Depolarizing 
Type Drugs
Intensifies
Block
Lessens Block
Reduction in 
magnitude but 
not of duration 
of block
1 1 . Nature of 
Paralysis
(a) In avian Elaccid 
muscle (Chick
Test)
(b) In hen nerve- Elaccid 
skeletal muscle 
preparation
(c) In frog muscle Antagonism to
contracture 
caused by 
depolarizing 
drugs (Low
Lessens Block
Intensifies
Block
Increase in 
magnitude and 
duration of 
block
Spastic
Contracture 
super-imposed 
on block 
Contracture 
(High Intrinsic 
Activity)
Intrinsic Activity)
TABLE I (contd.)
On Cat
5. Effect of 
administration 
of different 
depolarizing 
muscle relaxants
6 . Indirect 
tetanization of 
the partially 
blocked muscle
7* Effect of ether 
anaesthesia
8 . Effect of
(a) Previous 
tetanization of 
the motor nerve 
(h)Potassium
Non­
Depolarizing 
Type Drugs
Antagonistic
Contraction 
poorly sustained 
(Post-tetanic 
facilitation)
Increased effect 
(potentiation)
Antagonism
Antagonism
(c)Edrophonium Antagonism
(of short
duration)
(d)Neostigmine Antagonism
(prolonged)
Depolarizing 
Type Drugs
Additive
Contraction 
well sustained
No effect or 
antagonism
No effect
No effect or 
slight
potentiation or 
antagonism 
No effect or 
slight
potentiation or 
antagonism 
No effect or 
slight
potentiation or 
antagonism
TABLE I
A comparison of the pharmacological properties 
of depolarizing and non-depolarizing muscle 
relaxants. (After Paton & Zaimis, 1952;
Zaimis, 1959; Van Rossum, Ariens & linssen, 1958).
On Gat
1. Initial excitatory 
effect on skeletal 
muscle
Ron-
Depolarizing 
Type Drugs
Rone
Depolarizing 
Type Drugs
Transient
fasiculations
and increased
twitch tension
2. Varying order of 
sensitivity of 
different muscles 
(see Pages 74 
and 75)
3. Reversed order 
of species 
sensitivity
Both ’red’ 
and ’white’ 
fibres are 
relatively 
sensitive
Rat^Hare, 
TMonkey^Rabbit 
^I,lan>Dog^Cat 
7Hen
, Reduced
sensitivity of 
’red* fibres 
e.g. soleus. 
Increased 
sensitivity of 
’white’ fibres 
e.g. anterior 
tibialis
Hen at Han 
^Rabbit^Dog, 
^Monkey ^  Hare 
^Rat
4. Effect of
administration 
of different 
non-depolarizing 
muscle relaxants
Additive Antagonistic
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repolarization in the presence of a depolarizing 
agent can he explained, it is suggested, by a reversible 
change in the end plate receptors, Meyer (1937), causing 
them to become inert and insensitive to acetylcholine, 
and producing a 1 desensitization block1 (Katz &
Thesleff, 1957$ Axelsson & Thesleff, 1958). In 
consequence, the high ionic permeability of the end 
plate to ions cannot be maintained and conduction is 
impaired. Similar changes in the nature of the drug- 
receptor complex have been observed using high 
concentrations of acetylcholine itself (Katz & Thesleff, 
1957; Axelsson & Thesleff, 1958). Differences between 
the two main groups of neuromuscular blocking agents, 
observed from electrical recording techniques, have 
explained to a considerable extent their overall 
pharmacological activities and their differing responses 
to certain drugs. The major differences in the two 
main types are given in Table I (Paton & Zaimis, 1952).
Interruption of transmission at the neuro­
muscular synapse is not specific to neuromuscular 
blocking agents but is the common property of a 
chemically diverse group of drugs, the particular study 
of which is largely outwith the scope of this thesis.
Of these, drugs delaying the enzymatic hydrolysis of
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acetylcholine - the anticholinesterases - have 
received special consideration and been the subject of 
several reviews (Augustinsson, 1948; Koelle & Gilman, 
1949; Whittaker, 1951, Holmstedt, 1959). The effects 
of botulinum toxin at the neuromuscular synapse (Burgen, 
Dickens & Zatman, 1949) are believed to be largely due 
to a fall in the number of units of acetylcholine 
released by each nerve impulse {Wright, 1955), with a 
consequent reduction in the frequency of the spontaneous 
miniature end plate potential. No alteration in the 
quantal amount of acetylcholine released was, however, 
observed (Brooks, 1956),
Procaine-induced neuromuscular block has been 
ascribed to a diminished release of the transmitter 
substance by each nerve impulse (Harvey, 1939; Poldes, 
1959, 1960), while it is also believed to exert a 
depressant effect on the post junctional end plate 
membrane (Nicholls & Quilliam, 1956; Del Castillo &
Katz, 1957),
The action of these drugs at the neuromuscular 
synapse cannot be utilised in surgery. .
Muscle Relaxants and The Receptor Theory.
It is now generally accepted that 
pharmacologically active agents can be classified as
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specific or non-specific drugs (Beckett, 1956;
Beckett et al. 1956; Ing, 1959), i.e. two main types 
of chemical interference by drugs are envisaged. The 
term, fspecific1, is now generally used to refer to 
the action of those drugs which, by virtue of their 
unique chemical structure, possess the ability to 
react with particular molecular species within cells 
and form relatively stable combinations with individual 
cellular constituents. *Non-specific* drugs, on the 
other hand, depend for their action upon the modification 
of the physicochemical characteristics of living cells 
and so distort the normal sequence of biochemical 
events proceeding within them. In common with all 
attempted biological classifications however, no strict 
line of demarcation separates the two groups. Neuro­
muscular blocking agents are believed to act in a 
structurally specific manner, interacting with 
hypothetical receptors which Impose certain limiting 
spatial and electrical characteristics on drug molecules 
capable of forming complexes with them.
The concept of receptors was first formally 
postulated by Ehrlich, who defined the term as *that 
combining group of the protoplasmic molecule to which 
a foreign group, when Introduced, attaches Itself*
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(Ehrlich 3c Morgenroth, 1910). A similar view was 
inherent in the lock and key analogy of Fischer (1894) 
and in the work of Langley (1906) who, in order to 
explain pharmacological activity, conceived the idea of 
a deceptive substance1, which could be selectively 
altered by curare-like agents (Lucas, 1907). Current 
ideas concerning the nature of receptors, although 
considerably removed from those of Ehrlich, are still 
fragmentary and inferential. Hov/ever, much of the 
most accurate and fundamental information on drug 
action, including the work of Clark (1937), and Ing (1936) 
and in more recent times, the interpretation (Van Rossum 
et al. 1958) of the mode of action of muscle relaxant 
drugs by Ari&ns and Paton (1961), has depended upon a 
tacit acceptance of the receptor theory. More recent 
confirmation of the existence of a receptor has come 
from studies on the enzymatic hydrolysis of acetylcholine. 
These have revealed that certain drugs, including 
acetylcholine and carbaminoylcholine, induce 
neuromuscular block without impairment of acetyl­
cholinesterase activity (Altamirano, Schleyer, Coates 
& Uachmansohn, 1955), their effect being attributable 
to a predilection for a similar cellular entity - the 
postulated receptor.
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Little is known concerning the intimate 
nature of drug receptors. Early workers envisaged 
a fperIterminal network* (Boeke, 1929) or a molecular 
side chain of cellular substance (Langley, 1906), 
complementary in configuration and polarity to those 
drugs vjith Yirhich it combined. This view has not been 
confirmed by recent results obtained from electron 
microscopy (Estable, 1959) and a narrow but distinct 
space (150 to 600 &) between pre- and post synaptic 
structures has been shown to exist* It has recently 
been suggested (Cavallito & Gray, 1960) that a more 
realistic picture of the receptor surface might Involve 
a lattice of anionic groups dispersed in a roughly 
crystal shaped pattern.
Van Rossum and Ariens (1957) considered 
drug-receptor combination to Involve a general 
Interaction of complementary electrical fields of force 
originating in the drug molecule and in the tissue. 
Electrostatic and Van der Yfaals1 forces were assumed 
to play the dominant role and certain specific 
interactions within the general field of force determined 
the potency of a given drug. The relative unimportance 
of covalent bonding in the interaction of neuromuscular 
blocking agents with the receptor Is indicated by the
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reversible nature of the drug-re cep tor combination.
The receptor has also been regarded as being involved 
in an enzymatic energy - transport process (Drill, 1958), 
or as a protein or lipoprotein enzyme with which 
acetylcholine reacts as a coenzyme to release anions 
from a substrate in the muscle-cell membrane (Welsh,
1949)* The possibility that the receptor may 
structurally resemble acetylcholinesterase has also 
been suggested (Roepke, 1937), Although it is well 
established that many drugs act by interfering with 
enzymatic processes, it is dangerous to create the 
generalization that all drugs necessarily do so. 
Consequently, while certain similarities exist between 
the receptor and acetylcholinesterase, for example in 
their common interaction with acetylcholine, the 
combination of neuromuscular blocking agents with 
cholinergic receptors in the post synaptic membrane is 
believed to take place by a non-enzymatic process 
(Mattocks & Holtan, 1949; Jacobi, Stbesz & McIntyre, 
1950; Katz, 1956),
The suggestion has recently been made that the 
receptor need not be envisaged as a discrete physical 
unit but rather as a volume in space or sphere of 
influence, bounded and defined by enzymes, coenzymes
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and metallic ions (Martin-Smith & Reid, 1959). On 
the other hand, another school of thought believe the 
receptor to be a physical unit, possessing definite 
spatial and electrical properties. Attempts have 
been made to predict the molecular shape and electrical 
characteristics of the receptor by a consideration of 
similar features found in biologically active molecules, 
in the belief that the receptor would have properties 
complementary to those of the most active species 
(Pfeiffer, 1948; Ing, 1949; Kimura, Unna & Pfeiffer,
1949; Schueler, 1953). Resulting from this approach 
evidence has accumulated that linear bisquaternary 
ammonium compounds were more potent muscle relaxants 
than the corresponding monoquaternary agents (Barlow & 
Ing, 1948a,b; Paton & Zaimis, 1948a, 1949). This has 
led to the hypothesis that activity in bisquaternary 
and other active molecules (Pelikan & Unna, 1952) could 
be explained by the interaction of optimally spaced 
onium centres approximately 13 to 15 £ apart, with 
equidistant co-reactive groups of a biological 
cholinergic receptor system situated on the motor end 
plate. The concept of pharmacologically 1 bivalent 
molecules* was introduced (Barlow, 1955) to describe 
the action of bis-onium salts, for example hexamethonium,
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in combining with two sets of receptors at the same
time* The complex so formed, it was suggested, would
be twice as stable as that formed by a similar
•univalent* molecule for example, tetramethylammonium,
with one receptor. One end of the I bivalent* molecule
might act as an anchoring mechanism for the other which
would be kept in close proximity to the receptor
surface. It has become evident, however, that a
one-dimensional approach has over simplified the picture
of drug-receptor interaction. The inter-onium distance
in non-rigid molecules has no fixed value, on account
of conformational Isomerism arising from uninhibited
rotations about single car bon-car bon bonds in the
polymethylene chain (Cavallito, Gray & Spinner, 1954;
Macri, 1954). There is therefore no reason to assume
that the thermodynamically most stable conformation of
the molecule is that actually involved in complex
formation with the receptor. The inter-onium distance
in tubocurarine, at the time of complex formation with
othe receptor, formerly taken to be 15 to 15 A, as it
is in the extended conformation of the molecule, is
onow thought to be less (6 to 12 A) due to the molecule 
adopting a folded conformation.
Differences between conductimetrie measurements
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(Rice, 1956, 1958) and statistically calculated 
inter-onlum distances (Gill, 1959) have underlined the 
difficulty of assessing the precise molecular 
conformation participating in any particular drug- 
receptor combination (Cavallito & Gray, I960)*
The adumbration hypothesis (Loewe 3c Havery, 
1952) emphasized the need for a consideration of the 
overall molecular tectonic and bonding potentialities, 
in determining the degree of drug-receptor interaction. 
It ascribed the muscle relaxant potency of drugs to a 
spatial competition with acetylcholine, the adumbrating 
or umbrella-like structure of the molecule hindering 
access to the receptor site by steric interference.
A similar view has been advanced by ?/ien (1954) and is 
inherent In Y/aser’s theory concerning the nature of the 
cholinergic receptor (Waser, 1959, 1960).
The use of rigid molecules appears to offer a 
more accurate means of assessing the physical 
characteristics of drug receptors. Acceptance of the 
view that the characteristics of the receptor may alter 
in response to the presence of drug molecules, as 
suggested In the ’Induced fit* theory (Koshland, 1958), 
a premise of the theory of biological relativity 
(Martin, 1956), has however cast doubts upon the value
(CH3)3 N - /  V- N (CH3)3
2 1
I
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of this approach. In addition, the view that a .
limited degree of flexibility is necessary for activity
in this type of structure (Gill & Ing, 1958; Gill, 1959)
is supported by the lack of ganglion and neuromuscular
blocking activity observed in the rigid molecule of
ITMIPTIfN ?-hexamethyl-j>-phenylenediamine bisiodide (I)
(Wien 8c Mason, 1953)* Quaternary ammonium centres
which are separated by a rigid linking structure,
appear to be unable to yield sufficiently to permit
a close approach to the anionic receptor site. This
characteristic appears compatible only with a
tubocurarine-like action, which, it is suggested, does
not demand a close anionic-cat ionic combination
(Cavallito 8c Gray, 1960).
Other workers have attempted to interpret
pharmacological activity in terms of the 1 identity
distance1 (Long & Schueler, 1954) which is the distance
between peptide bonds in a maximally extended peptide
oand has a value of 3,61 A or, in terms of the distance
between two turns of an cC-protein helix which has a
ovalue of 5,5 A (Corey 8c Pauling, 1953), It is 
interesting to note that the distance 14.5 X postulated 
as the ideal inter-onium distance in bisquatemary 
ammonium neuromuscular blocking agents (Barlow 8c
Ing, 1948b; Paton & Zaimis, 1949) Is 4 x 3.61 £ and 
that the distance between the hydrogen bonding groups 
in oestrogens is approximately 3 x 3.61 A or 2 x 5*5 % 
(Fisher, Keasling 8c Schueler, 1952).
' Experimental evidence, supporting the view that
the receptor is a protein, has been provided by 
Uactugiansohn and his associates (Altamirano, Coates, 
Grundfest 8c Nachmansohp* 1953). Attempts have been 
made to isolate and characterize this protein by complex 
formation with radioactive muscle relaxants using the 
electric tissue of the electric eel. Initially, 
experimental evidence indicated strong, but probably 
unspecific, binding of gallamine to a mucopolysaccharide 
(Chagas, 1959). Subsequent work using a more refined 
technique has, however, led to the successful isolation 
and purification of a protein material (Ehrenpreis, 
1959a,b,1960) which showed many characteristics of 
the in vivo receptor substance especially in its 
ability to bind acetylcholine and muscle relaxant drugs 
(Schoffeniels 8c Nachmansohn, 1957).
Present day concepts of the nature of receptors 
have been considerably clarified by the creation of 
several pictorial representations based on experimental 
results. Such representations, although they may be
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without reality in much the same way as are the 
Kekulels structures for benzene, have stressed the 
value of three-dimensional molecular geometry in the 
drug molecule, including considerations of the position 
and electrical nature of the functional groups.
Examples of such an approach include the work of 
Lands (1951) on the muscarinic receptor, of Beckett 
and his associates (Beckett, 1956; Beckett et al. 1956) 
on the morphine receptor site and, particularly 
relevant to this thesis, the experiments of Nachmansohn 
and Wilson (1951) concerning acetylcholinesterase and 
of Waser (1959, 1960) on the structure of the 
cholinergic receptor. Nachmansohn and Wilson (1951) 
studied the molecular forces associated with the 
physiological activity of acetylcholine by means of 
acetylcholinesterase because of the ready availability 
of this enzyme in a highly purified and stable form 
(Nachmansohn, 1955). Information from an analysis of 
the effective molecular forces concerned in the 
acetylcholinesterase-acetylcholine reaction have been 
used to promote a better understanding of those forces 
involved in other transmitter interactions (Nachmansohn, 
1959b),
From an examination of the uptake of radioactive
I ch3 
/
N ©
x ch3
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muscarone (II) by the diaphragm of the mouse,
(Waser, 1957, 1959), using autoradiographic techniques,
concluded that the cholinergic receptor possessed a
three-dimensional pattern. A similar view had been
previously advanced (Jenden et al. 1954; Taylor, 1955)
in a suggestion that the receptor possessed molecular
sieve properties (Barrer, 1947) rather than a planar
surface arrangement. Prom the results of similar
experiments using radioactive muscle relaxants, Waser
also indicated that the receptor surface was a pore 
o12-14 A in diameter in the post synaptic membrane.
Many problems, however, concerning the intimate nature 
and function of the receptor remain unsolved while its 
postulated existence in sites other than the post- 
synaptic membrane (Riker et al. 1959; Rosenberg & 
Ehrenpreis, 1961) remains virtually unexplored.
Muscle Relaxants and the Theory of Biological Antagonism.
A direct consequence of the receptor theory 
of drug action, and an important factor in the 
establishment of structure-action relationships in 
neuromuscular blocking agents, is the principle of 
biological antagonism. This maintains that a drug 
competes with a natural substrate, or 1 essential 
metabolite1, or perhaps another drug, for the receptor.
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A wealth of experimental evidence from different 
hiological disciplines, Including bacteriology 
(Fildes, 1940; Woods, 1940) and pharmacology 
(G-addum, 1926; Ing, 1936; Clark, 1937), has confirmed 
the significance of this principle in a study of the 
underlying mechanisms of drug action (Work & Work, 1948; 
Sexton, 1949; Woolley, 1952; Albert, 1960).
Investigations of such mechanisms are best 
carried out using isolated organs, when the observed 
effect is mainly attributable to the Interaction of 
the drug under test with the specific receptor system, 
especially if equilibrium conditions prevail. It is 
illogical to consider the results from whole animal 
preparations where complications of distribution, 
transport, breakdown and excretion may affect to a far 
greater extent the overall drug response. On the 
other hand there are some examples where whole animal 
preparations may best indicate the nature of a 
pharmacological phenomenon, e.g. Adrenaline reversal. 
Furthermore, only by means of Isolated preparations 
can the time of exposure of the tissue and the 
concentration of the drug be controlled to a reasonable 
extent.
The concept of biological antagonism has been
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placed on a quantitative basis, by relating the 
measured biological response either to the amount of 
drug absorbed by the receptors or to laws governing 
enzyme kinetics. Experimental observations have 
been given theoretical expression by the derivation 
of a number of equations. All mathematical 
relationships so derived to explain drug action have 
been developed fundamentally from the law of mass 
action, an expression governing thermodynamic equilibria 
in chemical reactions. Biological systems, however, 
do not exhibit true thermodynamic equilibrium but 
exist in a steady state, in which the rates of chemical 
synthesis and breakdown are balanced.
The correlation of pharmacological activity 
to adsorption laws has been based on the mathematical 
equations derived by Freundlich (Clark, 1937) and 
Langmuir (1916, 1917, 1918) on the assumption that the 
degree of biological effect was a linear function of 
the fraction of the receptors occupied by the drug.
This premise has however been contested. The early 
assumptions of Clark (1937) and Gaddum (1937) though 
supported by Rocha e Silva (1957), have been questioned 
by Stephenson (1956), Nickerson (1956), Arlens et al. 
(1957) and Schild (1957), who for different reasons
35
have indicated possible exceptions to its overall 
applicability*
The Freundlich isotherm is unsuitable as a 
theoretical basis for the explanation of drug action, 
since it lacks thermodynamic validity and assumes an 
infinite degree of adsorption, incompatible vfith 
observed biological saturation phenomena. Although 
the Langmuir isotherm (Langmuir, 1916, 1917, 1918} 
has thermodynamic validity, practical difficulties 
arise in determining the concentration in the biophase 
and resort must be made to accepting the concentration 
in the external phase as a near approximation. This 
may invalidate the results obtained, Furthermore, 
in its original form, it is applicable only to 
bimole cular reactions and to unimole cular layers of 
adsorption. Therefore it is perhaps more realistic 
to employ the extended equation of Brunauer and his 
associates (1938), especially as evidence now exists 
that certain drug-receptor interactions may be 
trimole cular (Cavanaugh & Hearon, 1954).
Alternatively, the underlying mechanisms of 
drug action have been correlated to laws governing 
enzyme kinetics. In enzymology the principle of 
biological antagonism has been based on the
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Michaelis-Menten equation (1913), and on more recent 
extensions of this (Lineweaver & Burke, 1934;
Haldane, 1930; Kirschner & Stone, 1951), which were 
derived to explain the interaction of enzymes, their 
substrates and inhibitors. Michaeiis and Menten 
assumed that enzyme and substrate combined to form an 
intermediate complex and by applying the law of mass 
action to this reversible reaction, a relationship was 
obtained which provided an explanation for many 
experimental observations and several theoretical- 
experimental discrepancies (Work & Work, 1948). Since 
the Michaelis-Menten equation dealt specifically with 
enzyme systems, its applicability to non-enzymatic 
mechanisms is not readily apparent. However, the 
relationship established between the biological effect 
and the velocity of an enzyme reaction (Michaeiis & 
Menten, 1913), or the law of adsorption (Langmuir, 1916, 
1917, 1918), can be expressed mathematically in 
identical forms, although the former is a kinetically- 
derived relationship.
Thus equations derived from a consideration of 
chemical reactions, physical adsorption laws, or 
enzyme kinetics, may legitimately be applied to drug- 
receptor interaction. Their identical mathematical
■Ji
form, however, denies any means of distinguishing 
which of the three possibilities is responsible for 
the ultimate mechanism of the drug action.
In more recent years, the concept of biological 
antagonism has been extended to include instances 
where the substrate analogue was itself capable of 
eliciting a response (Chen & Russell, 1950; Purchgott, 
1955). Different degrees of antagonism consequently 
exist (Gaddum, 1957), and several mathematical 
expressions have been derived to explain them (Gaddum,
1937, 1943; Schild, 1947, 1954; Van Maanen, 1950;
Ariens et al. 1957).
For the purpose of this thesis, the explanation 
of the various types of pharmacological Interaction
H * ffdeveloped by Ariens and his associates (Ariens et al.
1957), has been chosen for study and application for 
the following reasons:
(a) The general applicability of the concepts Involved 
to different classes of pharmacological agents (Van 
Rossum & Ariens, 1959a,b,jc).
(b) The particular reference made to muscle relaxant 
drugs (Van Rossum et al. 1958; Van Rossum & Ariens, 1959a), 
offering a basis for Interpreting the intimate mode
of action of these drugs and the possibility of
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establishing the effect of certain molecular entities, 
particularly the ether oxygen function, on muscle 
relaxant activity.
(c) The procedure developed by Ariens and his 
associates, made use of a well known, suitable, 
laboratory preparation - the frog rectus abdominis 
muscle, - for the study of the properties of muscle 
relaxant drugs.
Ariens had been led to a reconsideration of 
the accepted views of biological antagonism by the 
existence of apparent discrepancies encountered during 
a study of certain drugs (Ariens, 1954). In many 
homologous series, certain members apparently possessed 
a dual mode of action, while presumably acting on the 
same receptor. The action of certain metabolite- 
promotor —  metabolite-inhibitor derivatives of 
£-amino benzoic acid (Ariens & Simonis, 1954), the 
mechanism of action of muscle relaxant compounds which 
both depolarized and inhibited depolarization (Raventos, 
1937; Grinzel, Klupp & Werner* 1951a,b,£), and the role 
of certain sympathicomimetics which possessed hyper­
tensive and hypotensive properties (Marsh, 1948) seemed 
paradoxical and inexplicable on the basis of accepted 
views. Ariens suggested an explanation of this dual
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behaviour by relating drug-receptor interaction to 
the two basic constants of affinity and intrinsic 
activity.
The affinity of a drug may be defined as the 
ability to enter into complex formation with a given 
receptor. It is directly related to the dissociation 
constant of the drug-receptor complex (Ariens, 1954), 
and this constant can therefore be used to assign to 
the affinity a numefical value. As defined by 
Ariens (1954), the affinity of a drug is the 
reciprocal of the dissociation constant of the complex 
formed by the drug and the receptor. In more general 
terms, affinity may be conceived as a product of a 
general interaction of electrical fields of force, 
originating in the drug molecule and the receptor 
itself, among which contributions from electrostatic 
and Van der Waalfs forces are prominent (Van Rossum & 
Ariens, 1957)*
The intrinsic activity, on the other hand, is 
a measure of the power of the drug-receptor complex to 
evoke a positive biological response. As originally 
defined (Ariens, 1954), it is measured by the 
proportionality constant a, relating the observed 
biological response to the proportion of receptors
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occupied when equilibrium between the drug and the 
receptor has been achieved. The stimulus to 
cellular activity may result, however, from changes 
in the electrical fields of force accompanying formation 
of the drug-receptor complex, rather than from simple 
static occupancy of the receptors (Paton, 1961),
In consequence, the Ariens proportionality constant 
may be split,Into two components, one being a rate 
constituent for the speed of dissociation of the 
drug-receptor complex as stressed by Paton (1961), 
and indicated by Ariens, and the other being a 
constant Indicating the effectiveness of the Inter­
action (Ariens & Simonis, 1960).
In this way, the intrinsic activity of a 
drug may be due to specific fluxes in the electrical 
fields of force responsible for the formation of the 
drug receptor complex.
Both intrinsic activity and affinity vary with 
the chemical structure, molecular configuration and 
physio-chemical properties of the drug. * In a 
homologous series, therefore, different degrees of 
intrinsic activity and affinity may be observed.
This approach has offered a means of explaining the 
mode of action of those compounds, hitherto
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unconsidered, whose activity fell somewhere between 
those evoking a response, high intrinsic activity, 
and those which induce receptor blockade, low intrinsic 
activity. Varying degrees of drug-receptor 
combination were thus believed to control a wide 
spectrum of pharmacological activity. This view 
permits new compounds to be logically studied on the 
basis of their fundamental mode of action*
All the mathematical expressions represent 
idealized theoretical situations, because of the
ft .simplifying assumptions made in deriving them (Ariens 
e t jal* 1957; Dickerson, 1957). In practice, perfect 
agreement between experimental and theoretical dose- 
response curves is rarely attained and discrepancies 
both in the slope (AriSns e t al. 1956a,b; Cavanaugh 
8c Hearon, 1954; Clark 8c Raventos, 1937; Gaddum, Hameed, 
Hathway 8c Stephen, 1955) and symmetry (Arifens et al» 
1957) have been observed. On the other hand, 
theoretical imperfections have been interpreted in 
several ways, without invalidating the basic 
assumptions. For example, a higher order of reaction 
than bimolecular (Cavanaugh & Hearon, 1954), or a 
difference in the drug concentration in the bath from 
that of the biophase (Furchgott, 1955; Arlfens et al.
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1957), has been suggested to explain the difference 
between the slope of theoretical and experimental 
dose-response curves.
Consequently, while the nature of the 
receptor system with which drugs react at the neuro­
muscular synapse remains hypothetical even today, 
the interaction of drug molecules with it is believed 
to obey certain definite mathematical laws, developed 
on an extended concept of the principle of biological 
antagonism.
The Classification of Muscle Relaxant Drugs.
It Is now apparent that not all compounds 
possessing muscle relaxant properties act by 
identical mechanisms (Zaimis, 1959), although it was 
former practice to group all such drugs together, 
regardless of their site or mechanism of action.
Thus quaternary ammonium bases, pyridine, quinoline, 
aconitine, muscarine and veratrine, were classified 
together as 1curarizing1 drugs though the manner in 
YJhich this effect was achieved varied greatly 
(Santesson quoted by Bovet, 1951). This practice 
has now been superseded by several attempts to 
subdivide muscle relaxants into logical divisions on
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the basis of their common chemical or pharmacological 
properties.
The first of these distinguished two main 
categories the f pa chy cur are s’and the ’leptocurares1 
(Bovet, 1951), The rpachycuraresf consisted of 
bulky molecules which were considered to have a 
tubocurarine-like mode of action, while the long, 
thin, flep to cur ares’ were assumed to act in a manner 
resembling acetylcholine. This stereochemical 
classification has proved unsatisfactory because of 
the lack of demarcation between the two types and 
because of.two quite different modes of action.
Thus several compounds which chemically resemble one 
class, show pharmacological properties befitting the 
other. For example, nicotine, which has a thick 
molecule and might be described as a ’pachycurare* 
causes neuromuscular block by depolarization in the 
cat (Paton, 1951), while tridecamethonium, a long 
thin molecular structure, has a tubocurarine-like 
action in the chicken (Zaimis, 1952).
The method of classification proposed by 
Paton and Zaimis (Paton, 1951, 1953; Zaimis, 1951, 
1952; Paton & Zaimis, 1952), in which neuromuscular 
blocking agents were divided into depolarizing and
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non-depolarizing drugs, has already "been described* 
This classification has been complicated by variation 
in the response of different species (Buttle & Zaimis, 
1949; Zaimis, 1952, 1953; Bigland, Goetzee, MacLagan 
& Zaimis, 1958), and of different muscles within the 
same species, to a particular muscle relaxant drug 
(Paton 8c Zaimis, 1952; Jewell 8c Zaimis, 1954). The 
effective antagonism of anticholinesterases to 
depolarization-block in certain species has stressed 
these difficulties (Bovet, Bovet-Hitti, Guarino, Longo 
8c Fusco, 1951; Su, Kao 8c Karp, 1951). Furthermore, 
the two-phase nature of the block induced by certain 
depolarizing compounds in laboratory animals, (Jenden: 
et al* 1951, 1954; Jenden, 1955) in an isolated Iruman 
preparation (Sabawala 8c Dillon, 1959), and in man 
(Brennan, 1956; Hodges 8c Foldes, 1956), together with 
the observation that their depolarizing effect may 
not account entirely for the block produced 
(Thesleff, 1955a, b,jc), appear outwith the scope of this 
classification*
By a consideration of both the chemical 
structure of the drug and the protein nature of the 
receptor system involved, Foldes (1954) attempted to 
overcome these difficulties and suggested the division
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of quaternary ammonium muscle relaxants into two 
main groups:
(a) Anti-depolarizing agents - e.g. tubocurarine.
(b) Depolarizing agents - e.g. decamethonium.
YJhile those of the first group produced a similar 
type of block in all species, that caused by 
depolarizing agents depended on the nature of the 
receptor protein of the species involved. In birds, 
amphibians and certain mammals (e.g. cat) the 
configuration of the receptor-protein could be altered 
relatively easily and depolarizing agents caused a 
depolarization block. On the other hand, where the 
receptor protein was less prone to configurational 
changes (e.g. monkey), decamethonium caused an 
anti-depolarization block. This classification 
fitted most experimental observations but once more 
appears too rigid to accommodate drugs possessing 
characteristics of either group (Zaimis, 1953), or 
those entirely different from both (Gesler & Hoppe, 
1956a.,b; Winter Sc Lehman, 1950). As a corollary to 
their theoretical treatment of drug-receptor inter­
action in which mathematical constants are translated 
into concepts of affinity and intrinsic activity
(Ariens _et &1, 1956), Ariens and his colleagues 
have utilized the nature of the dose-response curve 
obtained from experiments using the frog rectus 
abdominis muscle as a basis for the classification of 
muscle relaxant drugs (Van Rossum et al. 1958). This 
classification, confirmed by experiments using whole 
animal preparations (Ariens, 1954; Ariens ejb al.
1959a,b), eliminates certain difficulties inherent in 
that of Bovet (Bovet, 1951), while it extends those 
of Paton and Zaimis (Paton & Zaimis, 1952; Zaimis, 1952) 
and Poldes (1954)* In this classification, muscle 
relaxant drugs are considered to belong to three 
principal groups, the depolarizers or cholinomimetics 
having a high intrinsic activity, for example, 
decamethonium, the competitors or cholinolytics 
having a low intrinsic activity, for example 
tubocurarine, and the non-competitors, for example, 
prodeconium, which have an affinity for receptors 
other than those occupied by acetylcholine. The last 
named group may be further subdivided (Linssen, 1961) 
into compounds which are believed to block the 
synthesis of acetylcholine at the neuromuscular synapse, 
for example, the hemicholiniums (Schueler, 1955;
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Reitzel & Long, 1959; Kase 8c Borison, 1958), the 
inhibitors of acetylcholine release, for example, 
botulinum toxin (Ambache 8c Less in, 1955) and magnesium 
ions (Engbaek, 1952), and the anticholinesterases, for 
example, neostigmine (Holmstedt, 1959). This 
classification is not rigid and is based on both the 
molecular properties of the drug and on the inherent 
characteristics of the neuromuscular synapse. It 
recognises that variations in the dose level or 
molecular configuration of a drug may cause gradual 
changes in intrinsic activity and affinity, with 
consequent alterations from one category to another. 
Chemical Structure and Muscle Relaxant Activity in-- - - -■ ■ — ~ 11 1  ^ T 'T ~ - T _l._I ~ ~ Z  \  ~  . _
Synthetic Compounds.
Interest in synthetic muscle relaxants has 
been maintained over the past twenty years and a large 
number of drugs have been synthesized and tested.
The number of new substances reported is so considerable 
that it makes a complete bibliography impracticable 
and the diversity of chemical structures so wide as to 
render difficult the consideration of each individual 
chemical type. While compounds other than quaternary 
ammonium derivatives (Folkers 8c Major, 1937; Berger 8c 
Bradley, 1947), may possess muscle relaxing properties,
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the vast majority of compounds exhibiting this 
type of activity, including virtually all of those 
employed in anaesthesia, are quaternary ammonium 
salts. In consequence, a classification based on 
the quaternary ammonium group would appear to offer 
a logical means of discussing synthetic muscle 
relaxants.
Muscle relaxant activity represents an 
integrated product of many contributory biological, 
physical and chemical factors including accessibility 
of the drug to the site of action, the effective 
concentration which it attains in the biophase and 
the bonding characteristics of the drug-receptor 
complex (Cavallito, 1959). Virtually all quaternary 
ammonium salts of pharmacological interest are 
believed to exert their principal effects by mimicking 
or antagonizing the physiological actions of 
acetylcholine. Many of these compounds exhibit 
different pharmacological properties depending upon 
the concentration, the duration of effect and the 
specific site of action involved. Because they 
ionize completely, quaternary ammonium salts have 
an intense affinity for anionic receptors.
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The apparent absence of a membrane barrier 
surrounding the neuromuscular junction (Couteaux, 1947) 
facilitates access to this site of both ionized 
simple quaternary ammonium compounds and other more 
bulky molecular species as evidenced by the rapid 
onset of action of muscle relaxant drugs.
Consequently, variation in chemical structure may have 
relatively little influence on the potential ability 
of a quaternary ammonium compound to reach the 
anatomical site of action.
The muscle relaxant properties of onium salts, 
first recognized by Crum Brown and Fraser in 1869, 
have been the subject of several reviews, and 
reference may be made to the work of Trendelenburg, 
1923; Alles, 1934; Ing, 1932, 1936; Craig, 1948;
Bovet & Bovet-Nitti, 1948a,b, and references cited 
therein. The association of rather weak muscle 
relaxant properties with more potent cholinergic 
effects in many monoquaternary compounds has virtually 
eliminated the possibility of their clinical use 
(Huguenard & Martin, 1950)* The isolation of 
tubocurarine and the determination of the structure 
of its molecule (King, 1935; Wintersteiner 8c Dutcher,
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1943) revealed the presence of two quaternary 
ammonium groups. Together with the successful 
development of techniques for the clinical use of 
this compound (Bennett, 1941; Griffith & Johnson, 1942; 
Cullen, 1943), a stimulus was provided for the 
preparation and study of drugs whose molecule 
possessed two quaternary ammonium functions. This 
led to the pharmacological Investigation of a large 
number of aromatic and aliphatic derivatives 
containing two onium groups, among which were included 
some of the most active and clinically most useful 
muscle relaxants (Bovet & Bovet-HItti, 1948a,b,
Bovet, 1951; Barlow & Ing, 1948a,b; Paton & Zaimis, 
1948^,5; 1949; Collier & Taylor, 1949). For 
detailed discussions of the chemical and pharmacological 
properties of many of the compounds involved, reference 
may be made to the extensive reports available on 
the subject, a few of the more recent of which are 
cited here (Bovet, 1951; Paton & Zaimis, 1952;
Schneider, 1953; Cheymol, 1954; Papper & De Beer, 
Symposium 1955; Bovet, Bovet-Hitti & Msrini-Bettolo, 
1959; Hachmansohn, Symposium 1959^; Lewis, 196DbJ.
Bisquaternary compounds possess a more intense and 
prolonged neuromuscular blocking action than the
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related monoquatemary derivatives. This may “be 
due to the former possessing a greater ability to 
form bonds, i.e. a greater number of points of 
potential receptor attachment, producing an increase 
in the potential bonding energy of the drug-receptor 
complex. The design and investigation of 
polyquaternary derivatives containing three or four 
nitrogen functions was thus undertaken in the belief 
that a high degree of activity would be conferred by 
virtue of their being reactants with a polymeric 
hypothetical receptor system (Kensler, Langemann & 
Zirkle, 1954a; Kensler, Zirkla, Hatallana & Conduris, 
1954b; Edwards, Lewis, Stenlake 8c Zoha, 1957, 1958a,b; 
Carey, Edwards, Lewis & Stenlake, 1959; Edwards, 
Stenlake, Lewis & Stothers, 1959, 1961). In many of 
the most active polyquaternaries, the ratio of 
lipophilic to hydrophilic groupings is comparable to 
that of many active bisquaternary derivatives 
(Cavallito 8c G ray, 1960). This suggests that the 
enhanced potency of many bisquaternary muscle relaxant 
compounds may be due to these molecules having 
attained an optimum compromise between lipophilic and 
hydrophilic molecular bonding functions.
Introduction of hetero-atoms into the onium
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substituents may cause changes in the overall size 
and configuration of the molecule. This may also 
alter the cationic charge distribution, the secondary 
bonding characteristics of the compound and its 
ability to take up molecules of water. Among the 
most interesting molecular constituents associated with 
the quaternary ammonium moiety in many muscle relaxant 
compounds, is the ether oxygen function. Interest 
in this, originating from the muscle relaxant 
properties of diethyl ether itself (Auer So Melizer,1914), 
has been maintained by the presence of the ether link 
in tubocurarine (King, 1935) and other clinically 
useful, similarity acting drugs (Bovet, Depierre Sc 
De Lestrange, 1947; Collier, Paris Sc Woolf, 1948;
Collier, 1952; Levis, Preat Sc Dauby, 1953). Ether 
anaesthesia has also been observed to potentiate the 
muscle relaxant activity of non-depolarizing drugs 
(Foldes, 1959’:, 1950, and references cited therein)*
The ether link provides a valency angle (110° in 
diphenyl ether) approximately similar to that of the 
carbon-carbon link (109°28T), while replacement of a 
-C-C-C-chain by a -C-O-C-chain reduces chain length 
only slightly, (0.13 £) when extended conformations are 
compared. An oxygen atom may thus be interposed in
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an alkane chain without major stereochemical 
disturbance (Sexton, 1949). On the other hand the 
lone electron pairs on the ether oxygen atom confer 
polar properties and such molecules are capable of 
orientation at lipid-aqueous interfaces, for example, 
cellular membranes. Polar characteristics may also 
significantly affect the molecular lipophilic- 
hydrophilic ratio,altering the biological effect by 
influencing the ability of the drug to reach the 
hypothetical receptor site. Furthermore, a compound 
which is predominantly hydrophilic is also often 
hydrated and although quaternary ammonium functions 
themselves are believed to be non-hydrated, the 
presence of polar substituents may confer this 
property to the overall molecule. Polar groupings 
may thus be principally concerned with the distribution 
of the compound between 1 sites of activity* and ?sites 
of loss* and numerous examples indicate the reduced 
muscle relaxant potency of predominantly hydrophilic 
molecules (Barlow & Ing, 1948a,b; Hohmann 8c Jones,
1954; Thesleff 8c Unna, 1954).
The ability of the molecule to form Van der 
Waalfs bonds may also be influenced by the polar-
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conferring properties of the ether oxygen function.
These short, weak, secondary bonding structures 
contribute appreciably towards maintaining the 
stability of the drug-receptor complex. Moreover, 
hydrogen bonding between the drug molecule and 
certain hydrogen atoms, which may be located near the 
site of drug activity, may be made possible by the 
presence of the ether link. Formation of hydrogen 
bonds has often been shown to have a deleterious 
influence on muscle relaxant activity (Phillips, 1952, 
1955; Karczmar & Howard, 1955).
The ether oxygen link may also modify the 
distribution of the electrostatic charge on the onium 
centre itself (Taylor, 1951). Thus the inclusion of 
an oxygen atom to form a morpholine ring may reduce 
the electrical charge concentration on the onium 
group and reduce the potency of the compounds compared 
with that of their piperidine analogues (Cavailito,
Soria 3c Hoppe, 1950; Hazard, Cheymol, Chabrier, 
Corteggiani, Muller 3c Gay, 1953; Hazard, Cheymol, 
Chabrier, Corteggiani, Muller & Bourillet, 1954). 
Concentration of electrical charge on the onium group 
is generally favourable to activity in both depolarizing
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(Hiker, Roberts,'Reilly & Hoy, 1954) and non­
depolarizing drugs (Taylor, 1951).
From these considerations it might be expected 
that the presence of the ether oxygen function would 
unfavourably modify muscle relaxant potency.
Increased polarity, alterations in the charge 
distribution and bonding propensity of the molecule 
may, however, be offset by increasing the lipophilic 
bulk of the onium centres themselves or by increasing 
the length of the inter-onium chain. In consequence, 
changes in the intensity of activity induced by the 
presence of the ether oxygen are often subtle rather 
than dramatic. Detailed consideration of several 
of these changes occurring in synthetic muscle 
relaxants will now be given.
Monoquaternary Derivatives.
Few monoquaternary ether-containing derivatives 
possess muscle relaxant properties although simple 
alkoxytrimethylammonium salts (Rogers, Bovet, Longo 
& Marini-Bettolo, 1953) and several phenolic ether 
derivatives of choline (Rosnati, Angelini-Kothny,
1958; Winter & Lehman, 1950; Bovet, Depierre, 
Courvoisier & de Lestrange, 1949) are reported to
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possess this characteristic. The predominance of
cholinergic properties (Hey, 1952; Buchel, Guyonneau
!*
& Levy, 1957) in mono quaternary compounds is in 
keeping with similar pharmacological features generally 
observed in analogous non-ether derivatives. It is 
interesting to note that (-)-coclaurine (III), which 
closely resembles half the molecule of tubocurarine 
(IV, R = H), possesses no neuromuscular blocking 
activity in dogs,in doses up to 1 mg (Finkelstein, 1951).
Bisquaternary Derivatives.
Of those naturally occurring compounds which 
have now been chemically synthesised, tubocurarine 
itself, (IV, R = H) possessing two ether linkages, 
is the most outstanding (King, 1935, 1948; Wintersteiner 
& Dutcher, 1943). .
The (-)-isomer is virtually inactive on the 
rat (King, 1946). The isomeric (+)-chondocurarine (V) 
which differs from tubocurarine solely in the position 
of the methoxyl and hydroxyl substituents is 
approximately three times more potent on the rabbit 
than the latter (Wintersteiner, 1959). Tubocurarine 
dimethyl ether (IV, R « CH3 ) (Collier et aJ.. 1948; 
Collier & Hall, 1950) in which the phenolic groups of
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tubocurarine are converted to the methyl ethers, 
possesses similar qualitative properties to the '
parent compound* Quantitatively, potency varies 
considerably with the animal species employed. 
Tubocurarine dimethyl ether is reported to be more 
potent than tubocurarine itself on the monkey, rabbit, 
rat and in the human being but only equipotent on the 
mouse (Wintersteiner, 1959; Swanson, Henderson & Chen, 
1949). On the frog rectus abdominis muscle preparation, 
Tinder conditions which reduce the ionization of the 
phenolic groups (low pH), tubocurarine is more potent 
than its dimethyl ether (Kalow, 1954)• Increase in the 
size of the ether-containing alkyl radical generally 
reduces potency. Only the diethyl ether is more 
potent than tubocurarine while the di-n-butyl and 
the dibenzyl derivatives show a marked reduction in 
potency. The synthesis and investigation of 
molecules, the relaxant potency of which was comparable 
to that of natural products, initially involved 
aromatic nuclei containing ether functions either in 
the nucleus itself or in the interconnecting alkane 
chain. The preparation of these and other related 
compounds was inspired by the occurrence of similar
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molecular features in tubocurarine (Bovet & Bovet- 
Nitti, 1948a,b; Bovet, 1951). Many of these compounds 
were structurally complex, containing bulky ring systems 
with several substituents. Increasing molecular 
complexity rendered the correlation of changes in the 
biological response with specific physicochemical 
variables more difficult. Consequently, it is difficult 
to establish the precise role of the ether oxygen 
function in compounds of this type.
Among the most active products from this series 
of investigations were the decamethylene bis- 
tetrahydroisoquinolinlum derivatives (Collier 6c Taylor, 
1949; Taylor & Collier, 1951, 1952; Taylor, 1952). Of 
these, the N-methyltetrahydro derivatives were appreciably 
more active than the isoquinolinium analogues, 
indicating the favourable influence of concentration: 
of electrostatic charge on the onium nitrogen atoms 
for high muscle relaxant activity. 6,7-di- and 
6,7,8-tri-methoxy substituents on the benzene ring 
markedly enhanced the activity of the 
tetrahydroisoquinolinium derivatives, possibly by 
enhancing the lipophilic characteristics of the molecule. 
Of these compounds, salts of decamethylene-a,w-bis-
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|~1" (51>4f-dimethoxybenzyl)-l,2,3,4 - tetrahydro - 
6,7 - dimethoxy -2 - methy 1 1 soquino 1 incT] , (laudexium) 
were among the most important. This drug is a 
clinically useful (Bodman, 1952), long acting, 
muscle relaxant (Collier & Macauley, 1952) which 
has predominantly non-depolarizing properties.
Another related, non-depolarizing compound with a 
prolonged duration of action is reported to he seven 
times more potent than suxamethonium (VI) (Collier, 
Gladych, Macauley 8c Taylor, 1958). Although 
investigations were initially concerned with the 
design of compounds possessing features characteristic 
of tubocurarine, neuromuscular blocking activity is 
not confined to complex quinoline or isoquinoline 
structures hut is also the property of simpler 
molecules. Among ether-containing drugs of this 
type* the bisquaternary aromatic amines described by 
Bovet and his associates, for example bis-(2,2f- 
trimethylaminophenoxy)-l,5-pentane diiodide (VII), 
were as potent as tubocurarine Itself (Bovet, 
Courvoisier, Ducrot & Horclois, 1946, 1947).
Inclusion of the onium moiety as part of a piperidine 
ring system has also been reported to produce active
CH* —  a / CH> e
CH2-O CH2-CH2- N - C 2H5 21
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compounds (VIII; Fisher & Keasling, 1956, 1958) 
showing characteristics of both depolarizing (n^l 2 ) 
and non-depolarizing (n^l 2 ) muscle relaxants 
depending on the length of the inter-onium chain.
Other unsymmetric piperidine, hisquaternary, ether- 
containing compounds for example (IX) possess low 
muscle relaxant activity (Elpern, 1954). That the 
presence of the ether oxygen link may increase the 
potency of such compounds has been suggested by Pradhan 
and his associates who investigated several closely 
related di-n-butyl and dibenzyl piperidinium 
derivatives (Pradhan, Hay, Varadan & De, 1954).
, A number of hydroquinone di-ethers have also
been prepared and tested for muscle relaxant properties 
(X). A bibliographic summary and table including 
structural variations in these compounds have been 
provided by Bovet (1959). While no attempt has been 
made to evaluate the contribution of the ether oxygen 
function in these molecules, there is no evidence to 
suggest that muscle relaxant potency is enhanced by 
Its presence. Maximum activity was observed when 
the inter-connecting chain length was 12-15 atoms 
(Bovet, 1958). Among lower analogues (n= 2; R = CH3 ),
% N -(c H 2) n—  (cH 2) n—  *
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potency was low but replacement of a methyl by an 
ethyl group on each quaternary nitrogen group enhanced 
activity (Winter 8c Lehman, 1950). Modification;., in 
the activity of these compounds produced by alteration 
in chemical structure is influenced by species 
variation, which minimises the value of conclusions 
drawn from different literature sources concerning 
related compounds. The ortho and meta compounds 
(n = 2 ; R = C^H^) are more a c 't^V 0 *than the corresponding
r *
para derivatives (Bovet, 1951) while the corresponding 
bis-dimethylethyl ortho derivatives Diethamine (n = 2) 
and Dipropamine (n = 3) have also potent muscle 
relaxant properties (Winter 8c Lehman, 1950) and have 
been clinically investigated (Hunter, 1953a).
Variations in the basic hydroquinone structure have 
produced compounds possessing different degrees of 
activity. The insertion of a p,p>!-biphenyl (XI) centre 
moiety in which R = CH3 and n = 2 yielded a compound 
with slightly increased activity compared with the 
reference compound, (Bovet e t al. 1947; Levis et al. 
1953) while extended ether structures (Funke, Engeler, 
Jacobs 8c Depierre, 1949), for example p-xylylene-bis- 
(jj-trimethylammonium phenyl ether) (XII), also possess
appreciable activity (Funke, Krucker & Depierre, 1950). 
Ether-containing bisquaternary compounds have 
contributed to the development of the supporting moiety 
theory (Cavallini, Costa, Ferrari & Massarani, 1954; 
Cavallini & Massarani, 1959). This contends that 
pharmacologically active molecules consist of a radical 
moiety, which controls the type of biological activity 
exhibited,together with a supporting moiety which 
confers affinity for the site of activity. It is 
interesting to recall the analogy of the 'haptophore- 
toxiphile1 relationship conceived for the process of 
conferring immunity by Ehrlich. The value of the 
anchoring fhaptophore* group in enabling the active 
•toxiphile1 to be effective bears an obvious resemblance 
to the present day concept of a supporting moiety, as 
a contributory factor in explaining drug action. 
Experimental support for the supporting moiety theory 
has been provided by the investigation of activity in 
certain steroidal quaternary derivatives (Cavallini 
& Massarani, 1951) and in certain ether-containing 
quaternary derivatives of stilboestrol, hexoestrol 
and diphenylethane (Cavallini et al* 1954). The 
combination, in the latter compounds, of the
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‘stripped down1 (Gero & Reese, 1956; Gero & T/i throw, 
1 9 5 7 ) drug molecule or radical moiety, the quaternary 
ammonium group, and the supporting stilboestrol, 
hexoestrol or diphenylethane ether moiety produced 
drugs with high muscle relaxant activity.
Other structurally related ether-containing 
compounds investigated for neuromuscular blocking 
activity have included derivatives of biphenyl 
(Bovet ^t al. 1947; Levis et al# 1953) and dienoestrol 
(Hazard et al. 1954). Although muscle relaxant 
activity is a common feature of these drugs, the 
precise contribution of the ether oxygen function has 
not been evaluated. Interest has also been aroused 
in certain pyridazine ether-containing compounds 
(Steck, Brundage & Pletcher, 1954; Gesler & Hoppe, 1956) 
(XIII; n = 2 or 3) reported to exert their muscle 
relaxant effect by a presynaptic blocking action 
(Gesler, Lasher, Hoppe & Steck, 1959)* This effect 
is markedly influenced by the frequency of stimulation 
employed. The role of the ether-oxygen function in 
influencing muscle relaxant activity in certain 
phenolic ethers has been more fully investigated by 
Bovet (1951)9 who observed a similar curarizing
XGZ
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potency on the rabbit for certain ether and non-ether 
containing compounds (XIV). In derivatives of this 
type, therefore, the ether oxygen function is 
relatively unimportant. Pursuit of these studies led 
this school to investigate the effect of combining 
both ether and ester functions in the same molecule,
(Rosnati & Puschner, 1957) but no obvious advantage
vjas achieved (XV) I Rosnati, Angelini-Kothny & Bovet, 1958).
The difficulty of assessing the effect of the 
ether oxygen function in aromatic compounds is increased 
by the complexity of such structures and by the numerous 
Influences on overall biological activity contributed 
by resonance, steric hindrance and other factors 
previously discussed in this thesis. In view of this, 
a study of aliphatic ether-containing muscle relaxants 
appeared to offer a more useful means of further 
Investigation of this problem. The structure of 
many of these compounds has been based on that of 
decamethonium and consists of the Insertion of one or 
more ether linkages into the polymethylene chain 
linking two quaternary ammonium groups. The quantity, 
and the diversity of structure of the molecules 
investigated is considerable and a biblographic summary
©
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and structural table of many of the variants
Involved has been provided by Bovet (1959). Maximum
muscle relaxant activity is observed when the
interconnecting chain length comprises 11-16 atoms.
This Is longer than observed In the non-ether
analogues (Paton & Zaimis, 1949; Barlow 8c Ing, 1948b)
and reflects the reduction In the effective chain
length and the polar characteristics associated with
the presence of the ether oxygen function. The former
oconsideration alone (0*13 A) can hardly account for 
the marked reduction In potency observed by the 
introduction of one ether oxygen function in compounds 
of this type (Hay, Kohli 8c De, 1957). Among an 
extensive series of monoethers studied by Levis and 
her associates (XVI) (1953) and others (G.P.847000/1952; 
G.P.921,267/1954), appreciable short-acting muscle 
relaxant properties were observed, which increased 
with increase in the length of the polymethlene 
chain (n). Heplacement of methyl (R = CH3) by ethyl
(R = ^2^ 5  ^ radicals did hot significantly affect 
potency but increase in the size of the onium 
substituents beyond the ethyl derivative was claimed 
to increase the activity of these compounds (Pradhan^
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et al* 1954). The most active member, oxydipentonium 
(n - 5), has been successfully used in certain surgical 
procedures (Levis et al. 1952: Mundaleer, 1952; 
Montemartini, 1956).
Ganglion blocking activity associated with 
non-depolarizing muscle relaxant activity has also 
been observed in a series of bisquaternary, branched 
alkyl ethers (XVII) (Lenke, 1957). It is apparent 
from these considerations that the introduction of one 
ether oxygen function into straight chain, bis-onium, 
polymethylene derivatives reduces muscle relaxant 
potency. Introduction of a second ether function 
appears to reduce potency further and the alteration 
in total chain length is again disproportionate to the 
observed fall in potency (Thesleff & Unna, 1954). In 
compounds of the general type shown (XVIII), neuro­
muscular blocking potency (Girod 6c Hafliger, 1952) is 
not primarily related to the overall inter-onium 
chain length but to the middle part (n) and to a : 
lesser extent to the onium substituents (R). While R 
is ethyl and n is 1 0 , potency is not significantly 
influenced by the value of m (2,3 or 4), a simultaneous 
increase in the value of m and a decrease in the value
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of n reduces potency to a marked degree. The 
position of the ether oxygen in the chain may thus 
appreciably influence the activity of compounds of 
this type. Weak muscle relaxant properties have also 
been observed with lower, ethyl homologues (m =2 , 
n ■ 2,3,4) (Vanecek & Votava, 1955). Hazard and his 
colleagues (Hazard et al. 1953), investigating analogous 
compounds in which m and n were 2 , found the order of 
potency, in relationship to the cationic head 
substituents, to be least favourably influenced by the 
ether-containing morpholine group. The derivative 
in which m = 2 and n s 4, possessed potent cholinergic 
properties (Marsh & Herring, 1951). Muscle relaxant 
activity has also been reported in related quaternized 
ether-containing triamines (G.P.848,825/1952) and in 
certain quaternary ammonium polymers derived from 
alkyl vinyl ethers (G.P.1,005,273/1957). The
combination of an ester and an ether function in the 
one molecule has produced an active muscle relaxant of 
short duration, which has been used clinically (Prey, 
1955; Hunter, 1959). In this compound, prodeconium 
(n = 1 0 , m = 2 ), one methyl group on each nitrogen atom 
has been replaced by a propyl acetate moiety. It
(CH3\ S  -  O -  (CH2) n- 0  —  S ( c H3) :
m 21
R2 N -  (CH^)n
V
° ©
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produces a 'mixed1 type of block more closely related 
to tubocurarine than to decamethonium (Rendell-Baker,
& Foldes, 1957; Barbieri, Lodi & Malaguti, 1958), 
Polymethylene bis-(oxytrimethylammonium) 
derivatives (XIX n = 5*6 and 10) show anticholinesterase 
activity only (Palazzo, Rogers & Marini-Bettolo, 1954) 
while the polymethylene bis-(H-oxides) (XX n = 2 - / 2 )  
are devoid of muscle relaxant properties (Jerchel &
Jung, 1952). 'Decamethonium dioxide1 is similarly 
inactive (Hano, Wilimowski & Gieldanowski, 1958).
Polyquaternary Derivatives
From a series of fi-hydroxyethyltriethylammonium 
ethers synthesized and investigated by Bovet and his 
associates (XXI) (Bovet et al* 1947, 1949), gallamine, 
1 ,2 ,3 , tris-(p-triethylammoniumethoxy) benzene triiodide, 
v/as observed to possess the most potent tubocurarine- 
like muscle relaxant properties (Jacob & Depierre, 1950; 
Bovet & Bovet-Ritti, 1948a,b; Riker & Y/escoe, 1951;
Wien, 1948) and has proved a clinically valuable drug 
(Doughty & Ytylie, 1946; Mushin, Wien, Mason &
Langston, 1949).
The presence of a third quaternary ammonium 
function in the molecule, it was suggested (Riker &
c,h5 ch2-ch 2- o  - ch2-ch2-n  (c2hs)3
X NX
ch3x ch2- ch2- o  - ch2- ch2- n (c2h5)3
XXII
©/ ^ch2- ch2- o  - c h 2-ch 2-  N(C2Hs)_
® /  ©/ . 
c2h5 n — ch2- ch2- o - c h 2- c h 2- N(c^ls)
\ , ch2- c h 2- o - c h 2-c h2-n (c2hs)3
XXIII
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YJescoe, 1951), might modify the freedom of rotation 
of the other two side chains attached to the aromatic 
ring* In this way, the two terminal nitrogen groups 
may he kept at an optimal interatomic distance for 
muscle relaxant properties (Cavallito, Schliepor & 
0 !Dell, 1954; Hohmann & Jones, 1954). Pew aliphatic, 
polyquaternary ammonium,ether-containing compounds 
have however heen prepared. Vanecek and Votava (1955) 
prepared and investigated for muscle relaxant activity 
one tris-ammonium (XXII) and one tetra-ammonium (XXIII) 
ether-containing compound. Both were reported to 
possess weak muscle relaxant properties, the former 
"being slightly more potent than the latter. In neither 
case was the corresponding non-ether analogue 
investigated nor was any attempt made to evaluate the 
contribution of the ether oxygen function to the 
biological activity of the compound.
It is apparent from the literature cited, that 
many synthetic aromatic and aliphatic ether-containing 
derivatives possess muscle relaxant properties to a 
greater or less degree. It is equally apparent, 
however, that few attempts have been made to evaluate 
the contribution of the ether link to the observed
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biological effect and a study of the pertinent 
literature has underlined the existence of this 
problem rather than contributed to its solution.
A precise assessment of the part played by the ether 
oxygen link is made even more difficult, since different 
workers have employed different preparations and species, 
while analogous non ethers have seldom been tested under 
similar conditions. The compounds in a series of 
aliphatic, bis-choline ethers possessing ganglion 
blocking properties, which were synthesized and tested 
by Pakstorp and his associates (1953, 1954a,b,_c, 1955, 
1956, 1957a,b,_c), were reported to act by means of 
the attachment of one quaternary ammonium group to the 
receptor. It was deemed worthwhile to investigate the 
possibility of applying this hypothesis to neuromuscular 
blocking activity in certain of these compounds. While 
onium salts other than those of nitrogen have been of 
relatively little pharmacological interest, several 
investigations have been concerned with sulphur- 
containing derivatives. Early investigations described 
the reduced nicotinic activity of methylated onium 
salts of sulphur (Hunt & Renshaw, 1925) their weaker 
paralyzing effects being related to the larger radius
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of the sulphur atom (Ing & Wright, 1933) and to a 
reduction in the concentration of the cationic charge.
The sulphonium analogue of acetylcholine is much weaker 
than the parent compound (Prelog, Juhasz, Rezek &
Stern, 1942) while the insertion of two sulphur atoms 
into the molecule of suxamethonium (Della Bella,
Villiani & Zuanazzi, 1956) markedly reduced the potency 
hut not the type of muscle relaxant activity. Similarly, 
the disulphonium analogue of. decamethonium was less 
active than the parent compound while the ammonium^ 
sulphonium derivative ivas intermediate in potency 
(Y/alker, 1950). 5,6-Dithiadecamethylene- 
histrimethylammonium diiodide is reported to possess 
properties qualitatively and quantitatively similar 
to those of decamethonium (Hunter, 1953b). Replacement 
of nitrogen hy sulphur in several bis-onium ether 
compounds did not alter muscle relaxant potency 
(Vanecek & Votava, 1955). The evidence suggests, 
therefore, that the replacement of nitrogen hy sulphur 
in his-onium muscle relaxants has no advantageous 
effect on potency and seldom alters their qualitative 
pharmacological behaviour.
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Purpose of Research.
The work described in this thesis was 
undertaken to investigate the basic pharmacological 
mode of action of several new synthetic muscle relaxant 
drugs with a view to investigating, where possible, 
structure-action relationships among them. In this 
respect, particular attention was paid to the 
contribution to muscle relaxant activity, of the ether 
oxygen function, the effect of altering the length of 
the polymethylene chain, the number and nature of 
the onium centres present in the molecule and the 
nature of the alkyl substituents on the onium centres. 
Consequently a number of straight chain, polymethylene, 
poly quaternary ammonium compounds several of which 
contained one or more ether functions was investigated 
for muscle relaxant activity on both Intact animals 
and isolated tissue preparations. Several corresponding 
non-ether containing compounds were similarly tested.
In addition,three sulphonium analogues of decamethonium 
were examined for muscle relaxant activity. The 
effects of these compounds on the cardiovascular 
system and on ganglionic transmission were also observed.
Pharmacological investigations In the field
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of muscle relaxants have been Increasingly concerned 
over the past decade with placing the basic mode of 
drug action on a fundamental mathematical basis.
tfThe work of Paton (1961) and of Ariens and his associates 
(1957) has already been referred to and the systems 
of classification of muscle relaxants devised by the 
latter workers described (Van Rossum et al. 1958).
This procedure could, it was believed, logically be 
applied to investigate the contribution of the ether 
oxygen function and the effect of other molecular 
features on the activity of the compounds concerned 
based on the concept of drug-receptor interaction. 
Furthermore,this approach appeared to provide a simple 
method of distinguishing muscle relaxants of potential 
clinical value from those with little or no clinical 
value thus eliminating the considerable sacrifice of 
life entailed in the standard screening procedures 
adopted for drugs of this class. Consequently,an 
additional examination of the compounds described and 
others was made on the basis of their affinity and/or 
intrinsic activity values, using the frog rectus 
abdominis muscle preparation described by AriSns (1954}; 
and a correlation made of these results with those 
obtained using more conventional methods.
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EXPERIMENTAL METHODS
Experiments Using Cats,
In all these experiments, cats of either sex 
weighing between 2.0 and 5,0 kg were used. Anaesthesia 
was induced by intraperitoneal injection of sodium 
pentobarbitone solution (50-60 mg/kg). To facilitate 
the application, when necessary, of artificial 
respiration, the trachea was cannulated, the amount of 
air entering or leaving the cannula being controlled by 
an adjustable sleeve. The external jugular vein on 
one side was exposed, freed from connective tissue and 
a heparinised polythene cannula inserted with its 
pointed end towards the heart. The cannula was then 
connected by means of rubber tubing to a 50 ml burette 
containing normal saline solution. Drugs under 
investigation, dissolved in normal saline solution, 
were administered by means of a 1 ml graduated 
tuberculin syringe, injection being made into the 
rubber tubing connecting the burette and the jugular 
vein cannula. Each dose of drug was washed in by 
a suitable volume of saline (5 ml).
The Cat Gastrocnemius Muscle-Sciatic Nerve Preparation.
Cat skeletal muscle is characterized by a
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marked colour differential into two main groups of 
fibres and thence into three main types of muscle 
(red, white and mixed): '
(a) Red or slowly contracting fibres, e.g. soleus 
muscle. These are generally very resistant to 
depolarizing drugs (Paton & Zaimis, 1951; Jewell & 
Zaimis, 1954).
(b) White or more rapidly contracting fibres, e.g. 
anterior tibialis. These are relatively very 
sensitive to depolarizing drugs (Paton Sc Zaimis, 1951). 
Both types of fibres are sensitive to non-depolarizing 
drugs.
The gastrocnemius muscle consists predominantly 
of white fibres though a minority of red fibres are 
also present (Denny-Brown, 1928-29). It was chosen 
for these experiments since it combined the 
characteristics of both types of muscle fibres and 
thus appeared to offer the most accurate means of 
assessing the overall biological effect of muscle 
relaxant drugs on mammalian skeletal muscle. Further­
more, use of this muscle would, it was believed, be 
advantageous if the compounds under review were 
observed to possess clinical potentialities. The
Fig. 1. The cat gastrocnemius muscle-sciatic 
nerve preparation.
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preparation,similar to that described by Bulbring and 
Burn (1942), may be used to investigate both the 
qualitative effects of neuromuscular blocking agents 
and semi-quantitatively to compare the potency of new 
drugs with that of tubocurarine or de came thonium.
The animal having been prepared as described, 
one leg was arranged for indirect stimulation of the 
gastrocnemius muscle via the sciatic nerve. The leg . 
was held with its long axis perpendicular to the 
operating table and rigidly fixed by means of two 
clamps, one at the knee joint, and the other at the 
ankle , aa shown (Pig. !)• The gastrocnemius muscle was 
partially freed from surrounding tissues and the 
Achilles tendon severed at a point near to its insertion
,j ■
In the calcaneus. A strong linen thread was then 
sewn through the central end of the tendon and the free 
end of the thread led over pulleys and attached to a 
Brown-Schuster myograph lever, the writing point of 
which was adjusted to record the muscle contractions on 
a moving smoked surface. By means of an incision made 
through the skin covering the lateral aspect of the 
thigh, the sciatic nerve was exposed between the 
hamstring muscles and a pair of shielded platinum
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electrodes placed around it. The nerve was then 
stimulated supramaximally, using a Dobbie-Mclnnes 
square-\mve stimulator, at a frequency of 6 -8/min, at 
10 to 20 V and using a pulse width of 2*0 to 3.0 msec.
The stimulation and the tension on the gastrocnemius 
muscle (usually 0*2 - 0*3 kg) remained constant during 
any one experiment.
Recording The Blood Pressure Of The Anaesthetized Cat*
In these experiments, one of the common carotid 
arteries, on the opposite side of the neck from the 
cannulated jugular vein, was freed from the surrounding 
tissues and ligated as near the cephalad end as possible. 
A 1bull-dog* clip was placed around the artery, distal 
to the ligature and a heparin-filled glass artery 
cannula inserted into the artery with its pointed end 
towards the heart. The cannula was then connected to 
a mercury manometer by rubber tubing which was filled 
with heparinised normal saline solution as an 
anticoagulant. The pressure in the mercury manometer 
was set at approximately 1 2 0 mm of mercury to maintain 
equilibrium against the blood pressure of the animal.
The ,bull-dog* clip was then released and the blood 
pressure recorded on a smoked surface.
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The Nictitating Membrane Preparation,
The jaws of the animal were tied firmly over 
a brass rod which was clamped to two uprights fixed 
to either side of the operating table. This maintained 
the head in a rigid position throughout the recording 
of the contractions of the nictitating membrane.
The animal was then prepared as previously described.
By means of a fine needle, a linen thread was passed 
through the midpoint of the margin of the nictitating 
membrane of the right eye and tied firmly into place.
The thread was then pulled forward and to one side 
making an angle of about 30° with the long axis of the 
cat. It was led around pulleys and attached to a 
frontal-point writing lever and the contractions of 
the nictitating membrane recorded on a moving smoked 
surface.
The right cervical sympathetic chain was now 
dissected free from the combined vago-sympathetic 
trunk and ligated at as low a point as possible in the 
neck. The cervical sympathetic chain was severed 
just above the ligature, placed on a pair of platinum 
electrodes and kept moist with normal saline solution. 
Contractions of the nictitating membrane could now be
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elicited by stimulation of the cervical sympathetic 
nerve for short fixed periods of time (15 seconds each 
minute), at a frequency of 800 to 1200/min, at 8 to 15 V, 
the pulse width being 0.5 msec to 1.0 msec. A 
Dobbie-Mclnnes square wave stimulator was used. These 
values remained constant during any one experiment. 
Having obtained standard, reproducible responses from 
the nictitating membrane by stimulating the nerve trunk, 
the drugs under investigation were injected into the 
external jugular vein, one minute prior to the next 
period of stimulation.
Stimulation of the cervical sympathetic nerve 
chain reaches the nictitating membrane across the 
synapses of ganglion cells in the superior cervical 
ganglion. The nictitating membrane has no vagal 
(parasympathetic) innervation and can be used for the 
detection and estimation of sympathetic ganglion block. 
Therefore, if the drug under test possessed sympathetic 
ganglion blocking activity, a reduction in the height 
or elimination of the contraction of the nictitating 
membrane would be expected.
To record the effect of drugs on the respiration of the 
anaesthetized cat and rabbit.
Respiratory movements were recorded in the cat
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by means of a thread sewn into the skin of the 
epigastrium at a point along the midline. This thread 
was then led over pulleys and attached to a frontal- 
point writing lever. The common carotid artery on one 
side was used to record the blood pressure of the animal. 
After a record of the normal respiratory movements had 
been obtained, the drug under test, dissolved in normal 
saline solution, was infused (0*75 ml/min) into an 
external Jugular or a femoral vein, by means of a needle 
cannula attached to a Palmer’s slow infusion apparatus.
In order to establish a more accurate picture 
of the effects of neuromuscular blocking agents on the 
volume of air exchanged by the lungs, rather than on 
movements of the respiratory musculature, experiments 
were carried out using the method devised by Gaddum (1941). 
To effect a correlation between the respiratory and the 
neuromuscular paralyzing potency of new drugs, the 
rabbit was chosen as the test species. Thus the head 
drop dose could be compared to the dose producing 
respiratory paralysis. Eabbits, weighing between 1.5 
and 4*5 kg, were anaesthetized by administration of 
urethane solution 25 g/lOO ml (approximately 4.5 mg/kg) 
into a marginal ear vein. Cannulation of the trachea,
Conical flask 
500ml capacity 
(reservo/r)
vjMi Screw clip 
^  adjustable 
valve
(Oot/eC
y q /v* )*2
Palmer
J 1 Respirationt valve c© TrocAao
Gimbal lever
Tambour
membrane
Fig. 2. Diagram of the apparatus used to record 
respiration, modified from that of 
Gaddum (1941).
Approximate scale 1 : 5
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an external jugular vein on one side and the common 
carotid artery, on the other side of the neck from the 
cannulated vein, was then completed.
Experiments on the Respiration of the Anaesthetized 
Rabbit,using the method of Gaddum,
The central limb of a Palmer’s ’T 1 shaped 
respiratory valve was connected by means of rubber 
tubing to the trachea cannula. The valve was then 
connected to a conical flask, acting as a reservoir, 
and leading to a tambour which recorded the respiratory 
movements of the animal. The apparatus used is shown 
in the diagram (Fig. 2). The air pressure in the 
reservoir is adjusted by the screw-clip valve (C) to 
maintain the recording lever in a horizontal position# 
When the rabbit inspired, air was drawn from 
the reservoir faster than it entered through C and the 
consequent drop in pressure in the system was recorded 
by a depression in the tambour membrane and a rise in 
the lever. During expiration, the valve R^ closed, 
air entered the reservoir at C and normal pressure 
conditions were restored. The lever fell to its normal 
resting horizontal position. The expired air from the 
animal escaped by the outlet valve Rg* Alterations in
t ' ■
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the rate and depth of respiration of the animal could 
then be translated into changes in the frequency and 
extent of the lever movements. A recording of normal 
respiration was obtained for several minutes prior to 
administration of the drug into the external jugular 
vein. The infusion was carried out at a constant 
rate of 0.75 ml/min, using a Palmerfs slow infusion 
apparatus. Drugs (0.2 mg/ml)dissolved in normal saline 
solution were administered via the external jugular 
vein and,when spontaneous respiration had ceased, 
infusion of the drug was stopped and the animal placed 
on artificial respiration. The rate and time taken 
for infusion of the drug were used to calculate the 
respiratory paralyzing dose of the drug which was 
expressed in mg/kg.
Experiments using Avian Species.
lion-depolarizing neuromuscular blocking agents 
produce a flaccid paralysis in birds whereas depolarizing 
agents cause a typical spastic paralysis (Paton & Zaimis, 
1952; Zaimis, 1954). These effects may be readily 
demonstrated and the phenomenon can be adopted as a 
means of distinguishing between these two classes of 
compounds. Heuromuscular blocking agents of the
83
Intermediate type can be readily distinguished 
because they produce a response embracing characteristics 
of both the other types. Depending on the nature of 
the compound used, an initial spastic paralysis can be 
shown to change to a flaccid paralysis in the course of 
the animal^ response to the injected drugs.
Work on avian species has been extended to 
include nerve-muscle preparations (Ginzel eib al. 1951a, 
b,^; Pelikan, Smith & Unna, 1954; Thesleff & Unna, 1954; 
Crema, Scognamiglio & Bovet, 1959). These studies have 
primarily involved the use of the gastrocnemius muscle- 
sciatic nerve preparation of the chicken and have 
indicated that while non-depolarizing muscle relaxants 
cause only neuromuscular paralysis, depolarizing 
activity involves, in addition, a contracture i.e. a 
shortening of the muscle, independent of the degree of 
electrical stimulation applied. In the latter case 
both the shortening effect and the neuromuscular 
paralysis commenced simultaneously, but the maximum 
contractural effect is attained before the full depression 
of the twitch height is observed (Crema et al. 1959).
Experiments on Chicks.
Four to eight day old chicks were used in these 
experiments. Drugs dissolved in normal saline solution
The Chicken Gastrocnemius Muscle-Sciatic flerve Preparation.
The method described was essentially that used 
by Pelikan and his associates (Pelikan et al. 1954). 
Leghorn chickens of either sex weighing between 1.0 and
3.0 kg were anaesthetized by slow intravenous injection 
of sodium pentobarbitone solution (25-35 mg/kg) into 
a wing vein. In order to maintain anaesthesia, it was 
found necessary to inject sodium pentobarbitone solution 
frequently throughout the experiment (5-10 rag/kg at 
approximately 20 minute intervals). The sodium 
pentobarbitone solution was diluted with an equal 
volume of normal saline to facilitate the control of 
anaesthesia.
The trachea and the external jugular vein on 
one side were cannulated as previously described for 
experiments on the cat gastrocnemius muscle-sciatic 
nerve preparation. Likewise, the tendon of the 
gastrocnemius muscle of one leg was carefully isolated, 
cut and attached over pulleys to the lever of a 
Brown-Schuster myograph by means of a strong linen thread 
sewn through the cut end. The feathers and skin
were injected intraperitoneally using groups of six
chicks for each compound and observations made of the
nature and mode of onset of the paralysis induced.
covering the lateral aspect of the thigh were removed 
and the sciatic nerve exposed. Alternatively, access 
to the sciatic nerve could he gained by blunt dissection 
of the hamstring muscles on the dorsal aspect of the leg. 
The distal end of the severed sciatic nerve was then 
stimulated supramaximally using a Dobbie-Mclnnes square 
wave stimulator at a frequency of 6/min, at 12-25 V, 
the pulse width being 6 msec. The contractions so 
elicited were recorded on a smoked surface. Drugs 
under investigation were added via the external 
jugular vein followed by a fixed volume (5 ml) of normal 
saline solution.
The Rabbit Head Drop Method.
The Estimation of The Head Drop Dose (H.D.D.).
The basis of this method was outlined by 
Bennett (1941). The modification described by Varney, 
Linegar and Holaday (1949) was used. This method of 
assay is best suited to compounds having a fairly 
rapid onset of action and a duration of effect 
comparable to that of tubocurarine.
Rabbits of either sex, weighing from 1.5 to
3.0 kg were used for these experiments. Groups 
consisting of nine animals were used for each drug under

Pig. 3b. Rabbit 'Bleeding' Box with animal
prior to commencement of an experiment.
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investigation to permit statistical analysis of the
results. The rabbits were placed in individual 
bleeding boxes preferably constructed of perspex, with 
the head of the animal protruding through the opening 
at the front (Pig, 3). Drugs under investigation were 
diluted in normal saline to give a final concentration 
of 0,01 mg/ml and were administered through a marginal 
ear vein by means of a Palmer’s slow infusion apparatus. 
This enabled drugs to be given at a constant rate 
(0.75 ml/min) from an all glass syringe fixed in the 
apparatus. The animal usually remained quiet until 
just prior to the end-point of the experiment, when there 
was a brief period of restlessness. Intravenous 
infusion was discontinued only when the muscles of the 
neck were fully relaxed and toneless and a light tap on 
the muzzle produced no raising of the animal’s head.
At this point, the reading on the timing device of the 
slow Injection apparatus was noted and the difference 
between this and the original reading used to calculate 
the quantity of drug administered. When expressed in 
mg/ml of body weight this indicated the head drop 
dose (H.D.D.),
The experiment could also be adapted to
JB7-
indicate the type of muscle relaxant activity involved* 
Consequently, the effect of neostigmine (0*1 mg/kg), 
injected suhcutaneously into the rabhit 15 minutes 
prior to commencement of the experiment, was investigated* 
The ratio of the head drop dose for the neostigmine- 
treated animals, to the head drop dose for the untreated 
animals, liras determined. A ratio greater than unity 
indicated a tubocurarine-like paralysis, while a ratio 
less than unity was taken to indicate a depolarizing 
effect.
Experiments On Mice.
Estimation of the Approximate Median Paralysing Dose 
(P.P.50) and the Approximate Median Lethal Dose (L.D.50).
The method described is based upon that 
originally used by Thomson (1946) for the assay of 
insulin. Solutions of drugs, in normal saline, were 
intraperitoneally injected at different dose levels into 
groups of ten mice of either sex weighing between 20 and 
30 g* The mice were then placed on a fine-mesh wire 
screen inclined at an angle of 50° to the horizontal.
Those mice which developed a typical skeletal muscle 
paralysis and abruptly slid off the screen within a period 
of thirty minutes after injection of the drug, were 
considered to show a positive reaction. The dose at
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which. 5 out of 10 injected mice slid off the screen, 
was considered to he the approximate mediaii paralysing 
dose (P.D.50) and was expressed in mg/kg of hody weight.
In order to determine the approximate median lethal 
dose (L.D.50), the dose at which five out of ten mice, 
in a particular group, died within half an hour, was 
taken and expressed in terms of mg/kg of the hody 
weight.
Experiments on The Isolated Perfused Hahhit Heart.
The experiment was carried out according to the 
method of Langendorff (1895) and involved a perfusion 
of the coronary vessels of the heart through the aorta.
The recorded outflow of the heart is not necessarily an 
accurate assessment of the state of tonus of the coronary 
vessels, since the former is directly dependant upon 
the competence of the aortic valves. As a result of 
aortic incompetence, perfusion fluid may leak Into the 
left ventricle and so to the left atrium and thence to 
the exterior. Moreover, the volume of coronary 
perfusate may he Increased by a purely mechanical 
massaging effect which cardiac muscle, stimulated., by a 
cardiotonic drug, may exert upon the coronary vessels.
In consequence, an increase in the recorded outflow
may falsely indicate a coronary dilatation (Wegria, 1951).
recorder
Pig. 4. Diagram of the apparatus used to record 
the effects of drugs on the isolated 
rabbit heart. Modified from 
Langendorff (1895).
Approximate scale 1 : 5
89
The fluid draining from the heart is thus described 
as the rcardiac outflow*. By careful observation 
of the heart rate, the amplitude of the contractions 
and the cardiac outflow, an estimate of drug-induced 
alterations in the cardiac function and in the tonus 
of the coronary vessels., could be obtained.
Rabbits, weighing between 1.0 and 2.0 kg, were 
killed and exsanguinated. The thoracic cavity was 
exposed, the lungs removed and a thread tied loosely 
around the aortic arch near to the origin of the 
innominate artery. The venae cavae and the aorta 
were then severed, the pericardium removed and the heart 
dissected out and placed in warm hepar inised Locke Ts 
solution to prevent clotting. A stream of Lockefs 
solution was then run through the superior vena cava 
from a pipette and prior to the insertion of a cannula 
into the aorta, the heart was gently massaged. Care 
was taken to ensure that the tip of the cannula was 
distal to the ostia of the coronary artery.
The preparation was then set up by connecting 
the cannula to the perfusion apparatus as shown (Pig. 4). 
Perfusion of the heart with warm (37°C),oxygenated 
Lockofs solution containing double the normal 
concentration of glucose, to prolong the activity of
the preparation, was commenced at a constant rate and 
at a pressure of approximately 3 5 m  of mercury, 
measured by means of a manometer attached to the screw 
clip but not shown in the sketch, care being taken 
that no air bubbles entered the aorta. The temperature 
drop between the thermostatically controlled water bath 
and the cannula did not exceed 0#2°C, When the heart 
beat had become regular, which was usually after about 
fifteen minutes, a supporting thread was tied by means 
of a fine needle through the tip of the left ventricle,
A bent entomological pin inserted into the wall of the 
right ventricle and connected to a Starling heart lever, 
recorded the contractions of the heart on a smoked drum 
surface.
Drugs, dissolved in Locke’s solution, were 
injected into the rubber tubing attached to the aortic 
cannula by a 1 ml graduated tuberculin syringe. The 
heart rate was counted by inspection and the cardiac 
outflow recorded by a Thorp Drop-recorder.
Experiments Garrled Out Using The Isolated Guinea Pig Ileum.
Inhibition of the Peristaltic Reflex,
Three types of muscular movement are shown by 
mammalian small intestine:
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(a) Pendular motion, the frequency of which is 
dependent on the size of the animal.
(b) Changes in tone, which are superimposed on the first 
type of movement.
(c) Peristalsis.
The peristaltic reflex is elicited by an 
increase in intraluminal pressure from within the 
intestine and has the specific function of propelling 
the intestinal contents along the gut. It consists of 
two phases. Firstly, there is a preparatory phase 
which is associated with contractions of the longitudinal 
muscle of the intestine. These contractions are an 
inherent property of the muscle fibres themselves and 
remain unaffected by drugs interfering with nervous 
structures in the intestinal wall. The second phase 
is an emptying phase, in which contractions of the 
circular muscle of the intestine take place and this is 
controlled by the autonomic nervous system, and is 
susceptible to drugs (Trendelenberg, 1917; Feldberg &
Lin, 1949).
The appearance of the peristaltic reflex in 
response to an increase in intraluminal pressure is due 
to stimulation of pressure-sensitive receptors in the
intestinal mucosa. The nervous mechanism is controlled 
from within the wall of the intestine itself and 
consequently the cutting of extrinsic nerve fibres does 
not influence the reflex. It is, however, affected 
hy any interference with the sensory nerve fibres in 
the mucosa.
As the ganglia involved in the peristaltic 
reflex are probably parasympathetic in origin (Feldberg 
& Lin, 1949), inhibition of the reflex can be used to 
estimate the potency of drugs inducing parasympathetic 
ganglion blockade. The most commonly employed method 
of studying peristalsis is that of Trendelenburg (1917), 
who chose isolated guinea pig Intestine on account of 
Its having smaller pendular movements and less 
variability in tone, than that of other mammalian 
species. Guinea pigs of either sex weighing between 
0.3 and 0.5 kg were killed and exsanguinated and a piece 
of ileum (approximately 7-10 cm) removed from the region 
proximal to the Ileocaecal Junction. a  piece of thread 
was tied around the oral end of the segment and the 
thread attached to a writing lever. The caudal end 
was connected to a glass fU* tube connected via a valve 
to a Mariotte bottle containing Tyrode solution which
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Valve > * r )  controHinQuM 
pressure 1 of Tyrode's 
sol" in intestine
6oCtl» 
ra ised  to  
in itia te  
perieto leis
Moriotte 
bottle (on 
moveoble plotform)
Tyrode's
“''solution
To reservoir of
Tyrode's solution
Thermostatically 
controlled bath
Pig. 5* Diagram of the apparatus used to record 
the longitudinal and peristaltic 
movements of the isolated guinea pig 
ileum. Modified from Trendelenburg (1917)
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was placed on a moveable platform (Fig. 5). The 
bottle could be raised or lowered, as required, to 
subject the intestine to a regulated, intraluminal 
hydrostatic pressure. The level of the liquid in the 
bottle was similar to that in the organ bath which 
contained the intestine. All air bubbles were removed 
from the system and the neck of the bottle connected 
by rubber and glass tubing to a float volume recorder 
which was connected to a frontal-point lever writing on 
a smoked surface. The pendular movements of the 
intestine were recorded, at the same time, by means of 
a lever attached to the oral end of the preparation.
The temperature was maintained thermostatically at 30°C 
throughout each experiment. In order to prevent 
fatigue of the preparation, peristalsis was induced for 
only a short period (15 sec) each minute, a three minute 
time cycle being used. Drugs under test were added 
thirty seconds prior to the inducement of peristalsis 
and the effects on the peristaltic reflex and on the 
longitudinal contractions were recorded.
Experiments Using The Isolated Frog Rectus Abdominis Muscle.
These experiments were based largely on the 
method of Chang & Gaddum (1933) modified for muscle
Plasticine
Counterweight
Frontal Point 
Writing Lever
Pectus 
obdominis 
muscle
Platinum  
hook
20  ml 
Organ Bath
Filter
Funnel
Reservoir af Froq 
Ringers Solution
if^-Spring Clip
Oxygen Delivery Tube
Waste
Pig* 6, Diagram of the apparatus used to record 
the effect of drugs on the isolated 
frog rectus abdominis muscle.
relaxant drugs by Garcia de Jalon (1947), An adult 
frog was killed, decapitated and pithed. The skin of 
the abdomen was removed, the rectus muscle exposed and 
dissected from its insertion in the pelvic girdle to 
the point of insertion into the cartilage of the 
pectoral girdle. One half of this muscle, obtained by 
longitudinal dissection at the midline, was used in each 
experiment. A loop of thread was sewn through the 
xiphisternum and a longer thread tied around the pubic 
end. The muscle was then fixed, by means of the loop, 
to the base of a 10 ml organ bath filled with oxygenated 
Ringer's solution at room temperature. The long thread 
was then attached to a modified frontal-point writing 
lever. The apparatus used for these experiments is 
shown in Pig. 6.
Drugs under investigation, dissolved in normal 
saline solution, were added to the bath by means of a 
1 ml graduated tuberculin syringe. These drugs were 
first examined for their ability to induce a contracture 
of the rectus muscle. Accordingly, non-contracture 
inducing drugs (non-depolarizing) were quantitatively 
compared with tubocurarine as inhibitors of acetylcholine, 
while contracture-inducing synthetic compounds were
S5
In all experiments, at least two uniform 
submaximal contractions to the same dose of either 
acetylcholine or decamethonium were obtained, prior to 
the investigation of other drugs. A suitable time 
interval between each dose of acetylcholine was found to 
be approximately four or five minutes and the resulting 
contractions were recorded for periods of thirty to 
ninety seconds. In the case of decamethonium,v sufficient 
time, not generally exceeding twenty minutes, was allowed 
for the muscle to regain its original length after the 
contraction. The recording of the contractions 
themselves took approximately two to three minutes. 
Acetylcholine-inhibiting drugs were added from, thirty to 
sixty seconds prior to the addition of acetylcholine.
The muscle was washed a fixed number of times with fresh 
frog Ringer*s solution at the completion of each time 
cycle. Several additions of acetylcholine or 
decamethonium were needed for complete recovery, the 
length of time taken depending on both the nature and the 
quantity of the drug added to the bath. The concentrations
quantitatively compared with decamethonium, Conditions,
once established, remained constant throughout each
experiment.
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of agonists used to induce contractions of the muscle 
were of the order of 1.0 to 10.0 jig/ml of decamethonium.
Experiments Using Frog Rectus Abdominis Muscle Based 
On The Technique Of Ariens And His Associates. (Van 
Rossum & Ariens, lQSSa}.
These experiments weie performed using the 
isolated rectus abdominis muscle of the frog Rana 
temporaria. The dissection of the muscle and the 
setting up of the preparation were similar to those 
previously described. The contractures, induced by the 
action of agonistic drugs, were recorded on a smoked 
drum surface. In all cases the agonist chosen was 
decamethonium iodide (2 ^moles/ml) and cumulative 
dose-response curves were obtained by the stepwise 
addition of this drug in the following sequence 
a;a;2a;4a;8a; and so on (a = 0,01 ml added by an 
automatic-constriction pipette). Each dose of drug 
was left in contact with the muscle for 15 minutes to 
permit equilibration, then the concentration of drug 
was doubled by adding the next dose according to the 
sequence given above. 7/hen the maximum effect had been 
recorded, the muscle was washed thoroughly for one or 
one and one-half hours which was the time necessary for
Plasticine 
Counter Weight
Frontal Point 
Writing Lever
Rectus Abdominis 
Muscle
Oxygen Delivery 
Tube
Screw  C lip to 
"adjust rate  of 
o u tflo w
Glass
Capillary
Reservoir 
of Frog 
Ringers 
Solution.
Pig. 7. Diagram of the apparatus used for the 
continuous washing of the frog rectus 
abdominis muscle during experiments 
employing the Ariens' procedure.
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complete relaxation to "be attained. This could he 
carried out in the normal way by continuously emptying 
and filling the organ bath from the reservoir bottle. 
Alternatively, the washing could be accomplished 
automatically by inserting a fine glass capillary in 
the reservoir, equating the level of the Kinger^ 
solution in the reservoir with that in the bath and 
permitting the reservoir to empty its contents into the 
bath at a slow, predetermined rate (Pig. 7).
When x^ashing was complete the investigation 
of other drugs affecting skeletal muscle could be 
commenced.
Thus the potency of those drugs which possessed 
a qualitatively similar agonistic action to decamethonium 
could be measured by noting the height of the dose 
response curve elicited by their addition to the bath, 
as described. Compounds possessing other types of 
muscle relaxant activity could be investigated by their 
addition to the bath 15 minutes prior to the addition 
of decamethonium and their effect on the subsequent dose 
response curve recorded.
Log-dose response curves were constructed by 
expressing the effect of each concentration of the drug,
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as a percentage of the maximum effect recorded.
Experiments with each drug under investigation 
were repeated ten or twenty times and the results 
analyzed statistically. Experimental and theoretical 
dose response curves differ in slope hut Ariens has 
clearly stated that this difference in no way invalidates 
the use of the experimentally derived curves to compare 
the affinity and intrinsic activity values of the 
compounds investigated (Van Rossum & Ariens, 1959a;
Ariens & Simonis, 1960).
}
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in Group lc and Id.
Code No.
Chemical Structure
R1R2R3 n m | R4R5R6 X
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F.Sc P.16677 c h 3(G2H5)2 2 3 (CH3)3 X
P . Sc P.8302 CH3(g2h 5^2 2 3 c h3(c2h 5)2 I
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F*Sc P.8303 (C 2 H5 ) 3 2 3 (°2h 5^3 Br
P . Sc P. 16701 (c h3)3 3 3 (c h3)3 I
F.Sc P. 17843 (c h3)2C2h 5 3 3 f ° 2 H5 ^ 3 Br
F.Sc P . 8212 (C2H5)3 3 3 ( C2 R5 > 3 Br
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The chemical structure and code number of compounds
in G-roup lc and Group Id.
Group lc
Code Ho. R r !
E98 V e °2H5
E99 ch3
E100 ch3 ch3
E101 ch3 C2H5
E102 ch3 11-C3 H7
E103 c2h5 n- C 3H 17
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' 41“
TABLE II
Tho chemical structure and code number of
compounds in Group la and Group lh.
Group la
Code Uo# R R 1 X
E77 C2h5 C2h5 0
E78 c2H5 ch3 0
E79 c2h5 °2h5 ch2
E80 c2h 5 ch3 o CO
E96 c2H5 n-C^Hiy 0
E97 g 2h5 n-CgHy ch2
r I m -  (CH2 )2- X -  (CHg)2 - W _  (ch2 )2- x ~  (ch2 )2- n ^ r
R1 R R1 R1
______________________________   31 "
Group lh
E90 G2r5 g2r5 0
E91 °2H5 ch3 0
E93 C2H5 ch3 ch2
E94 C2H5 c2H5 CHg
E95 g2H5 n-C^Hy CHg
TABIIE III
The chemical structure and code number of
compounds in Group 2.
Code Humber - R R1 n
i ch3 °2H5 8
ii ch3 ch3 10
h i ch3 ch3 ■ 8
BESTJLTS
. On the basis of their chemical and 
^pharmacological characteristics, the compounds 
investigated have been divided into two main groups 
(1 and 2). Group 1 was further divided into la, lb,
lc and Id. The chemical structure of each compound,
together with a reference number, are shown in 
Tables II and III. In certain cases, the scope of 
the pharmacological testing was limited by the amount 
of material available. Compounds In Group Id were 
tested for neuromuscular blocking activity on the cat 
only; other pharmacological properties possessed by 
these drugs have been reported elsewhere (Fakstorp and 
his associates, 1954, 1955, 1956, 1957a,b,^). The 
results are presented under three main headings:
(a) Tests designed to investigate neuromuscular blocking 
activity and which use conventional techniques.
(b) Investigation of other effects Including those at 
autonomic ganglia, on the heart and on the muscles 
controlling respiration.
(c) Investigation of the mode of action of certain 
muscle relaxants on the frog rectus abdominis muscle 
using the Ariens1 technique.
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Experiments to investigate neuromuscular 
blocking potency were designed to classify the compounds 
according to the criteria (Paton & Zaimis, 1952) for 
depolarizing and non-depolarizing drugs of this type.
These criteria are as follows:
(1) Depolarizing drugs produce muscular fasiculation 
and briefly increase the tension of the muscle twitch 
prior to its depression.
(2) The ability of edrophonium and neostigmine to 
constantly antagonise the block produced by non­
depolarizing drugs and to potentiate, or only slightly 
antagonize, the block produced by depolarizing agents.
(3) The reciprocal antagonism of tubocurarine and
decame thonium to the block produced by depolarizing and 
non-depolarizing agents respectively.
(4) The ability of the muscle to maintain a tetanus 
during partial neuromuscular block by depolarizing 
drugs as confirmed by several workers including Burns 
and Paton (1951), Paton and Zaimis (1951). On the other 
hand the tension in indirectly tetanized muscle, partially 
blocked by non-depolarizing drugs, wanes rapidly (Paton
8c Zaimis, 1951; Hutter, 1952).
(5) The induction of a spastic paralysis, in avian
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muscle, by depolarizing drugs as opposed to the 
flaccid paralysis produced by non-depolarizing muscle 
relaxants.
(6) The ability of depolarizing compounds to induce 
a contractural response on the isolated frog rectus 
abdominis muscle and of non-depolarizing drugs to 
antagonize the contracture,
(7) The ability of neostigmine to effectively increase 
the head drop dose of non-depolarizing drugs in the 
rabbit.
Cat Gastrocnemius Muscle-Sciatic Nerve Preparation.
All the compounds, in the doses employed, with 
the exception of E91 and E100, induced complete or 
incomplete, reversible block in the cat gastrocnemius 
muscle-sciatic nerve preparation. The potency of the 
compounds varied considerably.
The N,N,lT,N-tetra-onium compounds (Group la), 
in doses of from 0.05 to 0.10 mg/kg, produced an 
approximately 50$ reduction in the amplitude of the 
muscle twitch and, with the exception of E78, all were 
appreciably more potent than tubocurarine. The 
lT,H,H-tris-onium compounds (Groups lb ahd lc) possessed 
only weak muscle relaxant activity. In all cases,
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maximum activity was associated with the presence of 
N - ethyl substituents and, although the ether 
containing derivatives appeared to he less potent than 
the corresponding non-ether compounds, there were no 
qualitative differences between them. The N,N-bis-onium 
ethers (Group Id) also possessed weak muscle relaxant 
activity comparable to that of compounds in Groups lb 
and lc.
All the compounds in Groups la, lb, lc and Id 
appeared to be free from initial stimulant effects and 
there was no evidence of muscular twitching or 
fibrillation.
The duration and degree of neuromuscular block 
induced by all the compounds in Group 1 depended both 
upon the magnitude of the dose employed and the number 
of doses administered. Neuromuscular block was more 
prolonged following the second injection of the same 
dose than following the first. Block caused by a 
third and similar dose was more prolonged than that 
following the second. The effect of a fourth injection 
of a similar dose often did not significantly differ 
from that of the third dose. Typical examples of 
these effects, which were also observed using tubocurarine,
Pig. 8. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. Contractions 
downwards. Indirect stimulation via the sciatic 
nerve. Drugs administered intravenously.
(i) At A, tubocurarine 0.10 mg/kg. There was an 
interval of 18, 24 and 26 minutes respectively 
between successive doses.
(ii) At B, E78 0.15 mg/kg. There was an interval of
60 and 90 minutes respectively between successive doses.
( i i )
Fig. 9. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. Contraction 
downwards. Indirect stimulation via the sciatic nerve. 
Drugs administered intravenously.
At B, compound F. & P.8303 10 mg/kg.
There was an interval of 23 and 35 minutes respectively 
between successive doses.
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are shown in Pigs. 8 and 9.
All the active compounds in Group 1 induced 
a fairly prolonged neuromuscular block and approximately 
30-60 min were required for recovery after approximately 
50$ reduction in twitch amplitude. The onset of 
paralysis and the time taken for the attainment of the 
maximum effect of each drug in this group were rapid.
Compounds in Group 2 possessed potent muscle 
relaxant properties resembling decamethonium rather 
than tubocurarine. Compounds I (0.1 - 0.5 mg/kg),
II (0.05 - 0.1 mg/kg) and III (0.1 - 0.5 mg/kg) reduced 
twitch amplitude while II (0.25 mg/kg) caused an initial 
Increase in twitch height without a subsequent reduction 
In amplitude. Generalized, intermittent, fasiculatory 
movements of the skeletal musculature were produced 
by compounds II and III. Hone of the compounds in 
this group was more potent than decamethonium.
The compounds in Group 2 further resembled 
decamethonium in that the onset of block was more, 
gradual, the attainment of the maximum effect more 
prolonged and the duration of effect greater than with 
tubocurarine and the compounds of Group 1* Thus a 
dose selected to produce an approximately 20$ block
Fig. 10. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia.
Contraction downwards. Indirect stimulation via 
the sciatic nerve. Drugs administered intravenously. 
At A, compound II 0.05 mg/kg.
Fig. 11. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia.
Contraction downwards. Indirect stimulation via the 
sciatic nerve.
At A, compound III 0.10 mg/kg.
There was an interval of 38 and 45 minutes respectively 
between sucessive doses.
Fig. 12. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. Contraction 
downwards. Drugs administered intravenously. Indirect 
tetanization via the sciatic nerve (1400 impulses/min) 
during partial block by:
a, Compound E78 0.10 mg/kg,
b, De came thonium 0.09 mg/kg,
e, Tubocurarine 0.20 mg/kg,
d, Compound E95 0.40 mg/kg,
f, Compound E94 0.30 mg/kg,
e, untreated muscle.
Pig* 13. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. Contraction 
downwards. Drugs administered intravenously. Indirect 
tetanization via the sciatic nerve (1400 impulses/min) 
during partial block by:
a, Compound F. & P.8303 20 mg/kg,
b, Compound E98 1 mg/kg,
c, Compound E101 20 mg/kg.
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required approximately 45 min for complete recovery* 
Following a subsequent and similar dose of the same 
3rug, given after complete recovery, the duration of 
the block produced by these compounds was more prolonged 
and more intense. The phenomenon was less marked, 
however, than with the compounds in Group 1. This 
can be explained by the more prolonged period of 
recovery from the effects of drugs in Group 2 during 
which a considerable degree of drug elimination may 
have occurred* These effects are shown in Figs. 10 
and 11.
Effect of Indirect Tetanization of the Partially 
Blocked Muscle.
The results can be divided into two distinct 
categories. The compounds in Group 1 behaved 
similarly to tubocurarine and to each other and typical 
effects are shown in Figs. 12 and 13. The poorly 
sustained responses of the partially blocked, indirectly 
tetanized muscle to the compounds E95 (Fig, 12d),
E94 (Fig. 12f), E78 (Fig. 12a), F. & P. 8303 (Fig. 13a), 
E10 (Fig. 13c) and E98 (Fig. 13b) were qualitatively 
comparable to those produced by tubocurarine (Fig. 12c) 
and different from the well-sustained tension of the .
Pig. 14. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia.
Contractions downwards. Drugs administered 
intravenously. Indirect tetanization via the sciatic 
nerve (1400 impulses/min) during partial block by:
a, compound I 0.3 mg/kg,
b, compound II 0.05 mg/kg,
c, decamethonium 0.02 mg/kg.
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tetanized mis o le partially "blocked "by decamethonium 
(Pig. 12b) which resembled that of the untreated 
muscle (Pig, 12e).
Pig, 14 shows the well-sustained tension of 
the tetanized muscle partially blocked by compounds II 
and III. It is obvious that their.behaviour is 
similar to that of decamethonium.
It is interesting to note that the responses 
of the muscle, partially blocked by the ether (Pig. 12a) 
and non-ether (Pigs, 12d and 12f) containing compounds, 
were qualitatively similar.
The Effect of Tubocurarine and Decamethonium on the 
Block Produced by Compounds in Groups 1 and 2.
When muscle relaxants with similar types of 
action are given successively, their effects are 
additive. Dissimilarly acting drugs may show 
antagonism (Hutter & Pascoe, 1951; Riker & Wescoe, 1951; 
Paton & Zaimis, 1952). The importance of these 
phenomena, in confirming the mode of action of the 
compounds under study, prompted an investigation of 
the effects of tubocurarine and decamethonium on the 
block induced by the compounds In Groups 1 and 2.
Investigations were carried out using a dose of
Pig. 15. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound E96 0,08 mg/kg.
At T, tubocurarine 0.025 mg/kg.
Pig. 16. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound P. & P.8303 10 mg/kg.
At T, tubocurarine 0.10 mg/kg.
Pig, 17, Oat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound E102 7.5 mg/kg.
At T, tubocurarine 0.1 mg/kg.
30"
Pig. 18. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound I 0.5 mg/kg.
At T, tubocurarine 0.1 mg/kg.
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a new compound and a dose of either tubocurarine or 
decamethonium selected to produce, when given alone, 
a measurable but not intense depression of the twitch 
he ight.
Tubo curarine.
When a dose of any one of the compounds in 
G-roup 1 was followed by a dose of tubocurarine given 
at the point of maximal depression of twitch amplitude, 
the intensity of the neuromuscular block was enhanced 
(Pigs. 15, 16 and 17). Thus, in Pig* 15 the dose of 
E96 (0.08 mg/kg) and the dose of tubocurarine 
(0.025 mg/kg) were each selected to produce a neuron- 
muscular block of about 40$. When the dose of E96 '
was followed by a dose of tubocurarine at the point 
of maximal depression, the degree of neuromuscular 
block was increased to approximately 80$. In this 
respect, both the ether and non-ether compounds in 
Group 1 behaved in a qualitatively identical manner to 
tubocurarine and to each other. On the other hand, 
the effect of tubocurarine on the neuromuscular 
blocking activity of the sulphur-containing decamethonium 
analogues was quite different (Pig. 18). A dose of 
compound I was selected to produce an incomplete but
Pig. 19. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound III 0.15 mg/kg.
At B, tubocurarine 0.20 mg/kg.
Pig. 20. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the
sciatic nerve.
At A, compound II 0.025 mg/kg.
At B, compound III 0.100 mg/kg.
At C, compound I 0.100 mg/kg.
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measurable paralysis and the injection of tubocurarine 
(0*10 mg/kg), at the point of maximal depression, 
increased the twitch height. In the case of 
compound III, the addition of tubocurarine to the 
partially blocked muscle did not produce the same 
antagonism as was seen with compounds I and II and a 
slight reduction in the amplitude of the twitch height 
was Initially produced. This was thought to indicate 
the presence of mixed blocking properties in this 
compound but subsequent observations, on other species, 
did not confirm this view* Consequently, although 
the effect was reproducible, the enhancing action, 
demonstrated in Pig. 19, may have been due to the 
administration of a very large dose of tubocurarine.
All three compounds in this group showed additive 
effects (Fig* 20).
De came thonium.
The mutually antagonistic effects of 
depolarizing and non-depolarizing substances (Dallemagne 
& Philippot, 1952; Hutter 8c Pascoe, 1951; Paton 8c 
Zaimis, 1952) were further Investigated by Injecting 
decamethonium (0.02 - 0.05 mg/kg) at the point of 
maximal depression of the muscle twitch.
Pig. 21. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound E103 30 mg/kg.
At B, decamethonium 0.30 mg/kg.
Pig* 22. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound E96 0.12 mg/kg.
At B, decamethonium 0.80 mg/kg.
Pig. 23. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound III 0.15 mg/kg.
At B, de came thonium 0.02 mg/kg.
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Immediately after injection of decamethonium, 
the height of the muscle twitch, partially blocked by 
compounds in Group 1, increased in amplitude and, within 
approximately five minutes (Pigs. 21 and 22), a complete 
reversal of the block was achieved. On the other hand, 
decamethonium produced an additive increase in the 
intensity of the block produced by the compounds in 
Group 2 (Pig. 23).
The investigations carried out using decamethonium 
and tubocurarine confirmed the classification of the 
drugs into depolarizing and non-depolarizing agents.
There was again no evidence of qualitative differences 
between the ether and non-ether compounds in Group 1. 
Effect of Ether Anaesthesia.
Ether anaesthesia has been reported to increase 
the effects of non-depolarizing neuromuscular blocking 
agents (Burns & Paton, 1951; Poldes, 1959, 1960), 
whereas the activity of depolarizing drugs appears to 
be only slightly increased or reduced by this agent 
(Paton, 1953). Other straight chain aliphatic ethers 
produce a similar effect. This effect was investigated 
using compounds in Groups 1 and 2. A dose of drug was 
selected to produce a consistent, measurable degree of
Pig. 24-. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A^, compound E77 0.05 mg/kg.
At A, compound E77 0.05 mg/kg during ether
inhalation.
Pig. 25. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia.
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound E78 0.050 mg/kg.
At B, compound E78 0.050 mg/kg during ether inhalation. 
There was an interval of 38 minutes between A and B.
Fig. 26. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia.
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound II 0.10 mg/kg.
At B, compound II 0.10 mg/kg during ether inhalation. 
At C, ether withdrawn.
5323480053482323482323482348232353535348235348234823535323235353
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neuromuscular block (approximately 20 - 50j£). The 
same dose was repeated, after full recovery had been 
attained, in the presence of ether vapour administered 
from a bottle connected to the artificial respiration 
pump. The administration of the anaesthetic was 
continued for a period of five minutes, and was begun 
immediately after the injection of the drug. The 
neuromuscular blocking action of each of the compounds 
in Group 1 was intensified by ether anaesthesia but 
the activity of those in Group 2 was influenced very 
little. Some typical tracings from these experiments 
are shown in Figs, 24, 25 and 26, No differences 
between the ether and non-ether compounds in Group 1 
could be observed from these experiments.
Studies On Drug Antagonism.
The activity of muscle relaxant drugs is 
potentiated, prolonged or terminated by a variety of
other agents each of which, in addition, possesses its\ ■
own characteristic pharmacological actions at sites 
other than the neuromuscular synapse (Paton & Zaimis, 
1952; Foldes, 1959), These may be employed in the 
laboratory as a means of investigating the nature of the 
block produced by new muscle relaxants. Thus
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anticholinesterases, by virtue of their ability to 
intensify the action of acetylcholine, antagonize the 
block produced by non-depolarizing agents (Chase,
Schmidt & BhattaCharya, 1947; Bulbring & Chou, 1947; 
Blaschko, Bulbring & Chou, 1949), but the block 
produced by depolarizing agents may be potentiated or 
only slightly antagonized (Hoppe, 1950; Paton, 1951). 
While the action of those anticholinesterases containing 
quaternary ammonium groups is generally believed to be 
due to the prolongation and intensification of the 
activity of acetylcholine (Hobbiger, 1952; Nastuk 8c 
Alexander, 1954; Katz 8c Thesleff, 1957), both 
neostigmine (Hiker 8c Wescoe, 1950) and edrophonium 
(Wescoe 8c Riker, 1951; Hougs & Johansen, 1958) exert 
a depolarizing effect at the neuromuscular junction*
The anticholinesterases, edrophonium and neostigmine, 
together with adrenaline, were selected for studies on 
the stability of the block produced by compounds in 
Groups 1 and 2. Each was injected into the cat at the 
point of maximal neuromuscular block or just as recovery 
commenced.
Edrophonium.
Partial or complete neuromuscular block, 
produced by the compounds in Group 1, was rapidly and
Pig. 27. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound E79 0.03 mg/kg.
At B, edrophonium 0.50 mg/kg.
Fig. 28. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound E96 0.04 mg/kg.
At B, edrophonium 0.50 mg/kg.
Pig. 29. Gat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound P. & P. 16677 20 mg/kg.
At B, compound P. & P. 8302 10 mg/kg.
At C, edrophonium 0.5 mg/kg.
Pig. 30. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound II 0.05 mg/kg.
At B, edrophonium 0.50 mg/kg.
Pig. 31* Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, decamethonium 0.05 mg/kg.
At B, edrophonium 0.50 mg/kg.
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completely reversed toy the Intravenous injection of 
edrophonium (0.5 - 1 mg/kg) at the point of maximum 
depression of the twitch height. The effect of 
edrophonium was however short-lived. After complete 
recovery of the twitch height following edrophonium, 
a second and similar dose of the drug produced a slight 
reduction in the degree of neuromuscular tolock.
Typical experiments are shown in Pigs. 27, 28 and 29,
The effect of edrophonium on the tolock produced 
toy the sulphur-containing decamethonium-like compounds 
in Group 2 was not so striking as that observed using 
compounds in Group 1, and doses of 0.5 mg/kg caused 
either a slight intensification or a slight reduction 
in the intensity of the tolock. All the compounds in 
this group toehaved similarly to decamethonium and to 
each other. Typical effects are shown in Pigs. 30 and 
31.
Ueostigmine.
The results obtained using neostigmine and 
edrophonium were qualitatively similar, although the 
effect of neostigmine was much more prolonged. Thus a 
second dose of drug given 30 minutes after the first had 
been reversed toy neostigmine, produced little effect.
In doses ranging from 0.02 to 0.10 mg/kg, neostigmine
Pig. 32. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound E80 0.12 mg/kg.
At B, neostigmine 0.02 mg/kg.
Pig. 33. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound E78 0.15 mg/kg.
At B, neostigmine 0.05 mg/kg.
Pig. 34. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Indirect stimulation via the sciatic nerve. 
Contraction downwards. Drugs administered 
intravenously.
At A, compound III 0.15 mg/kg.
At B, neostigmine, 0.15 mg/kg.
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effectively antagonized those compounds possessing , 
non-depolarizing properties (Group 1) hut had little 
intensifying or antagonizing effect on the predominantly 
depolarizing agents of Group 2. Characteristic 
tracings are shown in Figs. 32, 33 and 34.
In these experiments, the ether and non-ether 
containing compounds produced identical qualitative 
effects.
Adrenaline.
The mode of action of adrenaline at the 
neuromuscular synapse is not fully understood (Hunt & 
Huffier, 1950 and references cited therein).
Adrenaline is believed to exert a dual action on the 
motor end plate, increasing the quantity of acetylcholine 
released by indirect stimulation and stabilizing and 
decreasing the electrical excitability of the muscle 
fibre (Hm^evic & Miledi, 1958). One or other effect 
may predominate and consequently antagonism or 
potentiation may be observed. These effects cannot, 
it has been suggested (Linssen, 1961), be explained by 
its hyperpolarizing (Bulbring, 1956; Huidobro, 1960) 
or hyperglycaemic effects nor by an increase in the 
blood flow to the site of activity (Hunt & Huffier, 1950),
The antagonism of adrenaline to the effects of
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tubocurarine and other non-depolarizing drugs has 
heen amply confirmed (Gruber, 1914; Kosenblenth, 
Lindsley 8c Morison, 1936; Hutter 8c Loewenstein, 1955; 
Brown, Bulbring & Burns, 1948; West 8c ZTaimis, 1949),
On the other hand, adrenaline, in low concentrations, 
potentiated the action of tubocurarine and gallamine 
(Beckett 8c Ellis, 1955) in the rat (Montaguy 1955)* 
This effect was attributed to a diminished release of 
acetylcholine. A similar explanation was advanced to 
explain the inhibition, by adrenaline, of the early 
depolarizing phase and the polentiation of the late, 
non-depolarizing phase of acetylcholine, suxamethonium 
and decamethonium block (Beckett 8c Ellis, 1955). On 
the other hand, the stabilizing effect of low 
concentrations of adrenaline on the end plate might 
have been responsible (Poldes, 1959). The view that 
adrenaline may influence neuromuscular transmission by 
an anticholinesterase effect, has also been suggested 
(Poldes, 1959).
A dose of each of the compounds under study 
was selected to produce approximately 30-50$ of 
neuromuscular block and adrenaline was injected at the 
point of maximum depression of the muscle twitch.
Fig, 35. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound E77 0.04 mg/kg.
Pig. 36. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound E98 0.75 mg/kg.
At B, adrenaline 0.02 mg/kg.
Pig. 37. Cat gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, de came thonium 0.06 mg/kg.
At B, adrenaline 0.04 mg/kg.
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In all cases, a rapid but brief reversal of the block 
was obtained. In some cases, the twitch amplitude 
returned to control levels within a few minutes, but 
soon declined again almost to the level prior to the 
Injection of adrenaline. In such cases adrenaline was 
again given successively, until complete recovery was 
obtained. Characteristic effects are shown in Pigs. 35 
and 36. Adrenaline (0.04 mg/kg) also exerted a slight 
temporary antagonism on the block produced by 
de came thonium and the compounds in Group 2 although the 
effect was less pronounced than with the compounds In 
Group 1 (Pig. 37). A summary of the qualitative 
pharmacological properties of the compounds in Groups 
1 and 2, as determined using the cat gastrocnemius 
muscle-sciatic nerve preparation, is given in Tables IV 
and V, When the preparation was giving a consistent 
response, for example 50$ Inhibition of the twitch 
amplitude to a fixed dose of any of the drugs in either 
group, a dose of tubocurarine or de came thonium was 
selected which produced a similar quantitative effect. 
The approximate molar potencies, also included In 
Tables IV and V, were then calculated with reference to 
tubocurarine for drugs in Group 1 and to decamethonium
TABLE VI (continued)
Compound
Head Drop Doses (H.D.D.) Ho.Died
r Ho.
Injected
’ —
Molar Potency 
(tubo- 
curarlne 
= 100)
Individual
(mg/kg)
Mean i S.E.M. 
(mg/kg)
E90
3.4,
3.4, 
3.9.
3.57 t  0.15 1/3 5
E91
8 mg/kg 
produced no 
head drop.
- -
E98
2.31, 2.6, 2.4, 
2.34, 2.8, 2.4. 
2 . 50, 2.5,
2.3 2.8,
2.50 t  0.20 0/10 0.366
Tubo- 
surar ine
0.13, 0.17, 
0.15, 0.23, 
0.17, 0.23, 
0.24, 0.13.
0.16,
0.18 ± 0.02 4/9 100
Individual and Mean Head Drop Doses of compounds E77, 
E78, E79, E80, E96, E97, E90, E91, E98 and tubocurarine 
in the rabbit.
TABLE VI
Compound
Head Drop Doses (H.D.D.) Ho.Died 
Ho. 
Injected
l
Molar 
Potency 
(tubo­
curarine 
= 100)
Individual
(mg/kg)
Mean t  S.E.M. 
(mg/kg)
E77
0.21, 0.21. 
0.23,
0.28,
0.23,
0.23 t  o.Ol 2/5 108
E79
0.21, 0.19, 
0.16, 0.20, 
0.29, 0.20, 
0.21, 0.20, 
0.17.
0.20 i  0.01 4/9 125
E78
0.30, 0.37, 
0.35, 0*36, 
0.34, 0.37, 
0.35, 0.33, 
0.45.
0.36 i  0.01 0/9 66
E80
0.25, 0.33, 
0.27, 0.30, 
0.31, 0.29, 
0.29, 0.29. 
0.26,
0.29 t  0.01 4/9 82
E96
0.29, 0.28, 
0.30, 0.21, 
0.26, 0.22, 
0.30, 0.30. 
0.25,
0.27 i  0.01 6/9 96
E97
0.25, 0.23, 
0.25, 0.20, 
0.23, 0.28, 
0.24, 0.23, 
0.23.
0.24 i  0.01 6/9 110
TABLE VII
Individual and Mean Head Drop Doses of compounds 
I, II, II, Oxydipentonium and Decamethonium in
the rabbit.
Compound
Head Drop Doses (H.D.D.) No.Died 
No.
In.1 ected
Molar 
Potency 
(Beca­
me thonium 
= 100)
Individual
(mg/kg)
Mean ± S.E.M. 
(mg/kg)
*
I
1.8, 1.3 
2.1, 1.6. 
1.6,
1.68 t  0.01 1/5 12
II
0.42, 0.51, 
0.49, 0.42, 
0.53, 0.47, 
0.51, 0.47. 
0.44,
0.47 - 0.01 2/9 41
III
1.5, 1.0 
0.9, 1.1, 
1.1, 1.1, 
1.4, 1.6, 
1.9.
1.29 ± 0.33 3/9 14
Oxydi­
pentonium
0*55, 0.55, 
0.68, 0.55, 
0.54, 0.54, 
0.51, 0.56. 
0.56,
0.56 ± 0.01 4/9 23
Deca­
methonium
0.17, 0.13, 
0.15, 0.16, 
0.21, 0.19, 
0.17, 0.22,
0.28 .
0.19 t  0.02 3/9 100
Insufficient material to permit further observations
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for those In Group 2 according to the formula
Approximate Molar Potency of 
New Compound
Molecular Weight of Dose of Reference Compound
New Compound x producing a certain effect x 100 
Molecular Weight of Dose of New Compound
Reference Compound producing the same effect
The reference compounds, tubocurarine and decamethonium, 
were arbritarily assigned the value 100.
The Rabbit Head Drop Test.
On account of the limited amount of material 
available only the potency of compounds in Groups la, 2 
and compound E98 could be estimated. In addition, 
the head drop doses of oxydipentonium, decamethonlum 
and tubocurarine were estimated and the results shown 
in Tables VI and VII.
Whenever possible, groups of„ nine animals were 
used to permit statistical analysis. The duration of 
effect of the compounds In Group la varied between 
5 and 10 min and complete recovery took approximately 
20 min. In some cases, the animals were revived 
by strapping to an automatic resuscitator, which 
consisted of a mounted platform tilting through an
angle of 9cP to the horizontal. This was not 
successful in every case and E96 and E97 appeared 
particularly toxic. Compounds II and III were much 
shorter-acting than those in Group 1 and apparently 
complete recovery was observed after approximately 
5 min. In keeping with similar observations on 
the cat, the ether-containing compounds were less 
potent on the rabbit than the corresponding non-ethers. 
The sulphur-containing de came thonium analogues were 
qualitatively similar to, but quantitatively weaker 
than de came thonium.
The Effect of Neostigmine Upon The Magnitude of The 
Head Drop Dose.
The head drop dose of the compounds in Group la 
and tubocurarine were found to be appreciably increased 
by. subcutaneous injection of neostigmine (0.1 mg/kg)
15 min prior to injection of the drug under study.
This Is in keeping with the well known antagonistic 
effect of neostigmine on tubocurarine-like compounds 
on other preparations and species as already discussed 
and is in contrast to the slightly Intensifying effect 
exerted by the anticholinesterases on compounds of 
Group 2 as Indicated by a reduction in the head drop do
Head Drop Doses (H.D.D.) of compounds E77, E78, E79, 
E80, E96, E97 and Tubocurarine, in the rabbit, before 
and after treatment with Neostigmine and the ratio
H.D.D.(neostigmine treated)/H.D.D. control.
TABLE VIII
Compound
Mean Head Drop Dose (H.D.D.) 
- S.E.M. (mg/kg)
Neostig-
Ratio:m^netreated
ControlControl
Neostigmine 
(0.10 mg/kg), 
subcutaneously 
treated
E77 ' 0.23 ^ 0.01
(Five rabbits 
used)
0.33 * 0.01 1.43 P 0.001
E79 0.20 i  0.01 0.29 ± 0.02 1.45 P 0.001
E78 0.36 t  0.01 0.53 t  0.02 1.47 P 0.001
E80 0.29 1 o.Ol 0.50 t  0.01 1.72 P 0.001
E96 0.27 t  0.01 0.37 t  0.01 1.37 P 0.001
E97 0.24 t  0.01 0.40 + 0.01 1.67 P 0.001
Tubo­
curarine
0.18 t  0.02 0.30 i  0.02 1.67 P 0.001
TABLE IX
Individual and Mean Head Drop Dose (H.D.D*) of 
compounds I, II and III and de came thonium in the 
rabhit before and after treatment with neostigmine 
and the ratio H.D.D. (Neostigmine treated)/H.D.D. control.
Name or 
Code Ho. 
of
Mean Head Drop Dose (H.D.D.) 
- S.E.M. (mg/kg)
Neostigmine 
Ratio treated
ControlCompound
i
Control
Neostigmine 
(0.10 mg/kg) 
subcutaneously
i 1.68 ± 0.02 * +1.60 i  0.13 0.95
i i i 0.47 ± 0.01 0.34 ± 0.03
i
0.72 ’
1 1 1 1 1.29 t  0.33 1.17 i  0.33 0.91
it
De ca­
me thoniuir
L  ____ __
i 0.19 - 0.05 0.16± 0.01 0.84
Three observations only due to lack of material.
The qualitative and semi-quantitative properties of 
compounds E77, E79, E78, E80, E96, E97, E90, E94, E91, 
E93, E95 and Tubocurarine in the chick*
TAB IS X
Compound
Ho. of Injections 
required to 
induce paralysis 
(lmg/kg /min)
Type of
paralysis
observed
Approximate 
Molar potency 
(Tubo curar ine 
= 100)
E77 5 Flaccid 139
E79 3 Flaccid 230
E78 6 Flaccid 110
E80 4 Flaccid . , 158
E96 3 Flaccid 242
E97 3 Flaccid 242
E90 Ho paralysis 
after three 
injections 
5 mg/kg
E94 5 Flaccid 101
E91* 6 Flaccid 16
E93 9 Flaccid 52
E95 6 Flaccid 88
Tubo- 
curar in
5
9
Flaccid 100
Oxydipen- 2 
tonium 1
Spastic 250
*5 mg/kg /min
The qualitative and semi-quantitative properties of 
compounds I, II, III and decamethonium on the chick.
TABLE XI
Com­
pound
No. of Injections 
required to 
induce paralysis 
(1.0mg/kg/30 sec)
Type of
paralysis
observed
Approximate 
Molar potency 
(Deca­
me thonium 
= 100)
I 6 Spastic
Flaccid
33
II 3 Spastic 66
i ..
III 4 Spastic
Flaccid
48
Deca­
methonium
2 Spastic 100
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The head drop doses before and after treatment with 
neostigmine and the ratio of these effects are shown 
in Tables VIII and IX.
Experiments on Avian Muscle.
Chick paralysis test.
Following intraperitoneal injection of compounds 
in Groups la and lb (1 to 5 mg/kg every minute until 
death ensued), a typical tubocurarine-like flaccid 
paralysis was observed*. The sulphonium analogues of 
de came thonium (Group 2) produced different effects. 
Compounds I and II (1.0 mg/kg every 30 seconds until 
death ensued) produced an Initial spastic paralysis 
which became flaccid prior to death. Compound II 
(1.0 mg/kg every 30 seconds until death ensued) and 
oxydipentonium (1.0 mg/kg every minute) produced a 
typical decame thonium-like, spastic paralysis.
In all of these tests, groups of six chickens 
were used, the results indicating the number of 
Injections required to produce paralysis are shown in 
Tables X and XI.
Hen Gastrocnemius Muscle-Sciatic Nerve Preparation.
This preparation Is primarily of value as a 
means of differentiating between depolarizing and 
non-depolarizing muscle relaxants. It may also be 
used, semi-quantitatively, to compare the approximate
The molar potency and the type of neuromuscular 
blocking activity produced on the hen gastrocnemius 
muscle-sciatic nerve preparation by Group lc compounds, 
E99, E100, E101, E102 and E103.
TABLE XII
Name or Code 
Number of 
Compound
Approx. Molar 
Potency 
(Tubocurarine 
= 100)
®ype of Neuro­
muscular Block 
Produced
E98 20.0 Non-Depolarizing
E99 15.0 Non-Depolarizing
E100 * Non-Depolari zing
E101 5.0 Non-Depolarizing
E102 5.2 Non-Depolarizing
E103 46.0 N on-D e p o1ari zing
* Insufficient material to permit quantitative 
estimation.
Fig. 38. Hen gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, oxydipentonium 0.10 mg/kg.
At B, compound II 0.02 mg/kg.
At C, compound III 0.05 mg/kg.
At D, de came thonium 0.02 mg/kg.
At E, compound I 0.50 mg/kg.
Pig. 39. Hen gastrocnemius muscle-sciatic nerve 
preparation. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound E100 20 mg/kg.
Fig. 40. Hen gastrocnemius muscle-sciatic nerve 
preparations. Pentobarbitone anaesthesia. 
Contraction downwards. Drugs administered 
intravenously. Indirect stimulation via the 
sciatic nerve.
At A, compound E101 20 mg/kg.
At T, tubocurarine 0.1 mg/kg.
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potencies of new compounds with those of decamethonium 
and tubocurarine (Table XII).
The compounds tested on this preparation 
included those of Groups la, lc and Group 2. All the 
compounds in Group 2, together with oxydipentonium, 
produced both a contracture and a contraction of the 
gastrocnemius muscle confirming their depolarizing 
activity. Compounds I and III were much less potent 
than II which was approximately equipotent with 
decamethonium. Typical tracings are shown in Fig. 38.
The onset of paralysis was rapid and the duration of 
block brief. The maximum contraeture-producing activity 
was observed prior to the attainment of the maximum 
inhibition of twitch height.
On the other hand, compounds in Groups la and 
lc were devoid of contracture-inducing properties and 
behaved qualitatively like tubocurarine. The duration 
of action was found to be more prolonged than when these 
compounds were tested on a similar preparation In the cat. 
It should be noted, that compound E100, in which the 
onium substituents were entirely methyl radicals 
exhibited no depolarizing properties. Characteristic 
tracings are shown In Figs. 39 and 40.
-ig. 41. Isolated frog rectus •
AT, * US abc*ominis muscle,
contractions were due to 0.01 mg/kg
acetylcholine acting for 4 5  sec.
At A> ° and S' compound E80 2, 4 and 6 / ,
At B, d  and p  f  ■. ^ s / m l respectively
and P’ ^bocurarine 2, i 5 flTM, - „ . *
respectively. 1b0
Pig. 42. Isolated frog rectus abdominis muscle.
All contractions were due to 0.01 mg/ml acetylcholine 
acting for 45 sec.
At A, C, E and G, tubocurarine 0.5, 1, 1.5 and 
0.5 j-Lg/ml respectively.
At B, D and P, compound E97 1, 2 and 3 |xg/ml 
respectively.
Fig. 43. Isolated frog rectus abdominis muscle. 
All contractions were due to 0.025 mg/ml 
acetylcholine acting for 45 sec.
At A, D, E and G, compound E79 1, 1.5, 2.0 and
2.5 jj.g/ml respectively.
At B, C, F and H, tubocurarine 1.5, 0.5, 2.0 and
2.5 M,g/ml respectively.
Pig. 44. Isolated frog rectus abdominis muscle. 
All contractions were due to 0.01 mg/ml 
acetylcholine acting for 30 sec.
At A, C, E and G, tubocurarine 3.0, 4.0, 2.0 and
1.0 respectively.
At B, D and P, compound E103 20.0, 10.0 and
30.0 M-g/ml respectively.
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Fig, 45, Frog rectus abdominis muscle. The 
relative potencies of tubocurarine and compound E103 
in inhibiting the contracture induced by acetylcholine
Pig. 46. Isolated frog rectus abdominis muscle.
All contractions were induced by drugs acting for 
2 minutes.
At A, C, E, Gr, I, K and M, de came thonium,
2.5, 1.0, 2.0, 6.0, 3.5, 3.0 and 1.5 M-g/ml respectively. 
At B, B, P, H, J, L and compound III,
8, 5, 10, 50, 75, 100 and 25 ng/ml respectively.
Fig. 47, Frog rectus abdominis muscle. 
Comparative estimation of the contracture- 
inducing properties of decamethonium and 
compound III.
TABLE XIII
A comparison of the potency of the compounds E77,
‘ E78, E79, E80, E96, E97, E98, E99, E100, E101, E102 
and E103 v/ith tubocurarine and of compounds I, II 
and III and decamethonium on the frog rectus abdominis 
muscle.
Compound Code Number Approximate Molar Potency 
Tubocurarine = 100
E77 375
E78 77
E79 208
E80 26
E96 63
E97 72
E98 7
E99 4
E100 1
E101 2
E102 2.5
E103 LO•o 1—1
Approximate Molar Potency 
Decamethonium = 100
I *
II 50
III 7.0
* Could not be estimated. Please see Fig. 48 
opposite page 120.
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Frog Rectus Abdominis Muscle.
Results obtained using this preparation 
confirmed the division of the compounds studied into 
depolarizing (Group 2) and non-depolarising (Groups la, 
lc) agents.
Rone of the compounds tested in Groups la and 
lc caused any direct stimulant effect. Each produced 
graded inhibitory effects on acetylcholine-induced 
(1 - 10 {j,g/ml) contractions, acting similarly to 
tubocurarine (Figs. 41, 42, 43 and 44). On this basis, 
a comparison of these drugs with tubocurarine was made. 
The potency of these compounds, as measured by the 
degree of inhibition of acetylcholine-induced 
contractions is shown in Table XIII. The potency of 
each compound was determined graphically as shown in 
the example (Fig. 45).
Compounds I, II and III (1.0, 0.2 and 1.0 mg/kg 
respectively) produced a contracture and augmented the 
effects of acetylcholine on this preparation. Fig. 46 
shows typical examples of the contracture-Inducing 
effects of these compounds. All were, however, weaker 
than decamethonium, the order of potency being 
decamethonium ^ 1 1  III ^  I (Fig. 47 and Table XIII). 
Compound I possessed very weak stimulant properties.
Pig, 48. Frog rectus abdominis muscle. 
Comparison of the contracture-inducing 
properties of decamethonium and compound I* 
It is obviously Impossible to compare 
quantitatively the effects of each drug on 
this preparation.
Fig. 49. Cat. Pentobarbitone anaesthesia.
Blood pressure record from common carotid artery. 
Drugs administered intravenously. Vertical scale 
on left hand side indicates the blood pressure in mm 
of mercury.
At A, B and C, compound E91 0.5 mg/kg, 0.75 mg/kg 
and 1 mg/kg respectively.
At S, normal saline (0.9$), 4 ml.
At T, tubocurarine 1 mg/kg.
At D and E, compound E79 0.05 mg/kg and 0.1 mg/kg.
At F and G, compound E80 0.05 mg/kg and 0.1 mg/kg.
At H and I, compound E90 0.05 mg/kg and 0.1 mg/kg.
Fig. 50. Cat. Pentobarbitone anaesthesia. Blood 
pressure record from common carotid artery. Drugs 
administered intravenously. Vertical scale on 
left hand side indicates the blood pressure in mm 
of mercury.
At A, compound E97 0.1 mg/kg.
At B and C, compound E96 0.2 mg/kg and 1.0 mg/kg. 
respectively.
At and T2 > tubocurarine 0.5 mg/kg and 1.0 mg/kg 
respectively.
At D, E and F, compound E78 0.05 mg/kg, 0.15 mg/kg 
and 0.20 mg/kg respectively.
At S, normal saline (0.9^), 3 ml.
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Inspection of the slopes of the log dose-response 
curves (Fig* 48), showed that a quantitative comparison 
of compound I and decamethonium was impossible* These 
results prompted a further investigation of the basic 
mode of action using the Ariens1 technique.
Results of Tests Other Than Those Designed to Investigate 
Neuromuscular Blocking Potency. .-----           —------------------------ ' f  ■
Effect on the Blood Pressure of the Anaesthetized Cat.
None of the compounds in Groups la, lb and lc 
produced any significant rise or fall In the blood 
pressure of the cat even when administered in doses in 
excess of those required to induce complete neuromuscular 
block (Figs. 49 and 50). Tubocurarine (0.5 - 1.0 mg/kg), 
on the other hand, produced a significant fall in blood 
pressure when tested on the same preparation, attributable, 
It has been suggested, to a block of transmission of 
sympathetic vasoconstrictor impulses at the ganglion 
synapse (Landmesser, 1947) and to the liberation of 
histamine (Paton, 1951). The more potent muscle 
relaxant compounds In Group Id, which were reported to 
possess comparatively weak ganglion blocking properties, 
produced no significant changes in blood pressure levels 
and in larger doses produced a slightly hypertensive 
effect which might have been associated with anoxia.
Fig. 51. Oat. Pentobarbitone anaesthesia. Blood 
pressure record from common carotid artery. Drugs 
administered intravenously. Vertical scale, on 
left hand side, indicates the blood pressure in mm 
of mercury.
At T, tubocurarine 0.10 mg/kg.
At A, compound F. & P. 16677 20 mg/kg.
250 r Hg
■VV/A''%VAV»>,V,V,V,W*N
mm
250 -  Hg
150
50 1 t
C
30"hi ii J
Fig. 52. Oat. Pentobarbitone anaesthesia. Blood 
pressure record from common carotid artery. Drugs 
administered intravenously. Vertical scale, on left 
hand side, indicates the blood pressure in mm of 
mercury. Recordings from three different animals. 
At A, (from left to right) compound I 0.1, 0.5 and 
0.6 mg/kg respectively.
At B, (from left to right) compound II 0.05 and 
0.25 respectively.
At 0, compound III 0.1 mg/kg.
Fig. 53. Cat. Pentobarbitone anaesthesia. 
Contractions of the nictitating membrane elicited 
at 3 minute intervals by preganglionic stimulation 
of the superior cervical nerve trunk at a frequency 
of 1200 impulses/min, 10 V and 1.0 msec for 15 sec. 
Drugs administered intravenously 30 sec before 
stimulation.
At A, B and C, compound E94 0.5, 1.0 and 2.0 mg/kg 
respectively.
At D, E, F and G, compound E95 0.5, 1.0, 1.5 and
2.0 mg/kg respectively.
At H, compound E96 0.5 mg/kg.
Fig. 54. Cat. Pentobarbitone anaesthesia. 
Contractions of the nictitating membrane elicited 
at 3 minute intervals by preganglionic stimulation 
of the superior cervical nerve trunk at a 
frequency of 1000 impulses/min 10 V and 1.0 msec 
for 15 sec. Drugs administered intravenously 
30 sec before stimulation.
At A and B, compound E77 0.5 mg/kg and 1 mg/kg 
respectively.
At C and D, compound E78 0.5 mg/kg and 1 mg/kg 
respectively. .
At E, compound E79 0.5 mg/kg.
At F, compound E80 0.5 mg/kg.
At G, compound E96 0.5 mg/kg.
At H, compound E§7 1 mg/kg.
At T, tubocurarine 0.5 mg/kg.
Fig. 55. Cat. Pentobarbitone anaesthesia. 
Contractions of the nictitating membrane elicited 
at 3 minute intervals by preganglionic stimulation 
of the superior cervical nerve trunk at a frequency 
of 800 impulses/min, 10 V and 1.0 msec for 15 sec. 
Drugs administered intravenously 30 sec before 
stimulation.
At A, compound I 0.5 mg/kg.
At B, compound III 0.3 mg/kg.
At C, compound II 0.5 mg/kg.
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On the other hand, those compounds possessing potent 
ganglion blocking properties, for example compounds 
F, Sc P. 16575, F. Sc P. 16677 and F. Sc P. 16678, produced, 
as expected, a significant hypotensive action on this 
preparation (Fig* 51).
The depolarizing compounds of Group 2, in doses 
sufficient to produce partial neuromascular block 
(0*05 - 0*5 mg/kg) exerted no significant effect upon 
the blood pressure, but in larger doses (0.2 - 0.5 mg/kg) 
compound II produced a prolonged rise (Fig. 52).
Estimation of Ganglion Blocking Activity.
Cat Nictitating Membrane Preparation. Sympathetic 
Ganglion Blockade.
Following injection of compound E94 (1 mg/kg), 
a slight reduction in the height of the contraction of 
the nictitating membrane was observed (Fig. 53) but none 
of the other compounds in Groups la, lb, lc or 2, 
produced any sympathetic ganglion blocking effect (Fig. 54). 
Compound II (0.5 mg/kg) produced a prolonged contraction 
of the nictitating membrane (Fig. 55). In contrast 
to these effects, tubocurarine (0.5 mg/kg) always 
produced a marked reduction in the height of contraction 
of the nictitating membrane (Fig. 54).
Fig. 56. Guinea Pig ileum. Composite picture.
The effect of drugs on contractions of the 
longitudinal muscle layers (upper trace) and on 
peristalsis (lower trace) recorded by Trendelenberg1 
method (1917). Volume of bath used was 50 ml.
At A, compound I 0.5 mg.
At B, compound II 0.1 mg.
At C, compound III 0.5 mg.
At D, decamethonium 0.1 mg.
At E, hexamethonium 0.2 mg.
At T, tubocurarine 0.5 mg.
Fig. 5V. Guinea Pig ileum. Composite picture.
The effect of drugs on contractions of the 
longitudinal muscle layers (upper trace) and on 
peristalsis (lower trace) recorded by Trendelenberg* 
method (1917). Volume of bath used was 50 ml.
At A, compound E77 1 mg.
At B, compound E79 2 mg.
At C, compound E91 1 mg.
At D, compound E95 2 mg.
At E, hexamethonium 1 mg.
At F, compound E98 20 mg.
At T, tubocurar ine 1 mg.
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Compounds in Group Id have all been reported 
to possess ganglion "blocking properties when tested 
on a similar preparation. A.full account of their 
properties has been provided by Fakstorp and his 
colleagues (1954, 1955, 1956, 1957a,b,^),
Guinea Pig Ileum - Parasympathetic Ganglion Blocking 
Activity.
Hone of the compounds In Group la ( 1 - 3 mg) 
or Group 2 (0.1 - 0.5 mg) (Fig. 56) exerted any ganglion 
blocking activity on this preparation. Compounds E77 
(1 mg), E78 (3 mg) and I (0.5 mg) slightly enhanced 
the longitudinal contractions of the gut without 
interfering with peristalsis. Among the compounds in 
Group lb, the tris-onium derivatives E91 (1 mg) and 
E95 (2 mg) blocked peristaltic movements (Fig. 57).
This action was especially marked in the former but none 
of the other compounds in this group exerted any ganglion 
blocking action. In Group lc, compound E98, in very 
high doses (10 - 20 mg) showed a ganglion blocking 
action but none of the other compounds in this group 
were active on this preparation.
Experiments Upon Mice.
Estimation Of The Approximate Median Paralyzing Dose (PD50).
- Compounds in Groups la, lb and 2 were tested on
ii
A comparison bf the Potency and Toxicity of 
compounds E77, E78, E80, E96, E97, E91, E93, E94 
and E95 and Tubocurarine, in mice.
TABLE XIV
Name or 
Code No. 
of
Compound
Approx. Mean 
Median 
Paralyzing 
Dose (P.D.50) 
mg/kg ± S.E.M.
Approx, Mean 
Lethal 
Paralyzing 
Dose (L.D.50)
mg/kg t  S.E.M.
Thera­
peutic
Index
(L.D.50)
(P.D.50)
Com­
parative 
Molar 
Potency 
(Tubo­
curarine 
= 100)
E77 (5) 0.21 t  0.004 0.61 ± 0.04 2.91 165
E78 (5) 0.36 t  0.02 1.2 ± 0.10 3.33 132
E79 (4) 0.20 ± 0.02 0.66 t  0.06 3.30 174
E80 (4) 0.20 t  0.02 0.76 t 0.11 3.80 165
E96 (5) 0.25 + 0.01 0.52 t  0.02 2.08 146
E97 (4) 0.24 t  0.01 0.74 ± 0.05 3.08 151
E91 (6) No Paralysis 
with 20 mg/kg
*• —
E93 (6) 2.15 t  0.35 14.6 ± 1.52 6.79 11
E94 (7) 0.90 ± 0.06 3.1 t  0.22 3.44 22
E95 (8) 2.0 f 0.16 8.0 ± 0.70 4.0 13
Tubo- 
curar ine 
(V)
0.25 t  0.01 0.52 ± 0.40 2*08 100
The number, in brackets, in the first column indicates 
the number of groups of animals tested.
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this species. All the compounds tested induced 
restlessness and Increased movement after approximately 
five to ten minutes. A period of quiet then ensued, 
prior to the loss of the animals1 ability to retain 
their positions on the inclined plane and the onset of 
paralysis. Recovery from paralysis was normally . 
complete within twenty minutes. The time of onset of 
action and the period required for recovery from 
paralysis were greater for the compounds in Group 2 
than for those In Group 1.
Estimation of The Approximate Median Lethal Dose (LD50).
The median lethal dose was determined in a 
similar way. Following an intraperitoneal injection 
of a minimal lethal dose of the compounds In Groups la 
and lb, there was a rapid development of a typical 
flaccid paralysis followed by failure of respiration. 
Respiratory collapse, In almost all cases, preceded 
cardiac arrest.
With compounds in Group 2, death was preceded 
by clonic convulsions and an extensor spasm of the 
hindlegs. The therapeutic ratio , as shown in
Table XIV, was highest for compound III and lowest for 
decamethonium.
The median lethal paralyzing dose for compounds
r .+>G)
To 5
"DC«D
O '
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in_>022
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Fig. 58. Diagram of the graphical estimation 
of the PD50 and the LD50 for compound E93 
(Miller & Tainter, 1 9 4 4 ). From original graph 
PD50 = 2.15 -0.27; 1D50 = 14.6 ± 1.52.
(Please see accompanying text).
TABLE XV
A comparison of the Potency and Toxicity of 
compounds I , II and III and Decamethonium in mice.
Compound 
and no. of 
Groups 
tested
Approx, Mean 
Median 
Paralyzing 
Dose (P.D.50) 
mg/kg t  S.E.M.
Approx. Mean 
Lethal 
Paralyzing 
Dose (L.D.50) 
mg/kg t  S.E.M.
Thera­
peutic
Index
(L.D.50)
(P.D.50)
Com­
parative 
Molar 
Potency 
(Deca­
methonium 
= 100)
I (5) 4.1 i  0.40 11.1 t  0.60 2.7 44
II (4) 4.1 t  0.43 9.3 t  0.60 2.3 44
III (6) 3.1 i  0.58 24.3 i  2.8 7.8 55
De ca­
me thoni^m^
1.9 ± 0.11 3.8 t  0.18 2.1 100
Method of calculating the mean P.D.50, L.D.50 
and their standard errors (S.E.M.) in mice for 
compound E95 (Miller & Tainter, 1944)*
TABLE XVI
. O 
O 
. 
£ Dose
(mg/kg)
Number
Paralyzed
w
Number
Killed
(g>
Probit
Value
i 1 40 4.75
2 2 90 6.28
3 5 10 3.72 •
4 6 20 4.16
5 7 40 4.75
6 8 60 5.25
Prom original graph, P.D.50 
Standard Error (P.D.50) 
Probit 4 = 1.0 
Probit 6 = 2.0 
2S = 1.0
Ho. treated (H) = 20
S.E.M. = 2S = 1^0 = 0.16
6.324
2.0, L.D.50 = 8.0. 
Standard Error (L.D.501
Probit 4 = 5.6 
Probit 6 = 11.0 
2S = 5.4
Ho. treated (H) = 80
S.E.M. = 2S = 5.4 = 0.60
V'ST* 8.944
P.D.50 = 2.0 ± 0.16
L.D.50 = 8.0 - 0.70
124
in Group Id, has been estimated by Fakstorp and 
Pedersen (1957£). The results of compounds in Groups 
la, lb and 2 were calculated by the graphical method 
described by Miller and Tainter (1944) and are shown in 
Table XV. The percentage paralyzed or killed in each 
group, at each dose level, was plotted on a logarithmic 
scale, as a probit value, against the dose (mg/kg) of 
drug producing the effect. The estimated PD50 was 
that dose corresponding to 50$ (probit 5.0) and could 
be read directly from the graph in mg/kg. The median 
lethal dose (LD50) was determined in a similar fashion.
In order to estimate the standard error of the
PD50 and the LD50, two additional values were read
from the graph (Fig. 58 and Table XVI). These
corresponded to the dose producing 16$ and 84$ (probits
4.0 and 6.0) of the effect, the difference between these
values being the estimated increment necessary to
increase the effects by two probits in this dose range
(2S). The approximate average standard error was
determined using the following formula
Approximate standard error of the mean (S.E.M.) ~ 2S
yffZlr
The value U indicated the total number of 
animals in the groups which would be expected to show
Fig. 59. Isolated rabbit heart, 
shows heart rate, lower tracing, 
Numbers represent the heart rate 
At T, tubocurarine 1 mg.
At A and D, compound E96 1 mg.
At B and C, compound E97 1 mg.
At E, compound E77 1 mg.
At F, compound E80 1 mg.
Upper tracing 
the cardiac outflow, 
in beats/min.
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results between 6.7$ and 93.3$ (probits 3.50 and 6.50) 
as described by Miller and Tainter (1944).
Experiments on the Isolated Perfused Rabbit Heart.
In view of the qualitative and quantitative 
aspects of the block produced by compounds in Groups 1 
and 2, only drugs in Group la were believed to possess 
clinical potentialities. Accordingly, their effects on 
the isolated, rabbit heart preparation were investigated. 
Hone of these compounds, in doses from 1.0 to 3.0 mg, 
produced any significant depressant or accelerating 
effect on the rate or amplitude of the heart. An example 
of a characteristic tracing is given in Pig. 59.
Prom the tests carried out, no toxic effects on 
the heart muscle of the rabbit could be detected.
Yi/hile it is impossible to forecast, from these experiments, 
the effect of these drugs on human cardiac muscle, the 
presence of toxic effects on this preparation would 
eliminate the possibility of their being clinically 
investigated.
Experiments on the Respiration of the Anaesthetized 
Rabbit and Cat.
The clinical importance of the action of 
muscle relaxants on the muscles controlling respiration, 
prompted an investigation of the effect of the more
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potent compounds upon respiration in experimental 
animals* However, on account of the lack of material, 
only the compounds in Group la and Group 2 were 
investigated, the former on the rabbit and the latter 
on the cat. -
Irrespective of the species employed, the 
continuous Intravenous infusion of the compounds under 
test (E77, E79, E80, E96, E97 and tubocurarine, 0.2 mg/ml; 
I, 1 mg/ml; II, III and decamethonium, 0.1 mg/ml) 
always resulted in respiratory paralysis. Spontaneous 
respiratory movements only returned following the use 
of artificial respiration although complete recovery 
was attained in every case.
Each drug was tested several times on different 
animals. The respiratory paralyzing dose was that 
administered during the first experiment on each animal. 
Subsequent doses, less than the first, were not 
included. The respiratory paralyzing doses of the 
compounds In Group la were similar to their head drop 
doses (H.D.D.) and all were more potent than tubocurarine 
in this respect. On the other hand, the doses of 
compounds I, II and III, required to induce complete 
respiratory paralysis In the cat, were less than those 
required' to paralyze respiration in the same species.
TABLE XYII
■I *  : -  - —
A comparison of the individual and mean respiratory 
paralyzing doses of compounds E77, E79, E80, E96 and 
E97 and tubocurarine on the urethane-anaesthetized 
rabbit and of compounds I, II and III and 
decamethonium on the pentobarbitone-anaesthetized cat.
Name or 
Code Ho. 
of Com­
pound
Respiratory Paralyzing Pose Potency 
(Tubo­
curarine 
= 100)
Individual (mg/kg) Average
(mg/kg)
E77 0.22, 0.24, 0.21 0.22 139
E79 0.10, 0.16, 0.14 0.13 235
E80 0.21, 0.26, 0.33 0.27 107
E96 ’ 0.26, 0.25, 0.30 0.27 119
E97 0.27, 0.24, 0.30 0.27 119
Tubo­
curarine 0.16, 0.26, 0.24 0.22 100
Potency 
(Leca- 
methoniun 
= 100)
I 1.5, 1.6, 1.1 1.4 8
II 0.36, 0.36, 0.36 0.36 31
III 0.42, 0.35, 0.45 0.41 24
Peca-
methonium
0.09, 0.11, 0.12 0.11 100
Pig. 60. Oat. Pentobarbitone anaesthesia.
Record of respiratory movements from the epigastrium. 
Vertical scale indicates the blood pressure in mm 
of mercury.
At C, intravenous infusion of compound III 0.20 mg/ml. 
At AR, artificial respiration commenced.
Rate of infusion of drug was 0.75 ml/mm.
Rate of respiration of animal at commencement 
of experiment was 18/min.
Fig. 61. Rabbit. Urethane anaesthesia.
Record of respiratory movements using the method 
of G-addum (194-1). Vertical scale indicates the 
blood pressure in mm of mercury.
At A, intravenous infusion of compound E79 0.20mg/ml. 
At AR, artificial respiration commenced.
Rate of infusion of drug was 0.75 ml/min.
Rate of respiration of animal at commencement of 
infusion was 92/min.
TABLE XVIII
Compounds investigated using the AriSns* procedure. 
The compounds investigated using this technique 
include tubocurarine dimethyl ether and tubocurarine 
(formulae opposite page 56) compounds E77, E78, E79, 
E80, E98, E99, E100, E101, E102, E103, I, II, III 
and decame thonium (formulae in Tables II and III 
opposite page 99) and oxydipentonium and compound 
E151 (formulae given below).
Name or 
Code No. 
of
Compound
Basic Chemical 
Structure
R n An­
ion
Type
of
Block
Oxydi­
pentonium
R3N-(CHg)n-0-(GH2)n_ltR3 c h 3 5 Cl" Depolar­
izing
E151 R3lt- (CH2 )n-N- (CH2) n-RR3 
l( R
c h 3 6 I- Non-De­
polar­
izing
Pig. 62. Prog rectus abdominis muscle preparati 
Ariens* procedure. Experimental recordings of 
contractures from three different pieces of 
tissue induced by;
At a, decamethonium (2 M,moles/ml)
At b, compound II (2 pmoles/ml)
At c, compound III (2 ixmoles/ml)
Volume of bath = 10 ml.
Numbers indicate the volume of drug 
solution added.
Pig. 63. Prog rectus abdominis muscle preparation. 
Ariens* procedure. Experimental recordings 
of contractures induced by;
At a, decametlioniurn alone (2 pmoles/ml)
At b, decamethonium (10 pmoles/ml) in the presence 
of compound E101 (100 (imoles/l)
At c, decamethonium (10 |j.moles/ml) in the presence 
of compound E101 (600 pmoles/l)
At d, decamethonium (10 pmoles/ml) in the presence 
of compound E101 (1000 umoles/l).
Numbers indicate the volume of decamethonium 
solution added.
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All the compounds of Group 2 were less potent than 
decamethonium. The results of these experiments are 
shown in Table XVII and characteristic tracings shown 
in Pigs. 60 and 61.
Experiments on the Isolated Prog Hectus Abdominis Muscle 
Using Ariens* Technique,
The chemical structures of the compounds whose 
mode of action was investigated using the experimental
if fi •procedure first described by Ariens (Ariens & de Groot, 
1954) are shown in Table XVIII. Cumlative log 
dose-response curves were constructed for agonists 
alone and In the presence of constant doses of non­
depolarizing muscle relaxants. The results, vihlch can 
be most conveniently expressed graphically, are shorn 
in Pigs. 64 to 71.
On the basis of these graphs, a classification 
of the drugs under investigation was made according to 
the original scheme devised by Ariens and his associates 
(Van Rossum et al. 1958). Typical experimental 
recordings are shown in Pigs. 62 and 63.
The interaction of a substance A with a 
hypothetical receptor system t fo ) containing R receptors, 
is represented by the equation
E* = y'oa
%K. * 1
CA-l
Pig. 64. Cumulative log dose response curves for 
decamethonium, oxydipentonium and compounds I,
II and III performed on the isolated frog rectus 
abdominis muscle. The variation in the maximum 
height produced and the displacement of the curves 
along the abscissa indicate the differences in the 
intrinsic activity and the affinity values of these 
compounds.
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whore E^ Is the effect of substance A, the 
dissociation constant of the complex R A, and a the 
intrinsic activity of drug A whose concentration is 
represented b y £  3J.
The maximum effect of a compound (E maximum), is 
proportional to its intrinsic activity. The dose of a . 
compound producing a constant fraction of the maximum 
response, for example 50$, is proportional to the value 
of the dissociation constant of the drug-receptor 
complex,
Pig. 64 represents a comparison of the agonistic, 
contracture-inducing properties of decamethonium whose 
intrinsic activity and affinity value xms arbritarily 
assigned unity, oxydipentonium and compounds I, II and 
III. The order of addition of the drug and decamethonium 
to the bath was determined from a table of random numbers 
assigning equal chances of coming first or second to 
either decamethonium or the drug with which it was being 
compared* Oxydipentonium and compound II were each 
compared with decamethonium in twenty experiments while 
compounds I and III were similarly investigated ten 
times. Using S1rudentTs t test (Snedecor, 1956) no 
significant difference in the intrinsic activity value 
of decamethonium, oxydipentonium and compound II
Emaximum
5 0 %  Em axim um
log moles/1.
Pig. 65. Prog rectus abdominis muscle. . Method 
of comparing the intrinsic activity and affinity , 
values of decamethonium and compound III.
Prom original graph,
Emaximum (decamethonium) = 1.0 (arbritarily assigned) 
Emaximum (compound III) = 0.6.
50$ Emaximum, (decamethonium) = antilog 0.72 = 5.25
50$ Emaximum, (compound III) = antilog 1.21 = 16.22
Affinity = JL_ ; Intrinsic activity is proportional
k a
to Emaximum (AriSns & de G-root, 1954).
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(0.2^P >  0.1) was revealed. There were, however, 
significant differences between the intrinsic activity 
values of decamethonium and compound I <*< 0.001) and 
between decamethonium and compound III (P^O.OOl) as 
indicated by the reduction in the maximum contractural 
height produced.
The value of the dissociation constant (K^) for 
eaeh drug was also calculated by determining that dose 
which produced 50% of the maximum observed biological 
response (Ariens & de Groot, 1954). The reciprocal 
of this value represented the affinity of the compound. 
Pig. 65 shows the calculation of intrinsic activity and 
affinity values for decamethonium and compound III.
These values, for all five compounds, appear In Table XIX 
and are discussed on page (50 .
The comparatively low intrinsic activity of 
compound I, confirmed by observations using the 
conventional frog rectus assay procedure, prompted a 
further investigation into the basic mode of action of 
this drug. Accordingly, a series of log dose-response 
curves were constructed for different molar doses of 
this compound and the response of each dose level 
expressed as a percentage of that observed using a 
solution of 1 mole/ml. The shape of the curves obtained,
Pig. 66. Cumulative log dose-response curves 
for various concentrations of compound I 
performed on the isolated frog rectus abdominis 
muscle. The agonistic and auto-inhibiting 
effects of this drug are observed as a gradual 
decrease in the maximum height and a displacement 
of the curves along the abscissa.
Fig* 67. Cumulative log dose-response curves 
for decamethonium performed on the isolated 
frog rectus abdominis muscle alone (0 p.moles/1) 
and in the prescence of constant concentrations 
(4, 8, 40, 80, 200 and 400 |jLmoles/l) of compound I* 
The agonistic and non-competitively antagonistic 
properties of compound I appear as a contracture 
and a decline of the maximum height of the curves.
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shown in Pig. 66, indicated that this drug possessed 
both agonistic and non-competitively antagonistic 
blocking properties. At higher dose levels, the 
auto-antagonistic action of the drug was apparent. 
Investigation of these properties, by constructing a 
series of log dose-response curves for decamethonium 
in the presence of different doses of compound I 
(Pig. 67) confirmed these properties. The dose of 
compound I employed in any one experiment remained 
constant throughout. Due to insufficient material, it 
was impossible to construct hyperbolic log dose-response 
curves for compound I alone, in order to confirm, 
quantitatively, the nature of the auto-interaction 
produced. The preponderance of experimental evidence 
obtained, however, is not incompatible with the view 
that compound III possessed auto-inhibitory, non­
competitive properties (Ariens e t al. 1957).
According to the Ariens* classification 
(Van Rossum et al. 1958), all the remaining compounds 
possessed Type 2, non-depblarizing properties. The 
dose of each drug chosen for initial investigation was 
related to Its molar potency compared to tubocurarine, 
as based on experiments carried out using the conventional
(C H ^  (C2Hs)N -(C H 2) 2-  O -  (CH2)2 -  5 -  (C H a V  O -  (C H jy  N f C ^ C H ^
CH3 C2H5 31®
Pig. 68. Cumulative log dose-response curves 
for decamethonium performed on the isolated 
frog rectus abdominis muscle, alone (0 p.moles/1) 
and in the presence of constant concentrations 
(100 and 300 p.moles/1) of compound E101. The 
competitively antagonistic properties of 
compound E101 appear as a displacement of the 
curves along the abscissa unaccompanied by any 
reduction in the maximum height.
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frog rectus assay method. The dose of tubocurarine
(tinitially used (1 jxmole/l) was that employed by Ariens 
(Van Rossum e t al. 1958). Subsequently whole multiples 
of this dose of tubocurarine and of the other compounds 
were investigated.
The compounds tested included tris- and 
tetra-onium compounds containing one or two ether 
oxygen functions together with several corresponding 
non-ether homologues. Of these, none possessed any 
contracture-producing properties on the frog rectus 
abdominis muscle preparation but when placed in the bath
t
prior to the addition of decamethonium, all displaced 
the log dose-response curve along the abscissa without 
affecting either the slope or the maximum observed 
contractural response. Thus, in the presence of 
constant doses of these compounds, the decamethonium 
log dose-response curve suffered a paralled displacement 
along the abscissa.
A typical example of these effects is shown in
Pig. 68.
The interaction of depolarizing and non­
depolarizing compounds has been discussed by Ariens 
and de Groot (1954). The mathematical relationship
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derived to represent this interaction has been expressed
as E max = %  x IgX/E max = maximum effect
Ea b  KtT" rAl EAB = combined effect
of A and B)
where and Kg are the dissociation constants of the
drug-recaptor complex produced by the depolarizing
agent A, £A  J  , and the non-depolarizing compounds
B, ^ B 3 ,  respectively. From this equation, if
parallel log dose-response curves are obtained
experimentally for an agonist alone, and in the presence
f  B 3of constant doses of an antagonistic drug, the term 
mast remain constant. That is, the observed parallelism 
is related to alteration in the rates of dissociation of 
the respective drug-receptor complexes involved. The
C b -rZ j i  determined for doses producing 50% of the 
maximam response, has been termed the inhibition index1
tt .Ariens & de G-root, 1954) and is constant when a truly
competitive antagonism between two drugs prevails. In
*consequence, for the interaction of such compounds, the 
inhibition indices may be used as a measure of the 
dissociation constants, or the affinities, of the compounds 
concerned. When several non-depolarizing compounds are 
investigated using the same depolarizing compound, for 
example decamethonium, since K^ for the latter is
log ^moles/l. Decamethonium
Pig. 69* Prog rectus abdominis muscle.
Method of comparing the 'inhibition indices' of 
compounds E100 and E151.
Prom original graph,
Inhibition Index (E100) = 100 100 =  6 . 6
Antilog 1.18 15.14
Inhibition Index (E151) = 100   = 100
Antilog 1.63 42.66
= 2.3
© © ©, , , 
lCH3) 2 (C2H5)N - (C H 2)2-0 -C C H 2)2-N -C C H 2) 2- 0 - ( C H a)2- N  (C2H5X C H 3) 2
CH3 C2Hs 31®
for decamethonium, performed on the isolated 
frog rectus ahdominis muscle, alone (0 p.mores/1) 
and in the presence of constant concentrations 
(100, 300, 600 and 1000 M-moles/l) of compound E.101. 
The competitively antagonistic properties of 
compound E101 in lower concentrations (100 and 
300 nmoles/l) gives way to non-competitively 
antagonistic effects at higher concentrations 
(600 and 1000 pmoles/l) as shown by the decline in 
the curves and the decrease in the maximum height.
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constant, the’inhibition indices1 are inversely 
proportional to the affinities between the receptor 
and the non-depolarizing compounds. Accordingly, 
inhibition indices* for these compounds in Group I, 
tested by the Ariens procedure, were calculated on this 
basis and the mean of at least three individual results 
taken in each case. An example of the method of 
calculating the inhibition indices* for compounds E100 
and E151 is given in Pig* 69. The results are shown 
in Table XX and discussed on page /SO,
When doses of these drugs were used, in excess 
of those normally required to completely inhibit 
acetylcholine-induced contractural responses, differences 
in the shape and height of the decamethonium log dose- 
response curves were observed. In addition to a 
non-parallel shift of the curves along the ordinate, a 
decline in the maximum height of the contractural 
response was also observed. The shape of these curves 
was characteristic of a non-competitive antagonism on 
the basis of the Ariensr classification (Van Kossum 
et al* 1958). An example of the transition from a 
competitively antagonistic to a non-competitively 
antagonistic drug is shown in Pig. 70.
The role of the ether oxygen function was
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Investigated by comparing tlie degree of displacement 
of the decamethonium log dose-response curve produced 
by equimolar doses of the ether-containing and the 
related non-ether compounds. In addition to 
oxydipentonium and decamethonium, four pairs of compounds 
were selected for this investigation. These were 
compounds E77 and E79, E78 and E80, E100 and E151, 
together with tubocurarine dimethyl ether and tubocurarine. 
All the compounds were employed in doses at which they 
antagonized decamethonium competitively. A similar 
qualitative effect was thus produced by all eight 
compounds, but quantitative variations in the degree of 
displacement of the decamethonium log dose-response 
curve were observed between the ether and the non-ether 
derivatives. The tetra-onium mono ether-containing 
compounds E77 and E78 respectively had a greater affinity 
for the decamethonium receptor site than the corresponding 
non-ether derivatives E79 and E80. On the other hand, 
the insertion of a second ether oxygen function, which 
had already been observed to exert a marked deleterious 
effect on potency, was associated with a reduction In
i
the affinity value of compound E100 below that of E151. 
Similarly tubocurarine dimethyl ether appeared to possess 
a lower affinity for the cholinergic receptor site in
Pig. 71. Cumulative log dose-response curves for 
decamethonium performed on the isolated frog rectus 
abdominis muscle alone (0 jamoles/l) and in the 
presence of equal concentrations of compound E77 
and compound £79. The difference in the displacement 
of the curves along the abscissa represents a 
difference in the affinity of the two compounds.
Both compounds E77 and E79 show competitively 
antagonistic properties.
^ig. 72. Cumulative log dose-response curves for 
decamethonium performed on the isolated frog 
rectus .abdominis muscle, alone (0 |jmoles/l) and 
in the presence of equal concentrations of 
tubocurarine and tubocurarine dimethyl ether.
The difference in the displacement of the curves 
along the abscissa represents a difference in the 
affinity of the ether and non-ether compound. Both 
tubocurarine and tubocurarine dimethyl ether show 
competitively antagonistic properties.
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the frog than tubocurarine itself. Typical examples 
of these effects are shown in Pigs. 71 and 72.
The insertion of an ether oxygen function at 
the expense of a methylene group into the molecule of 
decamethonium produced a slight reduction in the affinity 
value of the compound (oxydipentonium Pig, 64). Since 
no intrinsic activity differences could be detected, 
the effect of the ether oxygen function was concerned 
with the degree of drug-recaptor complex formation 
achieved (affinity) rather than with the power of this 
complex to evoke a positive biological response.
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DISCUSSION
The compounds investigated in this thesis 
all produce a relaxation of skeletal muscle hut not 
hy identical peripheral mechanisms* Application of 
the accepted criteria for the qualitative differentiation 
of muscle relaxants (Paton & Zaimis, 1952) showed 
that the compounds of Groups la, lh, lc and Id were 
non-depolarizing neuromuscular blocking agents, while 
those of Group 2 possessed depolarizing activity.
A study of these compounds failed to establish 
any clear correlation between chemical structure and 
pharmacological activity. Apart from the fact that 
the compounds did not form a regular chemical series, 
there also exist the general difficulties besetting 
the derivation of any structure - action relationships, 
as stressed by Clark (1957) and Ing (1959) and 
summarized by Reid (I960). The original concept of 
a two-point attachment of a bisquaternary salt to the
c  -
receptor (Paton & Zaimis, 1949; Barlow, 1955) has 
recently been subject to considerable criticism. In 
addition to the adumbration hypothesis of Loewe and 
Harvey (1952), already discussed (page 28), the theory 
of a one-point receptor attachment put forward to
Fig. 74. A diagrammatic representation of the 
maximally extended form (a) and the ion-pair complex 
formation (b) in which bis-quaternary salts can 
exist. In the former, the di-cation is involved, 
with two anionic sites but in the latter an ion- 
pair, involving only one anionic site, is concerned. 
(After Cavallito & Gray, I960).
I
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account for the ganglion "blocking potency of a 
series of bis-choline ether salts (Fakstorp &
Pedersen, 1957a,b) might also apply to neuromuscular 
blocking agents. Furthermore, the use of 
conductimetrie techniques (Brody & Fuoss, 1956) has 
clearly established that simple polymethylene 
bisquaternary compounds possess certain properties 
which are qualitatively and quantitatively different 
from those of mono quaternary derivatives. Even in 
dilute aqueous solution, these polymethylene, 
bisquaternary salts show a marked tendency to associate 
with other ions (Rice, 1956, 1958). In particular, 
the combination of a polymethylene di-cation with a 
single anion has been shown to be extremely stable.
This raises the possibility that in drug-receptor 
complex formation, the two cationic groups do not 
necessarily adopt a maximally extended conformation 
covering two anionic sites (Pig. 74a) but form an 
ion-pair complex with a single anionic site (Pig. 74b) 
(Cavallito & Gray, I960). Moreover, it has been 
suggested that for a two point attachment, the more 
likely conformation would be a compromise between the 
maximally extended form (Pig. 74a), favoured on account 
of its thermodynamic stability, and a less fully
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extended form favoured by considerations of entropy.
It is thus virtually impossible to consider the 
receptor site purely in terms of the interquaternary 
distance in the drug molecule.
Despite the difficulties just enumerated, 
several attempts have nevertheless been made to derive 
relationships between chemical structure and muscle 
relaxant activity. Among aliphatic compounds, attention 
has been focussed on the nature of the alkyl substituents 
(Paton & Zaimis, 1952; Barlow, Roberts & Reid, 1951; 
Thesleff & Unna, 1954; Edwards at al. 1959> Van Rossum 
& Ariens, 1959a), on the number and character of the 
onium groups in the molecule (Vanecek & Votava, 1955; 
Edwards el; al. 1958a,b, 1959* 1961) and on the nature 
and length of the inter-onium chain (Barlow & Ing, 1948a,b; 
Paton & Zaimis, 1949; Levis et al. 1953). Although no 
overall structure-action relationship emerged, it was 
nevertheless felt worthwhile to examine the series of 
compounds discussed in this thesis inasmuch as they 
related to these three variables.
(The Uature Of The Alkyl Substituents On The Onium Centres.
In the compounds investigated in this thesis, 
the alkyl groups attached to the onium centres were
limited to the methyl, ethyl and propyl radicals.
With the polymethylene bis-onium compounds I, II and 
III, which were predominantly decamethonium-like, the 
replacement of a methyl by an ethyl group was 
accompanied by a reduction in potency in all the 
animal species studied. Although conventional 
experimental techniques revealed no marked qualitative 
differences between compounds I and III, the replacement 
of a methyl by an ethyl group was shown, by the Ariens* 
procedure, (vide infra), to modify the nature of the 
block produced from depolarizing to non-competitively 
agonistic.
In the bis-choline ether series (Group Id), 
maximum neuromuscular blocking potency in the cat was 
observed with the bis-triethylammonium derivatives 
F. & P. 8212 and F. & P. 8303. At the same time, 
the potency of these compounds differed significantly 
from each other, indicating that the nature of the 
alkyl onium substituents was not the sole determinant 
of the muscle relaxant activity and emphasizing the 
role of other factors, especially the interonium 
distance. Ihe reduction in activity associated with 
the replacement of ethyl by methyl groups confirms
139
140
the findings of Thesleff and Unna (1954) for certain 
hisquaternary compounds and those of Edwards and his 
associates (1957> 1958a,b) for certain tris-onium 
derivatives. The fully methylated derivatives 
(P. & P. 16575 and P. & P. 16701) possessed very weak 
muscle relaxant properties hut no depolarizing 
characteristics were observed. The introduction of 
an n-propyl substituent into bisquaternary compounds 
of this type (Pradhan et al. 1954) does not appear to 
reduce potency or cause qualitative changes in the 
pharmacological activity.
Similar changes have been observed using the 
tris- and tetra-onium ether and non-ether derivatives 
described in this thesis. Maximum activity among 
compounds in Groups la, lb and lc was associated with 
the presence of ethyl groupings on the terminal 
quaternary ammonium centres. Por example, among the 
tetra-onium ether-and non-ether derivatives, E77 and 
E79 were the most potent on the cat, rabbit, mouse 
and frog. Muscle relaxant potency was slightly 
reduced by the introduction of propyl substituents 
(E96 and E97) or more dramatically by substitution of 
methyl for ethyl groups as in compounds E78 and E80.
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There was no evidence of any depolarizing properties 
in these compounds. Compound E94, in which all the 
quaternary ammonium functions carried ethyl 
substituents, was the most potent tris-onium 
derivative in Groups lb and lc. The compounds in 
Group lc, in which the central nitrogen atom always 
possessed at least one methyl substituent, had 
generally slightly weaker muscle relaxant properties 
than those compounds in Group lb in which the central 
nitrogen atom carried at least one, and the terminal 
groups two, ethyl radicals. Eor example, compound 
E98 was less potent than E90 on the cat and rabbit. 
The predominance of ethyl radicals has been 
consistently associated with non-depolarizing 
activity in compounds of this type. The complete 
absence of depolarizing characteristics in the purely 
methyl substituted analogue, E100, confirmed by 
experiments on the cat, the hen and the frog, and in 
compound P. & P. 16575 on the cat, is in keeping with 
similar observations by other workers investigating 
the type of neuromuscular blocking activity of 
hexamethonium (Thesleff & Unna, 1954) and the methyl 
analogue of gallamine (Hiker & Wescoe, 1951)1 It is 
thus seen that no generally-applicable principle has
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emerged relating the nature of the onium substituents 
to the type or degree of muscle relaxant activity 
and while early workers associated the presence of 
methyl substituents with depolarizing activity (Burns 
& Bale, 1915), there is now ample evidence to refute 
this generalisation. Moreover, tubocurarine, which 
is a bis-methonium compound is the classic example of 
a non-depolarizing agent.
The number and character of the onium groups.
There seems little point in attempting to 
formulate any relationship linking the type or degree 
of muscle relaxant activity with the number of the 
onium centres in the molecule. Becamethonium, 
suxamethonium and tubocurarine, all containing two 
quaternary nitrogen centres, are more potent than 
gallamine which has three. On the other hand, several 
tris-, tetra-, penta- and hexa-onium compounds show 
greater muscle relaxant potency than tubocurarine 
(Edwards et al. 1958a,b, 1959? 1961). Clearly other 
factors are involved in determining the potency of 
these compounds.
In the compounds described in this thesis, 
it is equally impossible to effect a proper comparison
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of the compounds in Groups 1 and 2, in which molecular 
shape and length and steric factors vary so considerably. 
Nevertheless, it is evident that in Group 1, the 
general order of potency of the tetra-onium compounds 
is much greater than that observed in the tris- and 
bis-onium derivatives. While it cannot be claimed 
that this is due solely to the extra onium functions 
involved, this factor, accompanied by an increase in 
the length of the chain between the terminal nitrogen 
groups, must be largely responsible. Moreover, the 
bis-onium compounds (Group Id) are slightly less 
potent than the corresponding tris-onium derivatives 
(Groups lc and lb). Thus compound E77* which contains 
four quaternary centres, is much more potent in the cat, 
rabbit and chick than compound E90 which contains three. 
Moreover, compound E90 is more potent in the cat than 
compound P. & P. 8212 which contains only two quaternary 
centres. The only difference between these three 
compounds is in the number of onium centres in the 
molecule.
There is little evidence, however, to suggest 
that the number of onium centres exerts a controlling 
influence on the type of pharmacological activity
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produced. All the compounds in Group 1 show 
qualitatively similar, muscle relaxant properties, 
a fact which strengthens the view that the number of 
onium centres in the molecule influences potency 
rather than the type of pharmacological activity 
produced (Edwards at al. I960)
The fall in muscle relaxant potency, previously 
noted on replacement of nitrogen by sulphur in bis­
and polyonium compounds (see pages 70 and 71 of this 
thesis), has been confirmed. Compound II possessed 
weaker muscle relaxant properties than decamethonium 
on the cat, rabbit, mouse, chick and frog although the 
type of activity remained unaltered. When compared 
with the results of Barlow and Ing (1948a), the potency 
of compound III on the rabbit was less than that of 
the octamethylene bis-l,8-trimethylammonium salt 
(Barlow & Ing, 1948a).
When the compounds in Group Id were tested for 
muscle relaxant activity on the cat, the results 
obtained failed to support the concept of a one-point 
receptor attachment. Compounds possessing similar 
inter-onium distances (P. & P.8212, P. & P.17843 and 
P. & P.16701) and (P. & P.16575, P. & P.16677,
Z
©
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F. & P.8302, P. & P.16678 and p. & P.8303) differed 
in potency (Table IV). Furthermore, maximum muscle 
relaxant activity was observed when the H-substituents 
on both centres were ethyl radicals and successive 
substitution by larger or smaller alkyl groups, on 
one or both onium centres, reduced potency.
At the same time there is no evidence to 
support the view (Paton & Zaimis, 1949) that muscle 
relaxant activity in bis-onium compounds is produced 
by a two point attachment.
The Nature and Length of the Inter-Onium Chain.
Relevant comparisons may be drawn between 
some of the compounds described by Edwards and his 
associates (1957, 1958a,b) and certain of those 
discussed in this thesis. The tris-onium compound 
dihexaazonium (XXIVa) and the corresponding tetra-onium 
derivative trishexatetrazonium (XXIVb) were respectively 
more potent than the corresponding compounds E94 and 
E80 which differed only in having one methylene link 
in the inter-onium chain. All these compounds 
possessed the same type of activity. On the other 
hand, compounds of Group Id, in which the inter-onium 
distances are greater than those in Group lb were, 
in general, less potent in the cat. In the ether
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derivatives of Group lb, the inter-onium distances 
were identical to those of compounds in Group lc 
hut the potencies on various species differed, 
emphasizing the difficulty of trying to assess the 
individual contribution of the length of the inter-onium 
chain to muscle relaxant potency. Moreover, there 
was no evidence to suggest that, in the compounds 
studied, alteration in the inter-onium distance 
modified the type of muscle relaxant activity. It is 
interesting to note that in other aliphatic polyquaternary 
compounds the inter-onium distance was believed to be 
an important determinant of the type of muscle relaxant 
potency observed (Edwards elb al. 1961).
In addition to the influence of variation in 
the length of the inter-oniuft chain, its nature may 
also significantly influence the pharmacological 
behaviour of synthetic muscle relaxants. Erom the 
results obtained, it is obvious that the replacement of 
a methylene group by an ether oxygen function has 
reduced potency in the cat, rabbit, chicken and mouse.
Thus compounds E77, E78, E96, E90 and E91 are 
respectively less potent on both mammalian species 
and on the hen than the corresponding non-ether 
compounds E79, E80, E97, E94 and E93* Similarly
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E99> E100 and E101 are respectively very much weaker 
in the cat than the related non-ether compounds E74,
E151 and E152, the activity of which was reported by 
Edwards and his colleagues (1959)* Similarly, the 
insertion of an ether oxygen function into the 
polymethylene chain of hexamethonium (compound E. & P. 
16701) or decamethonium (oxydipentonium) reduced 
muscle relaxant potency (Levis et al. 1953).
Compared to their relative potencies on 
mammalian species, compounds of Group la showed a 
different order of activity when tested on the frog 
rectus abdominis muscle preparation. On the frog, the 
ether containing tetra-onium compounds were more potent 
than the analogous non-ether derivatives.
Although no single factor can be held 
responsible for the difference in potency between the 
ether and non-ether containing compounds, several 
alternative or contributory explanations may be offered. 
Hone of the compounds can be assumed a priori to adopt 
a maximally extended conformation at the receptor site 
but even if they did, the small reduction in chain 
length (O.I3S) due to the insertion of an ether oxygen 
link seems inadequate to explain the observed fall in
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potency. In view of the high water solubility of 
the corresponding polymethylene non-ether derivatives, 
it seems unlikely that the introduction of one or two 
ether oxygen functions would greatly influence the 
absolute solubility of a compound. It may, however, 
alter the partition coefficient of the drug by changing 
the relative water and lipid solubilities. Ether 
oxygen functions could also enter into hydrogen 
bonding in the tissues to a greater extent than the 
corresponding non-ether containing derivatives.
It is evident that, in the compounds studied, 
the role of the ether oxygen function cannot be 
explained by the results obtained from the conventional 
experiments described. In consequence, an attempt 
was made to investigate this problem by an approach 
based on the interaction of these drugs with the 
cholinergic receptor system.
In view of the difficulties which surround 
attempts to derive structure-action relationships and 
to place new drugs in their proper perspective, there 
is a need for a method by which compounds, whose 
chemical structure is markedly dissimilar, as well as 
those more closely related in homologous series, can
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"be classified quantitatively and qualitatively on a 
common pharmacological basis. A method, which offers 
some hope of achieving this to a limited extent, has 
been described by Ariens and his associates. These 
workers, following the earlier investigations of 
Clark, Gaddum and Michaelis and Menten (vide infra) 
treated drug-receptor interaction mathematically and 
suggested that drug interaction could be considered 
in terms of two constants namely the affinity and the 
intrinsic activity, the nature of which has already 
been discussed. It must be stressed that this approach 
does not afford an explanation of the precise mechanism 
of action of the drugs investigated, but is a method 
of comparing the effects produced by a series of drugs 
on a quantitative basis provided that they do not act 
upon dissimilar receptors. The nature or structure 
of the receptor involved, in the application of this 
hypothesis to neuromuscular blocking agents, is not 
however implied. Consequently, acceptance of the 
Ariens1 hypothesis accommodates any of the suggested 
representations of the cholinergic receptor as 
previously described in the introduction to this thesis.
The affinity and intrinsic activity values of
TABLE XIX
The mean Intrinsic activity and affinity values 
for compounds I, II, III, oxydipentonium and 
decamethonium estimated hy the Ariens* procedure 
using the frog rectus abdominis muscle*
Compound and 
Ho* of 
Experiments
Intrinsic
Activity
Affinity
' Relative 
Affinity 
(De came thonium 
= i)
(20) 
De came thonium 1.0 0.19 i
(10)
Oxydipen tonium 1.0 0*16 0.84
(10) 
Compound I 0*32 0.025 0.13
(20)
Compound II 1.0 toi—i •o 0.68
(10)
Compound III 0.62 0.062 0.33
TABLE XX
The mean inhibition indices* and affinity values 
(3 observations) of a number of aliphatic polyonium 
neuromuscular blocking agents, tubocurarine 
dimethyl ether and tubocurarine.
‘ -  -­
Code Humber 1Inhibition 
Index1 Affinity
Relative 
Affinity ' 
(Tubocurarine 
= 1)
E77 . 0.0163 61.35 2.95
E79 0.034 29.41 1.41
E78 0.243 4.12 . 0.20
E80 0.307 3.26 0.16
E98 2.10 0.48 0.023
E99 2.60 0.39 0.019
E100 7.15 0.14 0.007
E101 6.33 0.16 0.008
E102 5.23 0.19 0.009
E103 1.96 0.51 0.025
E151 2.43 0.41 0.020
Tubocurarine 
dimethyl ether
0.168 5.95 0.27
Tubocurarine 0.048 20.83 1.00
the compounds investigated are shown in Tables XIX 
and XX. If a pictorial representation of the 
cholinergic receptor site is accepted, a number of 
suggestions may be put forward to explain the 
differences observed.
Replacement of a nitrogen atom in decamethonium 
by a sulphur atom (compound II) has not, by itself, 
significantly altered pharmacological behaviour but, 
together with a reduction in chain length, has reduced 
both the affinity and intrinsic values observed 
(compounds I and III). The reduction in the number 
of Van der Waal's forces associated with the tertiary 
sulphonium atom compared to the quaternary ammonium 
group and the increased size of the former may reduce 
the stability and the amount of drug-receptor complex 
formed. The combined effect of altering the inter-onium 
chain length and the nature of the centres themselves 
may also reduce the overall intensity of the cationic 
charge of the molecule and so impair the electrostatic 
bond mainly responsible for the production of muscle 
relaxant activity. Alternatively, the reduction in 
the chain length from ten (compound II) to eight 
methylene groups (compounds I and III) might also
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reduce the ability of the latter to form an ion-pair 
complex with one anionic receptor site. The adoption 
of such a conformation would enhance the charge density 
of the molecule by reducing the surface area of the 
charge. The reduction in intrinsic activity could 
therefore be explained by a reduction in the intensity 
of the onium cationic charges. Moreover, the reduced 
ability of compounds I and III to enter into ion-pair 
complex formation with one anionic receptor would also 
reduce the stabilising effect of Yan der Waal’s and 
other secondary bonding forces. This would reduce 
the affinity of the compounds concerned.
The replacement of a methyl by an ethyl group 
on each onium centre involves other steric factors in 
addition to those already discussed. These may be 
less marked in a maximally extended molecular 
conformation than in an ion-pair complex (Pig. 74b, page 
137). In the former (Pig. 74a) the ethyl group on each 
onium centre may sterically hinder the approach of the 
cationic charge to the anionic receptor berth and so 
reduce the intensity of drug receptor interaction. More­
over, a less readily definable steric effect may be due 
to the ethyl group diminishing the ability of the compound to
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alter its own conformation to fit that of the receptor 
site. By this means, the strength of the receptor- 
bonding effects of secondary forces, for example Van 
der Yifaalfs bonds, would be reduced. On the other hand, 
if an ion-pair complex formed between the two onium 
centres of the molecule and one anionic receptor has 
reality, then the ethyl groups present may also reduce 
the concentration of the 'twin* cationic-onium charges 
by sterically hindering their approach to each other 
as well as their combined approach to the anionic 
receptor. It should be stressed however, that since 
compound I exhibits the ability to combine with an 
additional receptor system, the above structure-action 
relationships may only justifiably be applied to its 
interaction with acetylcholine-like receptors.
Table XX shows the comparative affinity values 
for a number of non-depolarizing (Type II) muscle 
relaxants. Since there is no physicochemical evidence 
to indicate the conformation adopted by these .compounds 
at the receptor site, conclusions concerning the shape 
of the molecule are even more hazardous than those 
drawn concerning bis-onium salts. The non-depolarizing 
properties exhibited by these compounds compared to the
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Fig* 75* Frog rectus abdominis muscle. AriSns 
procedure. A graphical illustration of the increase 
in affinity brought about by changes in the molecular 
weight of the onium alkyl substituents in the homologous 
series of compounds E98* F99 and E103 (upper graph) 
and compounds E100, E101 and E102 (lower graph).
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predominantly depolarizing effects of bis-methonium 
salts cannot "be accounted for on the basis of the 
experiments described in this thesis. It has been 
suggested (Yan Rossum & Ariens, 1959_a) that the 
receptors for depolarizing compounds may differ from 
those occupied by non-depolarizing agents and that the 
molecular properties required for a high degree of 
affinity may vary in either case.
Prom the results, increased affinity values 
can be related directly to an increase in the bulk of 
the onium substituents in the two homologous series of 
compounds E98, E99 and E103 and E100, E101 and E102 
(Pig. 73). Ho other structural differences exist 
between the compounds in each series. Similarly, the 
marked difference in potency between compounds E77 and 
E78 and E79 and E80 can be directly related to the 
increased size of the N - substituents. The beneficial 
effect of fairly bulky alkyl substituents (ethyl and 
propyl) may be due to their shielding effect on each 
quaternary function. In addition, a close drug- 
receptor approach would be sterically hindered by such 
radicals favouring a tubocurarine-like effect (Cavallito 
& Gray, I960). Alternatively, assuming the existence
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of non-ionic satellite receptors (Meier, Tripod &
Bruni, 1955; Edwards et al. 1959) bulkier onium 
substituents might be preferentially held there and 
so help to induce neuromuscular block by preventing 
the access of acetylcholine to the anionic receptor 
pore.
The role of the ether oxygen function was 
investigated by an examination of five pairs of ether 
and related non-ether compounds under similar conditions. 
These compounds were tubocurarine and tubocurarine 
dimethyl ether, decamethonium and oxydipentonium, 
compounds E79 and E77, compounds E80 and E78, compounds 
E151 and E100.
Tubocurarine dimethyl ether (IY, E = CH^) 
(opposite page 56 of this thesis) contains two 
methoxyl groups instead of the two hydroxyl groups 
found in tubocurarine. Otherwise, the compounds are 
structurally identical and their modes of action also 
appear similar (Kirschner & Stone, 1951)* Eue to the 
difference in structure, tubocurarine dimethyl ether 
cannot carry any anionic charge while tubocurarine 
itself contains two phenolic hydroxyl groups capable 
of undergoing dissociation (Swann, 1951; Kalow, 1953)*
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The pK^ value of each hydroxyl group is however 
different, that in the ortho position to the methoxyl 
groups heing the less acidic. Consequently, it has 
been suggested that tubocurarine can exist in more 
than one ionized form (Kalow, 1954)• Maximum 
pharmacological activity was observed at pH 6.7 when 
the hydroxyl groups were virtually unionized. The 
existence of a partial zwitter ion at high pH values 
would, it was suggested, reduce the net cationic charge 
of the entire molecule by partial neutralisation of 
the cationic charge on both quaternary groups. At 
the anionic receptor site, therefore, the resulting 
partial repulsion of the tubocurarine molecule would 
prevent a close drug-receptor combination and might 
explain the lower activity of this molecule compared 
to the dimethyl ether (Kalow, 1954; Cavallito, 1959)• 
This explanation, however, fails to account for the 
very low potency of the di-n-butyl and dibenzyl ethers 
of tubocurarine (Wintersteiner, 1959). Moreover, the 
view that the number and the position of the methoxy 
substituents in molecules of this type contribute 
directly to the activity of the molecule as a whole 
is supported by the marked increase in potency
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observed in a series of U,U-dimethyl-l,10- 
decamethylenebis-tetrahydroquinolinium and 
tetrahydroisoquinolinium derivatives with increasing 
substitution of methoxy groups. The increased 
activity of tubocurarine, compared with that of its 
dimethyl ether, reported in this thesis, could be due 
to steric factors residing in the methyl substituents. 
Alternatively, the hydrogen atom of the hydroxyl 
group in tubocurarine may conceivably form a hydrogen 
bond with the receptor, a situation not possible with 
tubocurarine dimethyl ether. At certain pH values, 
however, slightly above the physiological range, this 
phenomenon will be annulled by the opposite effect 
of anionic dissociation. At this point, both 
tubocurarine and the corresponding dimethyl ether 
may be equiactive, (Swanson, Henderson & Chen, 1949; 
Swanson, Gibson & Powell, 1952).
In mammalian skeletal muscle, dimethyl 
tubocurarine is claimed to be much more potent than 
tubocurarine itself (Unna & Pelikan, 1951; Poldes,
Machaj, Hunt, McUall & Carberry, 1952). In contrast 
to its action on the rat (Holmes, Jenden & Taylor, 1951)> 
the effect of tubocurarine on the frog rectus appears
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to be uninfluenced by temperature variations (Van 
Maanen, 1950) and in consequence the species differences 
observed may be attributable to the specialized 
response of each neuromuscular synapse to methoxyl 
and hydroxyl substituents. There is, moreover, no 
reason to assume that frog and mammalian neuromuscular
»ifunctions are similar. On the basis of the Ariens1 
hypothesis, the particular function of these groups 
can be related to differences in the affinities between 
them. Kalow (1954) believes that the nucleophilic 
oxygen, in each hydroxyl group of the tubocurarine 
molecule, might be attracted to an electrophilic group 
in the mammalian muscle receptor. Since it is well 
established that the methyl group has a greater 
inductive effect than a hydrogen atom, there is a 
greater electronic density on the oxygen atoms 
available for bonding to the receptor in the dimethyl 
ether than in the unionized form of tubocurarine 
itself. Thus the dimethyl ether would appear the 
stronger drug. However the most pronounced electrical 
charge in drugs of this kind is found on the onium 
centre, while the presence of other substituents, 
including hydroxyl or methoxyl groups, can only modify
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this* Differences in the distribution of tubocurarine 
and its dimethyl ether in vivo (Collier ejfc al. 1948; 
Marsh, 1952) have indicated that the relative potency 
of these two compounds may also be influenced by 
differences in the permeability of the drug, the 
biophase concentration attained and the availability 
of each drug at the receptor site. The experiments 
reported in this thesis, carried out at pH 7.5 - 7.8, 
only indicate that the relative potencies of the 
compounds were the result of differences in the amount 
of drug-receptor complex formed. Their non-depolarizing 
competitive effects were also confirmed. However, it 
is also necessary to bear in mind that other differences, 
not indicated by the techniques employed, may also 
contribute to the potency of these drugs. Thus, while 
the dimethyl ether has a slightly higher lipid 
solubility than tubocurarine itself, it is no more 
effective in blocking conduction at the node of Ranvier, 
in a single nerve fibre preparation (Dettbarn, I960). 
Consequently, although a high degree of membrane 
permeability is an important factor in determining the 
activity of these compounds (Rosenberg & Ehrenpreis, 
1961), it appears unlikely that this feature is .
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res pons 11)16 for the higher potency of tubocurarine 
dimethyl ether observed in certain preparations. 
Furthermore, studies on the binding of tubocurarine 
and its dimethyl ether with the acetylcholine reoeptor- 
protein of the electric tissue of the electric eel 
(Electrophorus electricus) (Ehrenpreis, 1960), has 
again stressed the influence of the pH of the medium 
on activity in these molecules. While the dimethyl 
ether has less affinity than tubocurarine for the 
receptor protein at pH 7.5, the reverse order applies 
at pH 9.5. This phenomenon is presumably due to the 
ionization of the phenolic hydroxyl groups in 
tubocurarine at the higher pH and supports the view of 
Kalow (1954) already described and the results of the 
present investigation.
Oxydipentonium differs structurally from 
decamethonium in having one ether oxygen function 
inserted into the polymethylene chain separating the 
two quaternary ammonium groups. This would produce
i
an increase in the length of the polymethylene chain 
suggesting a decrease in the effectiveness with which 
the onium centres might combine with the receptor 
field. However, no significant difference in
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intrinsic activity from that of decamethonium was 
observed. On the other hand, a slight difference 
in affinity between the two compounds was apparent 
and this has been confirmed by other investigators 
(Van Rossum, 1960). Two main reasons may be suggested 
to explain this effect. Either or both may operate 
in determining the potency of oxydipentonium.
(a) Mere increase in chain length, which could, for 
example, also explain why unde came thonium is less 
potent than decamethonium (Paton & Zaimis, 1949).
(b) Particular physicochemical characteristics of the 
ether oxygen atom which might enhance an increased 
bonding at 1 sites of loss1 and a disturbance of the 
lipophilic-hydrophilic balance of the molecule.
The increased electron density on the oxygen 
atom could lead to an anti-bonding effect causing a 
reduction in the affinity of the ether-containing 
compound, as evidenced by the lower activity of 
oxydipentonium as compared to decamethonium. On the 
other hand, in the series of bis-choline ethers 
examined for ganglion-bioeking activity by Pakstorp 
and his colleagues (1957a,b), it was suggested that 
the proximity of the ether oxygen to the quaternary 
nitrogen might cause a drift of electrons from the
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oxygen atom which could then assume a partial 
positive charge. The ganglion-blocking potency of 
these compounds, which was in certain cases greater 
than that of hexamethonium, was suggested to be due 
to their stable attachment to the negatively charged 
esteratic site in the pictorial representation of the 
acetylcholine receptor suggested by Barlow (1955).
The drift of electrons through a carbon chain is known 
only to be significant however across one of two 
carbon atoms, but there remains the possibility of 
electron movement induced across space. Electron 
drift through the chain, moreover, will not occur 
where the ether link is symmetrically placed with 
respect to two onium groups.
While there is no direct evidence to suggest 
which of these mechanisms is operative, the reduced 
affinity of the ether-containing derivative 
oxydipentonium compared to decamethonium supports the 
view that, in this compound, the ether oxygen link is 
producing an anti-bonding effect. This view has been 
supported by the observation that the presence of two 
ether links in compounds chemically similar (Van Rossum
ti& Ariens, 1959a) was associated with a reduction in
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both affinity and intrinsic activity, when compared 
to decamethonium. Since the alteration in chain 
length produced by the replacement of two methylene 
groups by ether links is small, the anti-bonding 
effect of the oxygen functions may be largely 
responsible for the reduction in muscle relaxant 
potency produced. On the other hand, the observed 
effects may be the resultant of two opposite, rather 
than two synersistic mechanisms and the suggestions 
offered must be regarded only as. possibilities.
Similarly, when compounds E151 and E100 are 
compared several factors may contribute to the potency 
differences observed. Using the Ariens’ procedure 
however, these variations can be directly related to 
differences in the amount of the drug-receptor 
complex formed by each compound although no 
differentiation between the contribution of the ether 
oxygen and its effect on the inter-onium chain length 
can be made.
On the other hand, the role of the ether v 
oxygen function in the mono-ether tetra-onium 
compounds E77 and E78 can be more precisely defined.
In both cases introduction of an ether link increased
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the affinity of the compounds compared to that of 
E79 and E80 in which the ether function was replaced 
hy a methylene (-CH^) unit. I n  these cases, 
alteration in chain length and the change in the bond 
angles produced hy the ether function is very small 
and seems incapable of causing the potency differences 
observed. It is therefore more likely that the 
physicochemical properties of the ether oxygen itself, 
rather than the mere alteration in chain length is 
responsible. Consequently, the increased affinity
might be due to an intensification of the secondary 
bonding characteristics of the drug-receptor complex 
which increased the degree of general electrical 
field interaction attained.
In addition to the chemical and physicochemical 
considerations discussed, species variation could also 
account for the differences in the order of potency 
observed between ether and non ether compounds. In 
the cat, chick, rabbit and mouse, the ether derivatives 
are the more potent, while on the frog rectus abdominis 
muscle, the reverse is true. Although variation in 
the response of different species to muscle relaxant 
drugs is well established (Paton & Zaimis, 1952;
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Hoppe, 1955)» the interesting reversal in the order 
of potency caused by the replacement of one ether 
by one methylene link raises the possibility that 
additional contributory factors exist. Perhaps in 
whole animal experiments, the ether-containing 
compounds might undergo increased bonding at 1 sites 
of loss* or attain a reduced concentration in the 
biophase. Such considerations are obviously more 
relevant in 1 whole animal1 experiments than in those 
involving isolated tissue preparations. Alternatively, 
the physiological differences in structure between 
the synapse of mammals and frogs might be responsible, 
and investigations using tubocurarine dimethyl ether 
(Kalow, 1954) support this view. At the same time, 
the effect of variation in the pH values of the bath 
fluid (Kalow, 1954) on the potency of tubocurarine 
and its dimethyl ether, in the frog, indicates the 
difficulty of applying results obtained with certain 
kinds of chemical structures using an artificial 
environment. •
It is apparent that the ether oxygen function 
plays no dramatic role in the muscle relaxant activity 
of the compounds studied and in neither tubocurarine,
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its dimethyl ether nor the aliphatic structures 
examined is there evidence of its ability to 
qualitatively modify pharmacological behaviour. This 
view confirms that of Bovet (1951). It may, however, 
influence the ability of these compounds to combine 
with the cholinergic receptor by interfering with the 
general fields of force which contribute to the 
formation and stability of the drug-receptor complex.
As a result, the ether oxygen function may quantitatively 
alter the pharmacological activity of drugs of this 
type.
It is extremely difficult to compare the 
results reported in this thesis with those obtained 
by other workers. It is to be noted, however, that 
an increase in the muscle relaxant potency of several 
aliphatic compounds in the cat was attributed to the 
influence of an additional oxygen atom in the inter- 
onium polymethylene chain (Pradhan ejfc al. 1954).
No explanation of these effects were given but the 
slight alteration in chain length appears unlikely to 
be wholly responsible for the marked potency differences 
reported. The presumably low intrinsic activity of 
these compounds (all were tubocurarine-like) makes it
1.66
tempting to suggest that the extra ether oxygen 
function might have increased potency hy increasing 
the affinity of the compounds concerned.
The use of preparations from different species 
has further complicated the correlation of the results 
of different workers. Furthermore, the value of some 
of these preparations in the evaluation of muscle 
relaxants remains open to question. Yanecek and 
Yotava have, for example, advocated the use of the 
masseter muscle preparation of the rat (Eicholtz, 1949) 
as a superior means of pharmacologically investigating 
drugs of this type. Since this involves a direct 
stimulation of the muscle itself rather than an 
indirect stimulation via the motor nerve, conclusions 
concerning compounds whose pharmacological activity 
is believed to be primarily effected at the neuro­
muscular junction cannot be unreservedly accepted.
Many of these difficulties appear capable of 
resolution using the Ariens1 procedure which enables 
all compounds of this type to be classified qualitatively 
and their potency estimated. The results reported 
in this thesis from whole animal experiments have 
confirmed the value of the classification of muscle
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Ifrelaxant compounds made by Ariens and his associates 
(Van Rossum et al. 1958). It is interesting to 
observe a parallel between the affinity values of 
the compounds tested and their molar potency, compared 
to tubocurarine, obtained by using the conventional 
frog rectus assay method. Consequently adoption 
of the concepts of affinity and intrinsic activity 
renders the procedure particularly valuable as a means 
of minimising the difficulty of assessing the muscle 
relaxant properties of drugs evaluated by different 
workers.
itProm the practical point of view, the Ariens? 
procedure can be used to screen rapidly large numbers 
of new compounds. It is useful in the elimination 
of compounds possessing potentially undesirable 
properties without the sacrifice of large numbers of 
experimental animals. In this way the cost of the 
initial screening process can be considerably reduced 
and unnecessary waste of animal life avoided. The 
use of the method facilitates the study of the 
contribution of individual structural characteristics, 
in members of a homologous series, thus aiding the 
design of new compounds.
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Prom the clinical view point, the ideal muscle 
relaxant drug must exert a highly specific action at 
the neuromuscular synapse without producing adverse 
side effects. Many synthetic drugs, including those 
in current clinical use, lack complete specificity by 
virtue of their capacity to block autonomic ganglia, 
(tubocurarine) to liberate histamine (tubocurarine) 
or by the possession of anticholinesterase properties 
(hexafluorenium). Lack of specificity is more 
prevalent in non-depolarizing than in depolarizing 
agents.
For a drug to be considered worthy of clinical 
investigation, it must possess characteristics
superior to those of drugs in current clinical use.■ ■ ■
Compounds in Croup Id block synaptic transmission in 
both sympathetic and parasympathetic ganglia (Fakstorp 
and his associates, 1954, 1957a,b J(C ,  1958). This 
property, combined with their weak muscle relaxant 
properties renders the possibility of their clinical 
application extremely unlikely.
Among the tris- and tetra-onium compounds 
studied there was no evidence of any marked ganglion
Possible Clinical Application of the Compounds Studied.
blocking action while the lack of a hypotensive effect 
in the cat suggested the absence of histamine-liberating 
properties. The absence of serious non-specific 
characteristics was not however accompanied by evidence 
of any superiority over gallamine or tubocurarine.
Indeed while several tetra-onium derivatives were more 
potent than either of these drugs, this was offset by 
a slightly more discriminating effect on the respiratory 
muscles. Moreover the duration of the block produced 
appeared unlikely to fulfill the present demand for a 
short acting non-depolarizing muscle relaxant compound.
In spite of the reappraisal of decamethonium 
in recent years (Lawson, 1958) there appears to be no 
need for the introduction of further depolarizing 
muscle relaxants. Consequently since none of the 
sulphonium analogues possessed any advantages over 
decamethonium itself, there appears to be little point 
in offering them for clinical investigation. Furthermore, 
the appearance of a non-competitive component of action 
in compound I in addition to the general depolarizing 
effect of all the drugs in Group 2 is clinically 
undesirable on account of the lack of a suitable 
antidote for compounds of this type. The necessity 
of maintaining neuromuscular block by a single uniform
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mode of action raises the question of the apparent 
non-competitive block produced by very high doses of 
tubocurarine-like drugs. It is interesting to note 
that Everett (1948) regarded neostigmine as a Tlimited 
antagonist1 to tubocurarine in the rabbit. While 
neostigmine was effective against !just paralytic 
doses1 it was claimed to be ineffective against larger 
amounts of tubocurarine. There is no evidence to 
indicate whether this effect was caused by the 
anticholinesterase action of neostigmine or to deny 
the existence of a non-competitive component in the 
action of tubocurarine. While the phenomenon of a 
non-competitive component of action has not apparently 
affected the clinical value of tubocurarine since the 
doses used are presumably too small, clinical trials 
using dihexaazonium, a similarly acting muscle relaxant, 
suggest that it may have been responsible for the 
neostigmine-resistant block, which in some patients 
ensued with the use of this drug (Levy, 1959). On the 
other hand, the use of very high doses of the antagonist 
may have invalidated certain of the basic assumptions 
involved in the theory of drug antagonism, as 
discussed by Gaddum (1957) and Schild (1957).
One of the major obstacles in assessing the
potential clinical value of a synthetic compound lies
in the considerable variation in the response of
different species to muscle relaxant compounds.
The differences in the response of the frog compared 
to that of mammals has confirmed the futility of 
relying on one animal preparation to predict 
accurately the potency of new drugs (Hoppe, 1955).
ftConsequently, while the Ariens* procedure appears to 
be an invaluable screening technique, results from 
these experiments cannot by themselves warrant the .
immediate clinical trial of a synthetic muscle
relaxant. When the investigation of a particular 
compound, by this means, has revealed suitable 
pharmacological properties, a rigorous assessment on 
other species must also be made. In the final 
analysis, the potency of muscle relaxant compounds 
in man may only be obtained by their careful evaluation 
in man himself.
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Chapter I Is divided into four sections; 
the introduction, experimental methods, experimental 
results and the discussion.
The introductory section is devoted to a survey 
of certain aspects of the literature pertaining to 
neuromuscular blocking agents with particular reference • 
to the study of their pharmacological and electro- 
pharmacological effects at the motor end plate, their 
interaction with the hypothetical receptors at this 
site and the derivation of mathematical equations to 
explain these effects. The various systems of 
classification adopted to subdivide muscle relaxants 
are discussed and a review given of synthetic compounds 
with neuromuscular blocking activity. Attention was 
paid, in particular, to ether-containing compounds and 
to the possible contribution of this function to 
neuromuscular blocking activity.
A study has been made of the pharmacological 
action of a number of synthetic bis and polyonium 
compounds containing one and two ether oxygen functions 
together with their corresponding or related non-ethers. 
In addition, three sulphur-containing bis-onium compounds 
were examined for neuromuscular blocking activity.
SUMMARY OF CHAPTER I
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Attempts were made to draw structure-action relationships 
among these drugs and to assess, where possible, the 
role of the ether oxygen function in the pharmacological 
activity observed.
The methods used consisted of the conventional 
techniques commonly employed to evaluate neuromuscular 
blocking activity using the cat, rabbit, hen, chick, 
mouse and frog together with the method described by 
Ariens, based on drug-receptor interaction, and studied 
by means of the frog rectus abdominis muscle. The 
effects of a group of new compounds on the cardio­
vascular system, on autonomic ganglia, on respiration 
and on the isolated rabbit heart were also investigated.
On the basis of their pharmacological activity, 
the compounds investigated were divided into non­
depolarizing and depolarizing drugs. In the former 
group, many compounds were more potent than tubocurarine 
while none of the depolarizing compounds investigated 
was more potent than decamethonium. With the exception 
of the frog, where the reverse order of potency was 
true, the ether-containing polyonium compounds were 
less potent than the corresponding non-ether analogues.
By means of the AriensT technique, the qualitative and 
quantitative properties of those compounds investigated
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were confirmed and extended and their affinities 
and/or intrinsic activity values calculated.
Prom the results'obtained using more conventional 
methods, attempts were made to derive structure-action 
relationships among the compounds investigated. These 
were based on considerations of the nature of the alkyl 
substituents on the onium centres, the number and 
character of the onium groups, and the nature and length 
of the inter-onium chain. On account of the chemical 
dissimilarities among the compounds themselves, the 
relationships so derived were empirical and resort was 
made to the Ariens1 interpretation of drug receptor 
interaction. Accordingly, the activity of all the 
compounds investigated was placed on the common 
pharmacological bases of intrinsic activity and affinity 
and the role of the ether oxygen function in influencing 
the affinity of neuromuscular blocking compounds 
established.
In the course of this investigation, the AriensT 
technique has been fully evaluated as a preliminary 
method in the pharmacological testing of synthetic 
neuromuscular blocking compounds. None of the compounds 
investigated appeared to possess properties which might 
lead to their clinical use.
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STUDIES PIT THE &N1I-CH0LIUESTERASE ACTIVITY OF A NUMBER 
OF BIS- MD PQLYQNIUM, ALIPHATIC COMPOUNDS POSSESSING 
NEUROMUSCULAR BLOCKING PROPERTIES.
The term 1 choline-esterase * was first suggested 
to describe the acetylcholine-splitting activity of 
horse serum (Stedman, Stedman & Easson, 1932) and 
referred to a group rather than to one particular 
enzyme. The specificities of these enzymes for their 
substrates (Richter 8c Croft, 1942) rendered the original 
term fcholine-esteraser too vague and necessitated a 
classification of the enzyme concerned. The term 
ftrue-cholinesterase* was first proposed to include 
those enzymes which hydrolyzed choline esters present 
in the erythrocytes and in nervous tissues including 
acetyl-P-methylcholine but not benzoylcholine (Mendel 
8c Rudney, 1943). The name 1 pseudo-cholinesterase1 
was reserved for those enzymes obtained from serum and 
other tissues which were capable of hydrolyzing 
acetylcholine, benzoylcholine and several non-choline 
esters, but not acetyl-(3-methyl choline.
Critics of this method of classification 
(Click, 1945; De Laubenfels, 1943) applied the term 
?acetylcholine-esterase1 or 1 specific-cholinesterasef
(Hachmansohn & Rothenberg, 1945, 1946) to those 
enzymes, present in nervous tissue and erythrocytes, 
which preferentially catalysed the hydrolysis of 
acetylcholine.
The general term 1 cholinesterase 1 was then 
proposed to include both *acetylcholine-esteraseT and 
the various other enzymes of the serum and tissues, 
which hydrolyzed other choline esters, including 
benzoylcholine and butyrlcholine*
At the neuromuscular synapse, 1 specific- 
cholinesterase1 or 1acetylcholine-esterase1 exclusively 
and rapidly hydrolyzes acetylcholine liberated 
endogenously from the end plate receptors. Anti­
cholinesterases, by interfering with this process, may 
induce neuromuscular block in a manner resembling 
depolarizing muscle relaxants by permitting the 
accumulation of the transmitter (Briscoe, 1936; 
Rosenbleuth, Lindsley & Morison, 1936). In addition 
to their enzyme-inhibiting activity, anti-cholinesterases 
exert other independent effects at the neuromuscular 
synapse. In conditions where cholinesterase activity 
has been completely inhibited, both neostigmine (Riker 
& Wescoe, 1946) and edrophonium (Randall, 1950; Randall
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& Jampolsky, 1953) have been observed to exert a 
direct excitatory effect on mammalian skeletal 
muscle-nerve preparations and on the frog rectus 
abdominis muscle (Miquel, 1946), The action of many 
quaternary ammonium compounds, not hydrolyzed by 
cholinesterase, is often potentiated by anti­
cholinesterases e.g. decamethonium (Zaimis, 1951) and 
edrophonium (Cohen & Posthumus, 1955) . Certain other 
bis-quaternary esters including suxamethonium 
(Hansson, 1958) are so slowly hydrolyzed by cholinesterases 
that potentiation of their effects by anti-cholinesterases, 
acting as such, cannot explain the increased and 
prolonged pharmacological effects observed. This 
evidence would appear contrary to the view that 
enzymatic hydrolysis was responsible for the brief 
neuromuscular block produced by this drug (Castillo 
& De Beer, 1950).
The well established anti-acetylcholinesterase 
activity of many quaternary ammonium compounds (Cohen, 
Warringa & Indorf, 1955; Riker, 1953; Todrick, 1954), 
many of which possess muscle relaxant activity, led 
to the view that the active centre of acetylcholine- 
esterase resembled the anionic site of the end plate
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receptor on the postsynaptic muscle membrane. This 
hypothesis, first suggested by Roepke (1937), has 
been elaborated in more recent years to include a 
postulate of the receptor pattern itself, based on the 
activity of cholinesterase inhibitors (Cohen &
Posthumus, 1955, 1957; Cohen et al. 1955; Van Der Meer 
& Meeter, 1956). That anti-cholinesterases may exert 
more than one effect at the neuromuscular synapse is 
accomodated by this view but the resemblance claimed 
to exist between the cholinergic receptor and 
cholinesterase leaves unexplained the finding that 
P, (3-dime thy lbutyl acetate, a compound closely related 
to acetylcholine and a satisfactory substrate for 
cholinesterase, is devoid of acetylcholine-like activity 
(Banister & Whittaker, 1951).
The activity of muscle relaxant compounds as 
cholinesterase inhibitors appears to be more marked 
against ttrue1 rather than against 1 pseudo-cholinesterase 
(Cohen ejb al. 1955; Paton 6c Zaimis, 1949). This is 
in keeping with the view that 1 true1 cholinesterase is 
responsible for the destruction of acetylcholine at 
the site of its physiological action (Hawkins 6c Mendel, 
1947) and the weak anti-cholinesterase activity of
220
non-depolarizing drugs (Paton 8c Zaimis, 1949),
Anti-cholinesterase activity in polymethylene bis- 
onium compounds was most marked among the higher 
members of the series which, when compared with eserine 
possessed considerable activity (Paton 8c Zaimis, 1949). 
Decamethylene bis-quinolinium salts, for example, are 
almost as effective inhibitors of true cholinesterase 
as eserine itself (Blaschko 8c Holtan, 1949).
It is apparent that anti-cholinesterase activity 
may be a contributory factor in the observed muscle 
relaxant potency of new drugs. The investigation of 
this effect, especially in compounds chemically similar 
to those known to possess anti-cholinesterase properties, 
would, it was believed contribute to a better understanding 
of the mode of action of new drugs and confirm their 
qualitative separation on the basis of existing 
classifications (Paton 8c Zaimis, 1951; Van Rossum,
Ariens 8c Linssen, 1958). Accordingly, a number of 
bis- and polyonium, aliphatic, polymethylene compounds, 
whose other pharmacological properties have been 
previously reported (Carey, Edwards, Lewis 8c Stenlake,
1959; Edwards and his colleagues, 1957, 1958a,b, 1959,
1961; Levis, Preat 8c Dauby, 1953; Muir 8c Lewis, 1959), 
have been investigated for anti-acetylcholinesterase 
activity.
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Method
A cholinesterase-containing preparation from 
rat brain was made by the method of Fenwick, Barron 
and Watson (1957) and anti-acetylcholinesterase 
activity estimated, using the Yfarburg technique, by 
: a modification of Ammonfs method (1933). Acetylcholine
chloride was used instead of the bromide described by
\
! Fenwick and his associates. In each estimation, ai *
control flask containing no inhibitor and an additional
i 'j enzyme flask containing distilled water in the side
ij arm were used. The respiration of the brain tissueii| itself, unaffected by drugs, could thus be measured.
i
| As a result of the hydrolysis of acetylcholine
to acetic acid by the enzyme activity present in the 
rat brain, carbon dioxide was released from the Krebs1 
| bicarbonate solution contained in each test flask.
The inhibition of this process by drugs delaying the 
’ destruction of acetylcholine was used as a measure of
their anti-cholinesterase effect. Different molar 
concentrations of each drug were employed and the 
mean of three to six results, expressed as a percentage
reduction of the carbon dioxide evolved from the control
: flask and, allowing for the normal respiration of the
tissue alone, used as a measure of anti-cholinesterase 
activity. This was then plotted against the 
logarithm of the molar concentration of the inhibitor 
used. The negative logarithm of the molar concentration 
of the drug producing an inhibition of 50%, the 
pi 50, was then calculated according to the method of 
Blaschko, Bulbring and Chou (1949).
;/
Pig. 75. Method of comparing the anti­
acetylcholinesterase activity of compounds E17 
and E71 expressed as the PI50 values (Blaschko, 
Bulbring & Chou, 1949). The PI50 is the negative 
logarithm of the molar concentration of the drug 
producing a 50$ inhibition of carbon dioxide 
production.
Prom the original graph,
PI50 (compound E17) = 5 . 6  
PI50 (compound E71) = 5.4
The influence of inter-onium distance on
i
acetylcholinesterase activity, indicated hy 
the PI50 value, of a series of tetra-ethonium
aliphatic neuromuscular blocking compounds.
+ + + +
R 3IT -  (CH2 )n - N —  (CH2 )m- R - ( C H 2 )n - i m 3
R E  R R R = C2H3
41"
■ TABLE XXI
Code . 
Humber n m
Type of Heuro- 
muscular Block 
Produced
PI50
E36 6 6 Non-Depolarizing 3.5
E70 6 8 Non-Depolarizing 2.3
E71 8 6 Non-Depolarizing 5.4
E62 6 10 Mainly Non­
Depolarizing but 
with Depolarizing 
Peatures also
4.1
E72 8 8 Mixed, but mainly 
Non-Depolarizing
5.3
E63 10 6 MainlyDepolarizing
6.2
TABLE XXII (contd.)
Code
’ Ho. R *1 h X
ttfype of
Block
Produced
PI50
E18 CHg CHg 6 S Hon-De-
polarlzlng
3.5
E61 ch3 C2H5 6 S » 3.4
E60 «%h5
-
ch3 6 S ii 3.4
E64 CHg n-C^Hg 6 S n 4.2
E65 C2h5 XI-C5H7 6 S
L . .—
tf 4.2
The comparative PI50 values of a series of 
tris-onium aliphatic neuromuscular blocking 
compounds showing the effect of alteration in the 
onium centres, inter-onium chain length and the 
alkyl substituents on anti-acetylcholinesterase 
activity* +
rin + x ” sR _  (CH2)n- X  -  (CH2)n- H  - R  or
R' v R v _ +31" X " "f"R1
TABLE XXII
Code
Ho. R ? R 1 1 n X Type ofBlock
Produced
PI50
E24 °2H5 C2h5 6 N Non-De­polarizing
2.3
E41 c 2h5 C2H 5 8 N tr 6 . 0
E31 C2H5 C2H5 1 0 N De­polarizing
5.5
E74 C2H5 ch3 6 IT Non-De­polarizing
3.5
E75 c 2h5 n— C 3H7 6 IT 11 ca • CX
I
E76 C2h5 n-C4 Hg 6 N tt 3.6
E82 n- C 3H7 n-C 3H7 6 IT tt 3.5
E83 n-C3H7 C2h5 6 N ti 3.5
E84 n- C 3H7 ch3 6 IT w 3.7
E93 C2H5 CII3 5 IT it Nil (at m/ 2 0 0  
conc.)
E94 C2H5 g2H5 5 N tt tt
E27 C2H5 C2H5 6 S n 3.3
E40 C2H5 C2H5 8 S rt 5.7
E30 G2H5 C2H5 1 0 s Mixed 5.9
TABLE XXIII
The comparative PI50 values of a series of bis-onium 
aliphatic neuromuscular blocking agents, showing the 
effect of alteration of the inter-onium chain length, 
the alkyl onium substituents and the onium centres 
on anti-acetylcholinesterase activity.
•R +> R 1
r 1 n  +  X  =  s '
R  _  H - ( O H p )  -  X  ' R
R a or
✓ R2 i -  X  =  H - R  ■
v R t
Code
No. R % n X
Type of 
Neuro­
muscular block
produced i
PI50
C6 CH5 ch3 6
-j-
N(CH3 )3 Non-de­
polarizing
3.0
CIO ch3 ch3 1 0 n(ch3 )3 Depolarizing 5.1
C10E °2H5 C2E5 1 0
j .
r(c2h5 )3 Non-de­polarizing
5.1
Cll ch3 ch3 1 1
"J*
k(ch3 )3 Mainlydepolarizing
5.4
C12 ch3 CH3 12 N(CH3)3 Mixeddepolarizing
5.5
C13 ch3 ch3 13 H(CH3 )3
"'aridr no n- ~ 1 1 
depolarizing 5.7
I ch3 C2H5 8 S(CH3C2H5) Mainlydepolarizing
2.9
II ch3 ch3 1 0
+S(CH3 )2 Depolarizing 4.9
III ch3 ch3 8 s(ch3 )2 Depolarizing 4.0
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Results and Discussion
The pI50 values for the compounds investigated 
are shown in Tables ZZI - XXET together with the 
qualitative nature of the neuromuscular block produced.
An example of the calculation of the pI50 values for 
compounds E17 and E71 is shoY/n in Eig, 75* Erom 
the opposite page it can be observed that certain of 
the compounds investigated (compounds E30, E40, E41,
E63, E17, E35> Ex) possessed anti-cholinesterase 
activity only slightly less than that of eserine and 
neostigmine. On the other hand, many compounds 
possessed negligible activity in concentrations not 
exceeding M/200, It is obvious that anti-cholinesterase 
activity varied with alteration in chemical structure 
and the results of the investigation can best be 
discussed on this basis.
Effect of Change in the Interonium Pi stance on 
Anti-cholinesterase Activity.
Interonium distance and especially the distance 
between the first or last onium centres in the polyonium 
compounds, is clearly an important factor in the 
anti-cholinesterase potency of the compounds tested. 
Increase in the number of methylene groups from five
224
(compounds E93 and E94) to ten (compound E31) 
increased potency. A very sharp rise in potency 
was observed when the chain length increased from six 
to eight methylene groups (compounds E24 and E41; 
compounds E27 and E40; compounds E36 and E72). An 
increase in the effective chain length "beyond ten 
methylene groups (compounds E35, E17 and Ex) did not 
however, enhance potency. Similar results were 
observed using bis-onium derivatives (compounds C6, CIO, 
Cll, C12, C13 and the fully ethylated analogue of 
decamethonium) and are in agreement with those of 
Paton & Zaimis (1949) who reported an increase in 
anti-cholinesterase activity in a series of polymethylene 
bis-methonium compounds until the compound containing 
twelve methylene groups was reached. Potency was 
reduced however as the interonium chain length reached 
eighteen methylene groups.
This effect appeared to be dependent only on 
interonium distance and was unaffected by the size of 
the onium substituents or the nature of the onium centres 
themselves.
Effect of Increase in the Number of Onium Centres on 
Anti-cholinesterase Activity.
Providing that the interonium distance remains
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constant, increase in the number of onium centres 
does not decrease anti-cholinesterase activity.
The slight increase in anti-cholinesterase activity 
with increase in the number of onium centres sometimes 
observed (for example, compounds E24, E36 and E73; 
decamethonium and compound E5l)> is not comparable to 
the marked influence on potency produced by altering 
interonium chain length, and cannot be regarded as a 
major factor in determining the anti-cholinesterase 
potency of these drugs.
Effect of the Presence of one Sulphonium Atom.
In the N, E, N (compounds E24, E41 and E31) and 
N, S, E-ethonium series, (compounds E27, E40 and E30), 
it is clear that replacement of a quaternary nitrogen 
atom with a tertiary sulphur atom produced no dramatic 
alteration in anti-cholinesterase activity. Similar 
effects were observed in the bis-onium compounds II 
and decamethonium. These results parallel observations 
on the comparative muscle relaxant potency of these 
compounds. The compounds E17 and Ex in which the 
sulphur atom of each is uncharged, were as expected, 
more potent than the corresponding E,S,E-sulphonium 
derivatives, indicating the importance of interonium
2 2 6
distance in determining the anti-cholinesterase 
activity of these compounds.
Effect of Increasing the Size of the Alkyl Substituents 
on the Onium Centres.
Increase in the alkyl group size is less 
important than increase in the interonium distance hut 
in both the N, IT, 3T-(compounds E74, E24, E75, E76, 
and E83) and N, S, N-(compounds E18, E27, E60, E6l,
E64 and E65) tris-onium series the presence of more 
bulky substituents was generally associated with a 
slight increase in potency. In each series, the 
ethonium derivatives E24 and E27 respectively were the 
least potent. (
Many compounds capable of inducing muscle 
relaxant properties have an affinity for acetylcholine- 
receptors both in the post synaptic membrane and on 
acetylcholine-esterase itself. Consequently, although 
a number are primarily neuromuscular blocking agents, 
they also possess anticholine-esterase activity 
especially at higher concentrations. Moreover, 
certain drugs may induce muscle relaxation by virtue 
of their anticholine-esterase properties as indicated 
in the AriSns* classification (see page 46 of this
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thesis). Por example, benzoquinonium is reported 
to have approximately one-quarter the anti­
cholinesterase activity of neostigmine (Hoppe, 1951).
The contribution of the anti-cholinesterase 
activity to the muscle relaxant potency of the compounds 
structurally similar to those investigated in this 
thesis, can only be approximately estimated from these 
results. Although the anti-cholinesterase action of 
decamethonium, when compared to eserine, is appreciable, 
this effect is not believed to account substantially 
for the muscular fasiculations and initial stimulatory 
effects observed with this drug (Paton & Zaimis, 1949). 
Consequently, in those compounds in which anti­
cholinesterase potency is less than that of decamethonium, 
it is unlikely that the accumulation of acetylcholine 
at the end plate is significantly contributing to the 
paralysis observed. On the other hand, in those 
compounds which possess a greater anti-cholinesterase 
activity than decamethonium (compounds E63* E41, E40,
E31 and E30) this possibility cannot be so readily 
dismissed. It is interesting to observe that in each 
of these compounds, the distance between the charged 
onium centres (eight or ten methylene groups) is 
considerable. However, while i^ appears that anti-
2.28
cholinesterase activity is associated with a fairly 
large interonium distance, one cannot be certain of 
the effective distance involved since, as has been 
already indicated in this thesis (page 137), 
bisquaternary salts, at least, readily undergo ion 
pair complex formation. Conclusions concerning the 
distance between anionic sites on the acetylcholine- 
esterase enzyme itself cannot therefore be drav/n from 
a consideration of the chemical structure of maximally 
effective compounds.
That anti-cholinesterase activity may not be 
contributing to the muscle relaxant potency of compounds 
of this type has been emphasized by the observations 
that anti-enzymic effects are not always associated 
with depolarizing properties. Thus compounds E40,
E41, E72 possess a relatively high degree of 
acetylcholine-esterase activity, in comparison with 
the other compounds tested, yet are predominantly 
non-depolarizing muscle relaxants. Furthermore, the 
presence of depolarizing features in the neuromuscular 
blocking effects of certain polyonium derivatives, 
for example compounds E63, E31 and E30, may be 
independant of the anti-cholinesterase activity 
observed. In particular the comparable anti-
cholinesterase activity of decamethonium and its 
fully ethylated analogue, decaethonium, which is a 
non-depolarizing drug, suggest that the structure of 
acetylcholine-esterase and the cholinergic receptor 
may not possess identical features. On the other 
hand, it has heen implied that the receptor for "both 
acetylcholine-like effects and cholinesterase activity 
may he a single, though diffdrentiated entity (Cohen 
& Posthumus, 1955; Cohen jst al. 1955). The existence 
of independant fA 1, fB* and fC f groups on the receptor 
might, it has heen suggested, he responsible for 
combination with complementary centres of a reactant 
drug molecule. The fA' groups are concerned with the 
interaction of specific cationic-effector drugs 
responsible for depolarization, the fCf groups with 
non-specific cationic drugs which block the receptor 
without inducing depolarization and the ’B 1 groups 
which react with the esterase-active centre of the 
molecule. Cohen and his colleagues further suggested 
that the inhibition of true cholinesterase was a non­
competitive effect, irreversible by high substrate 
concentrations and brought about by steric hindrance of 
the active site. Consequently, the union of a drug 
and the anionic component of the postulated receptor
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could proceed without significantly affecting the 
inhibition of true cholinesterase. Differences 
in the anti-cholinesterase potency of non-depolarizing 
and depolarizing drugs can he explained on this basis. 
Conversely, the similarity in anti-cholinesterase 
potency and the qualitatively different neuromuscular 
blocking effects between decamethonium and decaethonium 
could be due to differences in affinity for the fA f or 
fCf groups of the postulated receptor site.
The results of the present investigation 
support the view that acetylcholine-esterase activity 
and depolarizing muscle relaxant properties are not 
brought about by drug interaction with identical 
receptors. The depolarizing activity of some of the 
compounds examined is thus believed to be independant 
of their anti-cholinesterase properties. Moreover, 
these results are not incompatible with the 
differentiation of a common receptor, as suggested by 
Cohen and his associates, into centres capable of 
combining with anti-cholinesterases and into specific 
and non-specific anionic sites.
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In the introduction to this chapter, the 
differentiation and classification of cholinesterase 
enzymes has been described and their role at the 
neuromuscular synapse discussed. The emergence of 
anti-cholinesterase activity in many quaternary 
ammonium compounds possessing neuromuscular blocking 
activity has been correlated with their qualitative 
effects at the neuromuscular synapse. The possibility 
that anti-cholinesterase effects contributed, in whole 
or in part, to depolarizing activity prompted the 
present investigation of a number of bis- and polyonium 
neuromuscular blocking agents.
Anti-acetylcholinesterase activity was estimated 
manometrically using a cholinesterase preparation from 
rat brain and a wide range of activity, -calculated as 
the pI50 value, observed. Hone of the compounds tested 
was more potent than eserine or neostigmine.
The greater anti-cholinesterase-inhibitory 
action of depolarizing compared to non-depolarizing, 
agents has been confirmed but a direct correlation 
between depolarizing effects and anti-acetylcholine- 
esterase activity could not be established. These
CHAPTER I I  -  SUIiMARY
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results are not incompatible with the view that the 
cholinergic and acetylcholine-esterase receptors are 
probably not identical. The correlation of anti­
acetylcholinesterase activity with the chemical 
structure of the compounds investigated has also been 
attempted.
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TABLE XXV
Formulae of Physiological Saline Solutions*
Salts g/l.
Frog 
Ringer* s 
Solution
Tyrode * s 
Solution
Lo eke1s 
Solution
Sodium Chloride 6.5 8 . 0 0 9.00
Potassium Chloride 0.14 0 . 2 0 0.42
Calcium Chloride 
(Anhydrous)
: 0 . 1 2 0 . 2 0 0.24
Sodium Dihydrogen 
Phosphate ; o.oi
0.05 -
Sodium Bicarbonate 0 . 2 0 1 . 0 0 0.50
Magnesium Chloride
................ .
0 . 1 0 -
Glucose - 1 1 . 0 0
- L
1 . 0 0
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APPENDIX I
' In Table XXV, opposite this page, are given 
the formulae of the physiological saline solutions 
used in the experimental work described in this thesis.
ifThe frog Ringer*s solution used in the Ariens* 
procedure contained, in addition, glucose (lg/3j.
All the chemicals used were of *Analar* quality and 
glass distilled water only was employed. Aqueous 
stock solutions of certain salts were prepared to 
facilitate the preparation of a saline solution.
These stock solutions could be used for at least two 
weeks after their preparation. Sodium bicarbonate 
solution was however freshly prepared. Glucose was 
added in the solid form to each batch of saline 
• solution.
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APPENDIX II 
Commercially Available Materials
Throughout this thesis, the names of 
certain commercially available drugs have been 
abbreviated for convenience. The list of drugs 
used, together with their shortened names is as 
follows:
(1) Acetylcholine chloride is described as acetylcholine.
(2) (+)-Tubocurarine chloride is described as 
tubocurarine•
(3) (-)-Adrenaline hydrogen tartarate is described 
as adrenaline. .
(4) Hexamethonium iodide is described as Hexamethonium.
(5) Decamethonium iodide is described as decamethonium.
(6 ) Neostigmine methyl sulphate is described as 
neostigmine.
(7) Edrophonium chloride is described as edrophonium.
(8 ) Sodium pentobarbitone is described as pentobarbitone.
(9) Ether anaesthetic is described as ether.
(1 0 ) Oxydipentonium di-chloride is described as 
oxydipentonium.
(11) (+)-0,0-Dimethyl tubocurarine di-iodide is
. * described as tubocurarine dimethyl ether.
(12) Eserine salicylate is described as eserine.
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The chemical nomenclature of the compounds 
investigated in this thesis are shown below. Their 
structural formulae together with the. general code 
number are shown in Tables II and III (opposite 
page 99), and Tables XXI - XXIV opposite page 223.
Compounds described in Chapter I,
1* 7,7,13,13-Tetraethyl-7,13-diazonia-10-
oxanonade cylenebis- (trie thyl-ammonium) te tra- iodide 
is described as compound E77.
2. 7,13-Diethyl-7,13-dimethy1-7,13-diazonia-10- 
oxanonadecylenebis-(diethyl me thyl ammonium) tetra- 
iodide is described as compound E78.
3. 7,7,13,13-Tetra-ethyl-7,13-diazonianonadecylenebis- 
(triethylammonium) tetra-iodide is described as 
compound E79.
4. 7,13-Die thy 1-7,13-dime thy 1-7,13-diazonianonade cylenebis- 
(die thy lme thyl ammonium) te tra-iodide is described
as compound 80,
5. 7,13-Diethy1-7,13-di-n-propy1-7,13-diazonia-10- 
oxanonade cylenebis- (die thyl-n-p ropy lammonium) 
tetra-iodide is described as compound E96.
6 * 7,13-Diethyl-7,13-di-n-propy1-7,13-diazonianona- 
decylenebis-(diethyl-n-propylammonium)tetra-iodide 
is described as compound E97.
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7. 6,6-Diethyl-3,9-dioxa-6-azoniaundecylenebis
(triethylammonium) tri-iodide is described as 
compound E90.
8 . 6-Ethyl- 6-me thyl- 3,9-dioxa- 6-diazoniaunde cylenebis 
(diethylmethy1-ammonium) tri-iodide is described as 
compound E91.
9. 6-E'thyl- 6 - me thyl- 6 - az oniaunde cy 1 eneb is- 
(diethylmethylammonium) tri-iodide is described 
as compound E93.
10. 6 ,6 -Diethyl-6-azoniaundecylenebis- (triethylammonium) 
tri-iodide is described as compound E94.
11. 6 -Ethyl-6-n-propyl-6-azoniaunde cylenebis-
(die thyl-n-propy lammonium) tri-iodide is described 
as compound E95.
1 2 . 6-Ethyl- 6-methyl- 3,9-dioxa- 6 - azoniaunde came thylenebis 
(triethyl-ammonium) tri-iodide is described as 
compound E98. •
13. 6 ,6 -Dime thy 1-3,9-dioxa-6-azoniaunde came thylenebis 
(diethyl-methyl-ammonium) tri-iodide is described 
as compound E99.
14. 6 , 6 -Dime thyl-3,9-d ioxa-6-az oniaunde came thylenebi s 
(trimethyl-ammonium) tri-iodide is described as 
compound E100.
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15. 6-Ethyl-6 -methyl-3,9-dioxa-6 -azoniaundeca­
me thylenehis (e thyldime thylammonium) tri- iodide 
is described as compound E1Q1.
16. 6-Methyl-6-propyl-3,9-dioxa-6-azoniaundeca- 
methylenebis (dimethylpropylammonium)tri-iodide 
is described as compound E102.
17. 6-Me thyl-6 -propyl-3,9-d ioxa-6-azoniaunde ca­
me thylenebis(diethylpropylammonium)tri-iodide 
is described as compound E103.
18 . Octamethylene-l-ethylmethylsulphonium-8 -
dime thyl ethyl ammonium di-iodide is described as 
compound I.
19. De came thylene- 1-dime thylsulphonium-10- 
trimethylammonium di-iodide is described as 
compound II.
2 0 . 0 ctame thylene-1- d ime thyl sulphonium- 8 -
t rime thyl ammonium di-iodide is described as 
compound III.
21. 7,7-Dime thy 1-7- azoniatride came thylenebis- 
(trimethylammonium) tri-iodide is described as 
compound E151.
22. 7-Methyl-7-Ethyl-7-azoniatridecamethylenebis 
(dimethylethylaramonium) tri-iodide is described 
as compound E152.
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23 * 7-Methyl-7-Ethyl-7-azoniatridecamethylenebis
(diethyImethylammonium) tri-iodide is described 
as compound E74.
24 . , 2-Trimethylaminoe thyl-5-trlmethylaminopropylether
di-iodide is described as compound P. 2c P. 16575.
25. 2-Die thylmethylaminoe thyl-3 trimethyl amino propyl 
ether di-iodide is described as compound P. Sc P.
16677.
26. 2-Die thylmethylaminoe thyl-3 diethylmethylaminopropyl 
ether di-iodide is described as compount P. 2c P. 
8302.
27. 2-Triethylaminoethyl-3triethylaminopropyl ether 
di-bromide is described as compound P. 2c P. 8303.
28. 2 -Triethylaminoethy 1-3-dimethylethylaminopropyl 
ether di-bromide is described as compound P. & P.
16678.
29. 3-3Tbis(trimethylamino) di-n-propyl ether di-iodide 
is described as compound P. & P. 16701.
30. 3- (dime thyl thyl amino) ,3* - (trie thy lamino)-di-n- 
propyl ether di-iodide is described as compound 
P. Sc P. 17843.
31. 3-3fbis(triethylamino)di-n-propyl ether di-iodide 
is described as compound P. 2c P. 8212.
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non-available compounds investigated in Chapter II,
1. Decamethylene 1,10-bis-(triethylammonium) di-iodide 
is described as decaethonium.
2. Unde came thylene 1,11-bis- (trime thy lammonium) 
di-iodide is described as compound Cll.
3. Tride came thylene 1,13- bis- (trime thylammonium) 
di-iodide is described as compound C13.
4. 7 ,.7-Die thyl-7-azoniatride came thylenebis (triethyl­
ammonium) tri-iodide is described as compound E24.
5. 7-Ethy 1-7-me thy 1-7-axoniatride came thylenebis
(diethylmethylammonium) tri-iodide is described as 
compound E74.
6 . 7-Ethyl-7-n-propyl-7 azoniatridecame thylenebis 
(diethy 1 -n-propyl-ammonium) tri-iodide is described 
as compound E75.
7* 7-Ethyl-7-n butyl-7 azoniatridecamethylenebis
(diethyl-n-butylammonium) tri-iodide is described 
as compound E76.
8 * 7,7-Di-n-propyl-7 azoniatride came thylenebis
(tri-n-propyl-ammonium) tri-iodide is described as 
compound E82.
Chemical nomenclature of additional commercially
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9. 7-Ethyl-7-n-propyl-7 azoniatridecamethylenebis 
(ethyl-di-n-propylammonium) tri-iodide is 
described as compound E83.
1 0 . 7-Methy1-7-n-propyl-7 azoniatridecamethylenebis 
(methyl-di-n-propylammonium) tri-iodide is 
described as compound E84.
11. 9,9-Diethyl-9-azoniaheptadecamethylenebis
- (triethylammonium) tri-iodide is described as
compound E41.
12. 11,11-Die thy 1-11-azoniaheneicosylenebis 
(triethylammonium) tri-iodide is described as 
compound E31. . .
13. 9,9-Die thy 1-9- azoniaheptade came thylenebis 
(triethylammonium) tri-iodide is described as 
compound E72.
14. 7,7,14,14-Tetraethyl-7,14-diazoniaeicosylenebis 
(triethylammonium) tetra-iodide is described as 
compound E36.
15. 7,7,16,16-tetra-ethyl-7,16-diazoniadocosanebis 
(triethylammonium) tetra-iodide is described as 
compound E70,
16. 9,9,16,16-tetra-ethyl-9,16-diazoniatetracosanebis 
(triethylammonium) tetra-iodide is described as 
compound E71.
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17, 7,7,18,18 - te tra-e thyl-7,18-d iazonia te traco sane- 
bis(triethylammonium) tetra-iodide is described 
as compound E62.
18, ll,ll>18>18-tetra-ethyl-ll,18-diazonia-octacosane- 
bis(triethylammonium) tetra-iodide is described
as compound E63,
19, 7,7,14,14,21,21,28,28-octa-ethyl-7,14,21,28- 
tetra-azonia-tetratriacontane bis(triethylammonium) 
hexa-iodide is described as compound E73.
20, 7-Hethy1-7-thioniatridecamethylenebis (trimethyl- 
ammonium) tri-iodide is described as compound E18.
21, 7-Ethyl-7-thioniatridecamethylenebis (triethy 1- 
ammonium) tri-iodide is described as compound E27.
22, 9-E thyl-9-thioniaheptade came thy lenebis (trie thyl- 
ammonium) tri-iodide is described as compound E40,
23, 1 1 -Ethyl-ll-thioniaheneicosylenebis(triethy1- 
ammonium) tri-iodide is described as compound E30.
24, 7-Methyl-7-thioniatridecamethylenebis(dimethylethy1- 
ammonium) tri-iodide is described as compound E61.
25, 7-Methyl-7-thioniatridecamethylenebis(diethyImethyl- 
ammonium) tri-iodide is described as compound E60.
26, 7-n-butyl-7-thioniatridecamethylenebis(di-methy1- 
n-butyl-ammonium) tri-iodide is described as 
compound E64.
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27* 7-Ethyl-7-thioniatridecamethylenebis(di-ethyl- 
n-propyl-ammonium) tri-iodide is described as 
compound E65.
28* 7-Dioxothioniatridecane-l,13-bis(triethylammonium) 
di-iodide is described as compound E35.
29. 7-Thiaoniatridecane-l,13-bis (trime thylammonium) 
di-iodide is described as compound E17.
30. 11-Thiaoniaheneicosylene-bis (trime thylammonium) 
di-iodide is described as compound Ex.
31. 7,7>14,21,21-Penta-ethyl-7,21 diazonia-14-thionia- 
heptacosylenebis (trie thylammonium) penta-iodide
is described as compound E58.
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A statistical comparison of the intrinsic activities 
of oxydipentonium and decamethonium. The order of 
construction of the dose response curves to these 
drugs (2 p.moles/l) was determined using a table of 
random numbers and assigning equal chances to either 
drug of being used first or second on the same piece 
of tissue.
APPENDIX III
Expt.
No.
1st Drug 
Added
2nd Drug 
Added
Height 
of 1 st 
Contract­
ure
Height 
of 2nd 
Contract­
ure
Diff. 
in
Height 
of 1 st 
and 2nd 
Contract­
ures
1 Deca­
methonium
Oxydi­
pentonium
1 2 . 8 1 2 . 0 0 . 8
2 w tt 13.8 13.3 0.5
3 Oxydi­
pentonium
Deca­
methonium
4.1 3.0 1 . 1
4 Deca-
methonium
Oxydi­
pentonium
7.7 6 . 0 1.7
5 Oxydi­
pentonium
Deca­
methonium
13.3 11.9 1.4
6 Deca­
methonium
Oxydi- 
pentonium
5.8 3.0 2 . 8
7 Oxydi­
pentonium
Deca­
methonium
3.6 2 . 6 1 . 0
8 it !» 3.3 3.1 0 . 2
9 Deca- 
me thonium
Oxydi­
pentonium 8.4 5.8
2 . 6
1 0 Oxydi­
pentonium
Deca-methonium!
6 . 0 5.8 0 . 2
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Expt. 
Ho.
1st Drug 
Added
2nd Drug 
Added
-Height 
of 1 st 
Contract­
ure
Ho ight 
of 2nd 
Contract­
ure
Diff.
in
Height 
of 1 st 
and 2nd 
Contract 
ures
t
1 1 Deca­
methonium
Oxydi-
pentonium
4.7 4.6 0 . 1
i
1 2 u n 8.9 8 . 1 0 . 8
13 j Oxydi- 
| pentonium
Deca­
methonium
2.7 2 . 2 0.5
14 j Deca- 
j me thonium
Oxydi- 
pentonium
5.9 j 4.6
____________ u  .......-
1.3
15 | Oxydi- 
i pentonium
De ca­
me thonium
4.5 |3.1 1.4
16 ! Deca- 
i me thonium■ 1 i - ■ ■
Oxydi­
pen ton ium
5.7 4.6 1 . 1
17 | Oxydi- 
[pentonium
Deca­
methonium
7.3 7.1 0 . 2
18 | "
. i .
tt 3.1 2.4 0.7
19 Deca­
methonium
Oxydi-
pentonium
11.9 lo .i 1 . 8
2 0 Oxydi­
pent onium
Deca­
methonium
13.0 11.1 
1
1.9
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The standard Student*s fjtf test was used 
to determine the significance of the difference of 
the means (x-^  and Sg) of the contractural responses 
of the frog rectus abdominis muscle to decamethonium 
and oxydipentonium.
2 —The variance (s ) from the mean (x) for each
set of variates was calculated hy the equation
2 2 2 2 s = Sx —  (Sx) where Sx is the sum of squares of x,
n , %2: (Sx) is the square of the sum of xn—j.
and n is the number of variates.
The standard deviation of each set of variates (S.D.)
ois equal to the square root of the variance (s ).
The standard error of each mean (S.E.M.) was calculated
S Dfrom the formula (— — #) . The standard deviation from
yfn
the mean (Sd) for two sets of variates n^ and ng of
variance s-^  and Sg was calculated by the equation 
2 2
(Sd)^ = + • The value of T_t* was then
nl n2 _  _
obtained by applying the equation, t = X 1 " ~ x 2
Sd
where x^ and Xg represent the means of the two sets 
of variates. In tables of !t^distribution, to 
obtain the values of P (probability), the degrees of 
freedom (D,P.)were calculated from the expression,
D.F. = n-j_ + n2 —  2.
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The differences in the heights of the 
contractural responses in each experiment (shown 
below) were then compared as followss- 
De came thonium Oxy dipent onium
0.8, 0.5, 1.7, 2.8, 2.6 1.1, 1.4, 1.0. 0.2, 0.2,
0.1, 0.8, 1.3, 1.1, 1.8. 0.5, 1*4, 0.2, 0.7, 1.9.
Mathematical
Symbol De came thonium Oxydipentonium
sx
...
13.5 8 . 6
sx2 25.17 1 0 . 6
n 1 0 1 0
X 1.35 0 . 8 6
(sx)2 182.25 73.96
(sx2 )/n 18.225
-i . ,
7.396
s2 0.7716 0.356
S.D. (=J^*) 0.878 0.597
S.E.M. (=-±Ll2* 
yfn
0.2776 0.1887
sa 0.3357
t 1.4596
P 7 0 .1 < 0 . 2
From these results there is no significant 
difference in the heights of the contractural responses 
(intrinsic activities) of the two drugs.
